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Preface  
Over the past decades, nanotechnology became one of the most important 
scientific research areas, which has extended to many aspects of life (industrial, 
medical, biological, etc.), exploiting the unique physicochemical properties offered by 
the nanomaterial. Beside the involvement of the nanomaterials in the medical field, 
nanomedicine, the last few years witnessed a tangible progress in the production of 
consumer products that contain nanomaterials. Nowadays, more than 1000 consumer 
products containing nanomaterials are available in the market such products are, 
personal care products (e.g. sunscreen, skin lotions, etc.), food additives, cleaning 
products, sealants, paints, electronics, fuel cells, tires and many other products. 
Unfortunately, this vast use contrasts with the limited attempts to evaluate the harmful 
effects of nanomaterial on public health and environment. This fact highlights the 
need and importance of nanotoxicology.   
Along the thesis, we will explore the toxicity of engineered SPIONs based on 
polymeric route on, cells, blood and organs, as necessary steps for the development of 
a new nanomaterial. This work occupies the thesis that encompasses of five chapters.  
Chapter 1 has the title “General Introduction and Purpose of the Thesis”. This 
chapter is a general introduction including the basic definitions of nanotechnology, 
nanomedicine and nanotoxicology. It displays the importance of nanomedicine in 
solving several medical and pharmaceutical problems, and the great impact of the use 
of nanomaterials at the therapeutic and diagnostic levels. Also, explains the magnetic 
properties of magnetic nanoparticles followed by some examples of the impact of the 
use of superparamagnetic iron oxide nanoparticles at the diagnostic and therapeutic 
levels. In addition, in this chapter we discuss the cautions and the steps to be aware of 
during designing a new nanomaterial. Then, we review the importance of the 
nanotoxicity studies provided with some examples of the effect of nanomaterials on 
the cells, blood, environment, etc. Finally, the chapter explains the main purpose of 
the thesis and describes the general features of the materials to be used. 
Chapter 2 has the title of “In vitro cytotoxicity studies of superparamagnetic 
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iron oxide nanoparticles”. This chapter starts with an introduction about the 
nanotoxicology, viewing some examples about nanohazards and their effect on the 
public health, which in turns underline on the importance of the preventive measures 
and the nanotoxicology studies. In addition, explaining some of the items of study 
involving in nanotoxicology such as route of exposure and toxicological mechanisms 
of nanomaterials. The introduction section ends with explaining the tests used for 
cytotoxicity studies. The main purpose of this chapter is to study the toxicological 
behaviour of our bioferrofluids in vitro using various toxicological assays. This 
chapter displays the influence of many factors on the nanoparticles toxicity in cells 
such as cell type, bead hydrodynamic size, maghemite nanoparticle size, polymer/iron 
ratio, etc. In addition, discloses that the cell death is due to necrosis, with no evidence 
of reactive oxygen species production, and the small nanoparticles have an 
inflammatory effect compared with large ones, which are recommended to be used for 
further studies due to their lower toxic effect in compared to other sizes. 
Chapter 3 has the title of “Studies at the nano-bio interface level: uptake, 
subcellular localisation and endocytosis”. The chapter starts with an illustration of 
the importance of this type of studies, explaining the main components of the nano-bio 
interface, the factors affect the nanomaterial internalisation and mechanisms of 
endocytosis. The main purpose of this chapter is to understand the cytotoxicity caused 
by our bioferrofluids through studying the nanoparticles uptake and the uptake 
kinetics, subcellular localisation and mechanism of endocytosis. This chapter displays 
the influence of many factors on the nanoparticles uptake in cells such as 
nanoparticles size, cell type, nanoparticles concentrations and time of incubation. The 
obtained results explain the size and cell type dependent toxicity caused by our 
bioferrofluids. At the subcellular level, our nanoparticles exist in the endolysosomal 
compartments and the clathrin-dependent endocytosis is the mechanism that is 
responsible for nanoparticles internalisation. 
Chapter 4 has the title of “In vitro haemocompatibility studies of 
superparamagnetic iron oxide nanoparticles”. This chapter shows that the 
nanomaterial could act either as a pro-coagulant or hypo-coagulant agent, which in  
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turn, shed the light on the importance of this kind of studies, especially for 
nanomaterials that are developed for intravenous administration. A brief illustration 
for the blood coagulation mechanism, regulatory mechanisms and coagulation 
screening tests are also provided. The main purpose of this chapter is to study the 
toxicity of three different types of polymer coated SPIONs and their separated 
component in blood. This chapter displays the influence of the surface coating and 
surface charge on the toxicity behaviour of the bioferrofluids. The three types of 
bioferrofluids exhibit anticoagulant effect, with no effect on the blood count in vitro. 
No incidence of haemolysis was detected.   
Chapter 5 has the title of “Biodistribution studies of polymer coated 
superparamagnetic iron oxide nanoparticles”. This chapter starts with a brief 
review about the biomedical imaging and MRI, with an illustration of the basic 
principles of MRI and contrast agents. In addition, this chapter discusses the factors 
affecting the biodistribution of the nanomaterials. The aim of this chapter is to study 
the in vitro relaxation, in vivo biodistribution, and in vivo toxicity for two polymer 
coated SPIONs. The obtained results showed that our bioferrofluids are a good T2 
contrast agents with no toxic effect in vivo. 
 
 
 
  
 
 
 
 
 
Chapter 1 
General Introduction and Purpose of the 
Thesis 
1.1 Nanotechnology, nanomedicine and nanotoxicology terms 
 
Nanotechnology has garnered a great interest in last decades. According to the 
United States (US) Nanotechnology Initiative, Nanotechnology can be defined as “the 
understanding and control of matter at dimensions of roughly 1–100 nanometers, 
where unique phenomena enable novel applications” [1]. Nanomaterials have a size 
comparable to the size of the sub-cellular organelles and proteins Fig. 1.1, hence, they 
could be exploited to spy or interfere with the cellular machinery giving rise to a new 
branch of science called “nanomedicine” [2].  
Figure 1.1: Demonstration of the nanomaterials sizes compared with other items [3]. 
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The European Science Foundation (ESF) in its Forward Look Nanomedicine 
document defined nanomedicine as the following “nanomedicine uses nano-sized 
tools for the diagnosis, prevention and treatment of disease and to gain increased 
understanding of the complex underlying patho-physiology of disease” [4]. 
Although, the unique physicochemical properties of nanomaterials have a great 
positive impact on biomedical applications, the same properties can have a negative 
impact on the biosystem, since nanomaterials are characterised by a high surface to 
volume ratio, which may lead to increase their biological reactivity. In addition, their 
nano-size enables them to breach cells reaching critical sites inside, such as nucleus, 
mitochondria, etc., which may cause mutations or cell death [5].  
Besides the environmental exposure to airborne nano-sized materials coming 
from natural or anthropogenic sources [6], the rapid evolution in nanotechnology, 
which extends to many applications (biological, medical and industrial) [5,7,8], 
increases the risk of exposure. The issue of nanomaterials safety and nanotoxicity 
should be addressed, as a lesson learned from the medical science´s failure in the past 
centuries to take safety measures toward quartz and asbestos exposure [9]. Therefore, a 
new sub-discipline of the nanotechnology called nanotoxicology has emerged. 
Nanotoxicology could be defined as “science of engineered nanodevices and 
nanostructures that deals with their effects in living organisms” [6]. 
  We can conclude that nanotechnology, nanomedicine and nanotoxicology are 
three interconnected and closely dependent fields. Therefore, as any new nanomaterial 
can have an impact on the biological environment with consequences in the medical 
field, a series of toxicology studies should be carried during its development process. 
Therefore, for any nanomaterial developed for biomedical applications, toxicological 
studies should include: synthesis and characterisation with the possibility to minimise 
batch to batch variation, studying nanomaterial toxicity on cells (in vitro), studies of 
nanomaterial uptake and mechanism of internalisation (endocytosis), studies of 
nanomaterial toxicity on blood (haemotoxicity) particularly if the nanomaterial is 
developed for intravenous (iv) injection, studies of the nanomaterial biodistribution (in 
vivo) and their possible toxic effects on tissues and organs, evaluation of their
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application (therapeutic or diagnostic) efficiency and finally studying their toxic effect 
on the environment.  
As explained in more detail at the end of this chapter, this thesis will deal with 
some of these studies as a necessary step in the group for the development of a 
synthetic nanoplatform for biomedical applications. Along the thesis it will become 
clear that toxicological issues often depend of properties that are independent of the 
materials composition, e.g, aggregation and surface charges, in addition to their 
composition itself. Additionally, nanomaterials can be rather complex systems with a 
variety of components whose individual toxicity should also be addressed. There is 
therefore an interrelation between the nanomaterial, its components toxicity and its 
effects on the biological system it is being developed for. 
In the following sections we will revise each of these four fundamental aspects: 
nanomedicine, magnetic nanoparticles, nanomaterials and their design and 
nanotoxicity. 
1.2 Nanomedicine: a new way to address open medical and pharmaceutical 
problems  
There are many medical problems still waiting to be solved that are associated 
either with the diagnosis and/or with the treatment of some diseases. For instance, in 
the case of cancer, early diagnosis is considered a challenge in its treatment, which in 
many cases is not reached. Moreover, traditional cancer treatment methods 
(radiotherapy or chemotherapy) are associated with several complications such as the 
lack of efficient selectivity toward cancerous cells causing systemic toxicity [10]. 
Another treatment limitation is the inability of chemotherapy to overcome the 
multidrug resistance (MDR) mechanism -a mechanism of drug efflux from the 
cancerous cell cytoplasm to the extracellular space- that is associated with several 
tumour cells leading to treatment failure [11].  
Nanomedicine opens new hopes in solving diagnostic and therapeutic problems 
by developing nanomedicines -an overall term that includes nanopharmaceuticals,
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nanoimaging agents, and theranostics1 [12]-, and exploiting new physicochemical 
properties, since at the nano-level the material can acquire new properties (electrical, 
optical or magnetic) not present in the bulk state [13]. 
Nanomedicines can be organic such as liposomes, micelles, dendrimers, 
polymeric nanoparticles, fullerenes and carbon nanotubes or inorganic such as 
magnetic nanoparticles, metal based nanoparticles, ceramic nanoparticles and 
semiconductors. This versatility in composition and physicochemical properties opens 
the door for a wide range of medical applications [14]. Therefore, the second half of 
the 20th century witnessed the birth of the first generation of marketed nanomedicines, 
their use is varying between diagnosis and therapy, as shown in Table 1.1 where only 
those related to iron oxide are collected. A rather comprehensive account of 
nanomedicines already in the market can be found in ref. [12].  
1.2.1 Therapeutic nanomedicines 
 
The onset of the use of nanomedicines as therapeutic agents dates back to fifties, 
when the first polymer-drug-conjugate was synthesised by Jatzkewitz. This was a 
breakthrough in the manufacturing of nanomedicines as depicted in Fig. 1.2 [15]. The 
use of nanomaterials as therapeutic agents is a diverse field, ranging from drug/gene 
delivery systems, antimicrobial agents to antioxidant agents [2,12,16,17]. 
Traditional delivery strategies for certain drugs (especially anticancer) are 
associated with many prominent problems such as lack of selectivity which in turns is 
reflected on the toxicity, failure to avoid MDR mechanism, low bioavailability, the 
necessity of large dose to achieve high local concentration and fail to improve drug 
solubility [18]. Nanomedicine reduces these previous problems improving drug 
delivery strategies. This is achieved by drug encapsulation, surface conjugation or 
entrapment to the nanomaterials forming “targeted” drug delivery systems. 
As a result, these approaches transport drugs more efficiently to the target site, 
increase the local concentration of the drug in the target site, improve drug solubility  
                                                 
1 Theranostic is a nanomedicine concept which refers to the capacity of a product to act as a 
diagnostic and therapeutic tool simultaneously. 
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Table 1.1:  First generation of marketed iron oxide-based nanomedicines [12]. 
Product name Technology Indication Route of 
admin. 
Information source 
Superparamagnetic Iron Oxide Imaging Nanoparticles (SPIONS) 
Feridex (ferumoxide) 
Endorem (ferumoxide) 
Gastromark (ferumoxsil) 
Lumirem (ferumoxsil) 
Sinerem (ferumoxtran), same 
as Combidex 
Resovist 
SPION dextran coating 
SPION dextran coating 
SPION silicone coating 
SPION silicone coating 
ultrasmall particles (USPION) 
 
SPIONs 
liver imaging 
liver imaging 
GI imaging 
GI imaging 
lymph node imaging 
 
small liver lesions 
iv 
iv 
oral suspension 
oral suspension 
infusion 
 
iv 
Bayer Healthcare Pharmaceuticals 
AMAG Pharmaceuticals/Guerbet SAa 
AMAG Pharmaceuticals a 
AMAG Pharmaceuticals a 
Guerbet withdrew MAA for Sinerem in 2007 
AMAG Pharmaceuticals (phase III) 
Bayer Healthcare Pharmaceuticals 
Iron Oxide Supplements 
Venofer 
Ferrlecit 
Cosmofer 
various “generic” formulations 
iron oxide, sucrose 
iron oxide gluconate 
iron oxide, dextran 
iron oxide nanoparticles 
anemia 
anemia 
anemia 
anemia 
 
iv 
iv 
iv 
iv 
 
Freseniusa
Sanofi-Aventisa 
GRY-Pharmaa 
reviewed in refs 508, 509 
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and protect the drug from degradation. They also open the possibility to deliver a 
combination of drugs for a combination therapy, or to monitor the drug delivery by 
delivering a combination of imaging and therapeutic agents, and therefore all these 
previously mentioned advantages lead to increase patient compliance [18,19]. 
Drug targeting using nanomedicines is achieved by either passive or active 
targeting mechanism. Passive targeting is divided into two mechanisms: a) enhanced 
permeability and retention (EPR) mechanism, which exploits the leaky vasculature of 
tumour cells [20], b) localised delivery mechanism by intra-tumour injection of drugs 
conjugated to nanomaterials [21]. However, active targeting is achieved by direct 
conjugation of the nanomaterials to various signature molecules2 recognisers such as 
ligand [22], antibody [23] or aptamer [24], in order to trigger nanomedicines to 
specific pathological site.  
All the first generation marketed nanomedicines are passively targeted. For 
instance, Doxil (liposomes-encapsulated doxorubicin), was approved by the US Food 
and Drug Administration (FDA) in 1995. It triggered drug targeting through EPR 
mechanism and was used for the treatment of advanced ovarian cancer, metastatic 
breast cancer and HIV-treated Kaposi´s sarcoma [15]. Although more than 30 years 
have passed since the first description of ligand conjugated liposomes in 1980, only a 
handful of active targeted nanomedicines have reached to the clinical trial area, and 
none have made a significant clinical impact on human health [12,25].  
Continual advances in nanofabrication lead to production of nanomedicines not 
only able to protect the cargo from unfavourable conditions but also controlling its 
release as a response to physical or chemical stimuli such as light, heat, sonication, 
magnetic field, pH and redox change [26]. In addition, elongation for blood circulation 
time could be achieved through polymer coating [27]. 
An additional merit for nanomedicines as targeted drug delivery system is their 
ability to deliver drugs across blood brain barrier (BBB) [28]. The delivery property of 
nanomedicines is not limited to drugs only but also extended to genes [29] and 
                                                 
2 Signature molecules are biological molecules found in blood, other body fluids or tissues, 
which are signs of a normal or abnormal process, or of a condition or disease. 
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Figure 1.2: Timeline of nanomedicines development [15].  
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Figure 1.2 (continue): Timeline of nanomedicines development [15].
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vaccines [30]. In addition, nanomedicines could also act as agents for hyperthermia 
[31], tissue engineering helper [32], antimicrobial agents [33], antioxidant agents [34] 
and they may be consider as an active drug material by themselves [35]. 
1.2.2 Diagnostic nanomedicines  
 
Next to the therapeutic potential of nanomedicines, they are equally attractive as 
diagnostic tools either in vivo, ex vivo, or in vitro. Nanomedicines can serve as 
contrast agents for molecular imaging in vivo, thanks to their unique physicochemical 
properties whether optical [36,37] or magnetic properties [38], or due to their ability to 
conjugate to fluorescent markers [39]. Detection and/or measurement of a biological 
molecule were considered another challenge for nanomedicines that has been 
successfully achieved, as nanomedicines are involved in biosensing [40], lateral-flow 
immune assay (LFA) [41] and bio-barcode assays [42]. 
1.3 Magnetic nanoparticles (MNPs) 
MNPs are a class of engineered nanomaterials that can be manipulated under the 
influence of an external magnetic field. They are composed of magnetic elements, 
such as metals (Fe, Co, Ni), metal oxides (ɣ-Fe2O3, Fe3O4, CoFe2O4, CrO2) and metal 
alloys (FePt, FeCo, CoPd, CoNi, NiCoPd) [43].  
Due to their unique magnetic properties and their ability to function at the molecular 
and cellular level, certain MNPs are considered an attractive platform for medical 
applications [44]. In addition, they are important in basic research [45], industrial and 
environmental applications [46]. Iron oxide maghemite (ɣ-Fe2O3) and magnetite 
(Fe3O4) are the most commonly used MNPs for biomedical applications because of 
their biocompatibility and suitable superparamagnetic properties. 
The magnetic properties of MNPs are consequence of the nanomaterial electronic 
state. In a magnetic material, the open shell electrons possess two important 
characteristics: their spin state, which gives rise to a magnetic moment, and the 
magnetic interactions with neighbour ions. Depending on the material composition 
and temperature either one or both characteristics will affect the magnetism of the 
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 material. If there are no magnetic interactions or they are too weak as compared to the 
thermal energy, the material will be paramagnetic, as depicted in Fig. 1.3(a). 
However, if interactions are strong enough to propagate through the material, then 
they will induce magnetic ordering. Ferromagnets and ferrimagnets are examples of 
ordered magnetic materials with important industrial applications. They are commonly 
known as magnets and characterise by, in general, possessing strong magnetisation. In 
the case of ferromagnets, the magnetisation is the result of the parallel alignment of all 
the magnetic moments in the material Fig. 1.3(b). Ferrimagnets, as ɣ-Fe2O3 and Fe3O4 
however, are composed of ions with at least two different magnetic moments which 
align anti-parallel to one another Fig. 1.3(c). This results in the formation of two 
magnetic sub-lattices whose respective magnetisations do not compensate to each 
other. This unbalance in the sub-lattices magnetisation leads to a net magnetisation in 
the solid. In the bulk, materials with a net magnetisation minimise their free magnetic 
energy by splitting their magnetic structure into domains, as shown in Fig. 1.4. 
Figure 1.3: Magnetic moment orientations: (a) paramagnetic, the magnetic moments are randomly 
oriented in the absence of the magnetic field; (b) ferromagnetic, the magnetic moments align parallel  to 
each other under the influence of an external magnetic field; (c) ferrimagnetic, there is more than one type 
of magnetic ions that align anti-parallel without cancelling each other. 
 
The orientation of each domain magnetisation varies among domains giving a 
zero total magnetisation at zero magnetic field. If the magnetic material has a size 
lower than the size of a typical domain, about 20 nm, its behaviour will resemble that 
of a paramagnet in a large temperature region and it will be called superparamagnet. 
Differences will be a huge magnetic moment and the difficulty to follow an alternating 
magnetic field below a given temperature known as blocking temperature, TB [2]. 
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Figure 1.4: Size dependent magnetic properties of magnetic nanoparticles [2].  
 
1.3.1 Superparamagnetic iron oxide nanoparticles  
 
Iron oxide nanoparticles (IONPs) of sizes of about 20 nm and below are generally 
named superparamagnetic iron oxide nanoparticles due to their superparamagnetic 
nature. Therefore, SPIONs have a much larger net magnetic moment as compared to 
that of paramagnetic ions [2]. Due to their acceptable compatibility with biological 
systems, SPIONs are a subclass of MNPs considered of interest for biomedical 
applications. 
1.3.1.1 Medical and biological applications of superparamagnetic iron oxide 
nanoparticles  
 
Interest on SPIONs has dramatically increased since the last decades. Due to their 
reduced toxicity, large magnetic moments and superparamagnetic properties, they can 
be used in many medical applications which can be summarised as moving, sensing, 
image contrast and heating. Furthermore they can be functionalised with drugs, 
bioactive agents, peptides and nucleic acids making them a useful theranostic tool 
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[47]. These multi-functionalities are summarised in Fig. 1.5 and explained in the next 
paragraphs. 
 
 
 
Figure 1.5: Overview of possible 
modifications on iron oxide nanoparticle 
surface in order to design a nanoprobe for 
biomedical applications [48]. 
 
 
 
 
1.3.1.1.1 Use of superparamagentic iron oxide nanoparticles in diagnosis  
1.3.1.1.1.1 Magnetic resonance imaging (MRI) contrast agent  
 
MR imaging is one of the most useful non-invasive diagnostic tools, which is 
characterised by high resolution of soft tissues and non-exposure to radiation [49]. 
Contrast agents used in MRI are divided into two classes: (i) superparamagnetic 
contrast agents and (ii) paramagnetic complexes contrast agent. Superparamagnetic 
contrast agents, such as SPIONs, have a strong effect on the local longitudinal (T1) 
and transversal (T2) relaxation times of the protons, with a more pronounced effect on 
T2.These agents normally appear hypointense in the final image (negative contrast). 
The second class of contrast agents are paramagnetic compounds of high spin 
magnetic ions such as gadolinium, that mainly reduces the T1 relaxation time and 
results in a brighter signal (hyperintense) in the final image (positive contrast) [50]. 
The use of SPIONs as contrast agent has advantages over the use of more 
conventional paramagnetic gadolinium based solutions, as they have lower toxicity 
and sub-nanomolar range detection limits, exceeding that of gadolinium by a factor of 
100 as a result of their superparamagnetic properties [51].  
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Thus far, several SPIONs preparations have already been used for clinical 
practice, especially for liver MRI, such as Ferumoxides (i.e. Endorem® in Europe, 
Feridex® in the USA and Japan) coated with dextran [52], and Ferucarbutran (i.e. 
Resovist® in Europe and Japan) coated with carboxydextran [53], currently, these 
suspensions are discontinued. Furthermore, several SPION preparations have been 
investigated in human for imaging applications, such as: (a) Feruglose (PEG-feron, 
NC100150) (ClariscanTM), a preparation of iron oxide particles stabilised with a 
coating of carbohydrate-polyethylene glycol (PEGylated starch) [54], which 
development has been discontinued, and (b) VSOP-C184, a very small 
superparamagnetic iron oxide nanoparticles coated with citrate use for angiography 
which it is at clinical trial phase I [55–57]. 
Moreover, the use of IONPs as MRI contrast agents has been exploited in 
interesting applications in tissue engineering (TE) and regenerative medicine (RM) 
such as: the in vivo tracking of stem cells labelled with IONPs, and the in vivo 
monitoring of transplanted tissues. These applications require a system being able to 
be examined over a long term (even for weeks or months). IONPs, due to their low 
cytotoxicity, offer this possibility [48]. 
MRI and MRI contrast agents are explained in detail in chapter 5 where the 
biodistribution of the magnetic nanoparticles studied in this thesis is discussed.  
1.3.1.1.1.2 Magnetic separation for purification and immunoassay  
 
The property of MNPs to be remotely controlled by an external magnetic field 
makes them a strong candidate for cell labelling/cell separation, a technique called 
magnetic activated cell sorting (MACS®). In this technique, the used MNPs are 
attached to a ligand or an antibody for certain signature molecule that is expressed in 
target cells. A fluid in which the cells of interest exist is incubating with the MNPs, 
the solution is transferred into a column followed by application of an intense 
magnetic gradient. The cells of interest remain in the column attached to the MNPs 
while remaining cells flow through. MACS technique is helpful in cell separation and  
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in blood purification by removal of specific cytokines such as interleukin-1 or tumour 
necrosis factor. An example of cell labelling/cell separation using MNPs in vivo is 
explained by Galanzha et al [58]. They explore the role of MNPs in the detection of 
circulating tumour cells -a crucial problem for the development of metastasis, whose 
early detection has important prognostic and therapeutic implications-, they 
functionalised MNP with amino-terminal fragment (ATF) to target the urokinase 
plasminogen activator receptor (uPAR) that is expressed on many cancerous cells; 
these functionalised nanoparticles (NPs) facilitate the entrapment of circulating 
tumour cells in the blood vessels under a magnet overcoming the disadvantages 
associated with ex vivo [59] and in vivo [60] methods. The technique allows early 
diagnosis of cancer and potentially prevention of metastasis.   
In addition to cell separation, MNPs can also be used in immunoassays (e.g. 
detection of viruses or assays for several hormones) [61]. 
1.3.1.1.2 Use of superparamagnetic iron oxide nanoparticles in therapy  
1.3.1.1.2.1 Hyperthermia  
 
Hyperthermia based on MNPs is one of the most promising approaches for cancer 
therapy. The procedure involves the dispersion of MNPs throughout the target tissue, 
followed by the application of an alternating magnetic field (AMF) in the radio-
frequencies wave range, resulting in the conversion of magnetic energy into thermal 
one by hysteresis loss or Néel relaxation depending on the particle size. This heat is 
released to the immediately surrounding tissue, leading to increase the tumour 
temperature (41-46 ºC) which causes cell death by either apoptosis or necrosis. It is 
well established that tumour cells are more sensitive to the high temperature than 
healthy cells. Depending on the temperature and duration of heating hyperthermia 
either results in direct killing of tumour cells or increase their sensitivity to radio- or 
chemotherapy [62]. 
Conventional hyperthermia treatment (e.g. whole-body hyperthermia) inevitably 
damages healthy cells. MNPs based intracellular hyperthermia overcomes this 
shortcoming [63]. The concept of intracellular hyperthermia using dextran magnetite 
nanoparticles was proposed in 1979 by Gordon et al. [64]. The group at Berlin´s 
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Charité Hospital, led by Andreas Jordan, has been developing hyperthermia using 
MNPs since 1993 [65]. Nowadays, there are Clinical trials in phase II in Germany to 
perform hyperthermia on human patients using IONPs by direct injection 
hyperthermia (DIH) into two kinds of tumours: glioblastoma and prostate [66–69]. 
It has been reported that the nanoparticle physicochemical properties, such as size 
[70], surface coating [69] and charge [71] affect the specific absorption rate (SAR), 
which indicates the heat evolution rate in hyperthermia. In the case of magnetite, the 
SAR of 35 nm particles is much higher than that of 10 nm particles [70,72].  
Till now, hyperthermia is commonly based on the direct injection of highly-
concentrated NPs solutions into solid tumours, since the tumour passive-targeting of 
NPs leads to quite low particles concentration in the tumour cells. Therefore, a new 
trend geared toward synthesising specific targeted NPs for hyperthermia has emerged 
[73]. The problem of the systemic administration of these compounds is the low 
particle concentration within the tumour. To overcome this problem is at the forefront 
of current research, either by developing more efficient MNPs solution or by 
improving targeting. 
1.3.1.1.2.2 Drug delivery  
 
Conventional drug delivery is associated with several disadvantages such as low local 
drug concentration, systemic toxicity, etc. Therefore, development of new 
pharmaceutical techniques for targeted drug delivery has gained immense attention. 
MNPs are considered as a promising tool for targeted drug delivery. The magnetic 
functionality enables MNPs to be guided to certain target site using an external 
magnetic field gradient. 
Targeting can also be achieved through direct conjugation of a target moiety 
(antibody, peptide or aptamer) to the MNP surface. Several studies showed the ability 
of the MNPs to deliver the drug to its target site with better therapeutic efficiency than 
free drugs [74]. Two strategies are followed nowadays to exploit the magnetic 
functionality for stimuli-responsive drug delivery of MNPs: (i) application of  
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oscillating magnetic field, leading the particles to warm their coating and releasing the 
drug (ii) the capacity of MNPs to also heat their environment can lead to accelerate 
drug diffusion [44,75].  The delivery ability of MNPs is not limited to drug, but also 
extends to genes [76].  
Under correct design MNPs could act as a theranostic tool; thanks to their unique 
physicochemical and magnetic properties, as they would act as targeted drug/gene 
delivery carrier in a combination with MRI in order to monitor the delivery, and/or in 
combination with the hyperthermia to facilitate drug release and increase the 
therapeutic efficiency, or they would act by themselves as agent for hyperthermia and 
monitored by MRI. All these functions can be used simultaneously [77]. 
1.4 Hurdles in nanomaterials design for successful biomedical applications 
Adequate design does not restrict just to chemical aspects, as important 
requirements in a nanomaterial for its use in medical applications have also to be 
considered. Instead, it requires a holistic approach where the exchange of information 
between medical doctors and biologists, chemists, physicists, and materials scientists 
will pave the way to achieve this goal.  
This section focuses on some important aspects that should be taken into account 
while designing a nanomaterial for its biomedical applications.  
1.4.1 Nanomaterial core  
 
Choosing the nanomaterial core is an important issue that basically depends on 
the purpose of use and advantages/disadvantages considerations offered by the 
nanomaterial itself.  
As mentioned before, there are two types of nanomaterials; organic and inorganic, 
both are involved in many biomedical applications, therefore, we will briefly review 
some examples:  
 Quantum dots (QDs): they provide a mean for several biomedical  
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applications such as in vivo imaging, drug delivery, biosensing, cell 
labelling, immunolabelling, can be used in fluorescence resonance energy 
transfer (FRET) technology and serve as ideal flourophores for 
ultrasensitive, multicolour and multiplexing applications in molecular 
biotechnology and bioengineering [36,78,79]. These applications rely on 
the several advantages offered by QDs, such as water solubility, broad 
excitation spectra, tuneable emission spectra, narrow symmetric emission 
spectra and high photostability [80]. However, the toxicity of some QDs 
is one of the biggest obstacles for their use in biological systems [81]. 
 Superparamagnetic iron oxide nanoparticles: they offer attractive 
biomedical applications such as contrast agent for MRI [82], targeted 
drug and gene delivery system [83], agents for hyperthermia [69], 
bioseparation [84], immunisation [85], tissue repair [86] and 
detoxification of biological fluids [87]. Such a large variety of uses for an 
inorganic nanomaterial arises from their magnetic functionality, high field 
irreversibility, high saturation field, low toxicity, biodegradability, deep 
tissue imaging and their non-invasive tool characteristics. Thus, SPIONs 
can be moved or fixed by magnetic field gradients, they modify the 
relaxation time of neighbour protons providing strong contrast 
enhancement in MRI and they can convert magnetic energy into heat 
under the effects of an AMF in hyperthermia processes with lower 
adverse effects than radiotherapy or chemotherapy [88]. 
 Liposomes:  they are organic nanomaterials possessing several 
advantages such as amphiphilicity, biodegradability, low toxicity, ease 
modification and targeting potential [20]. They are, therefore, used 
extensively as a targeted delivery system for drugs, vaccine, anticancer 
and genes [89], as well as a mean for molecular imaging [90] and 
hyperthermia [31]. Although liposomes serve as a good model for 
targeted delivery, these nanomaterials are accompanied with several 
limitations such as lack of controlled release properties, limited drug 
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loading volume, oxidation of liposomal phospholipid and poor shelf 
stability [91].  
1.4.2 Stability  
 
The in vitro and in vivo stability of the nanomaterial suspension is an utmost important 
issue. In both cases, stability is achieved through grafting or adsorption of a polymeric 
surfactant or other modifiers to the nanomaterial surface, forming a layer that prevents 
nanomaterial flocculation [92]. Moreover, the polymer coating can decrease the 
protein adsorption to the NPs surface. As in the case of MNPs without surface 
modification, and according to the pH and the ionic strength of the suspending media, 
nanoparticles can tend to agglomerate, which in turns has a negative impact on their in 
vitro and in vivo behaviour and properties. Upon intravenous injection. Agglomeration 
of MNPs results in increasing the nanoparticle size, which in turn affects on:  
 The NP biodistribution. For instance, NPs with a size more than 200 nm 
accumulate more in the spleen [93],  
 The NP internalisation into the cell. As each cell has its own optimum 
size for higher NPs uptake,  
  The subcellular fate of the NPs. Since there are several mechanisms on 
the cell plasma membrane that are responsible for NPs internalisation, 
these mechanisms differ according to NPs size [94]. For example, NPs of 
60 nm size are internalised through a mechanism known as caveolin-
mediated endocytosis, which bypasses the endolysosomal system and 
ends at the cytoplasm. On the other hand, NPs with about 120 nm size are 
internalised through a mechanism known as clathrin-mediated 
endocytosis, which ends at the endolysosomal system. In some cases this 
is undesirable due to the harsh acidic condition that may cause acid 
etching of the MNPs causing a loss of magnetic properties and inducing 
toxicity. In contrast, presence of the nanomaterial in the endolysosomal 
compartements maybe favourable, as it is the case of stimuli-responsive 
nanomaterials, releasing their cargo (e.g. drugs) under acidic condition, 
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 The superparamagnetic properties of the NPs. Since the increase in size 
over a given value reduces superparamagnetic properties. 
Besides size effects, the hydrophobic surface of a NP has also a negative impact 
on its behaviour, since upon intravenous injection, NPs become in contact with blood 
that contains about 3700 types of plasma proteins. Several types of protein called 
opsonin, such as immunoglobulin, complement proteins, etc., are adsorbed at the 
hydrophobic surface of the NPs forming a protein corona, which produces signals to 
macrophages to come in order to eliminate the NPs from the circulation and send them 
to the liver, spleen or bone marrow. This process is known as opsonisation, see Fig. 
1.6(a). 
Protein corona formation affects to the NPs circulation time, biodistribution, 
clearance, cellular uptake and immunogenicity. A way to resist the protein adsorption, 
thus increasing NPs blood circulation time, and to reduce NPs aggregation is to carry 
out surface modification through polymeric coating. The used polymers are either 
synthetic or naturally and they are either physically or chemically adsorbed to the NPs 
surface. The most commonly used polymer is polyethylene glycol (PEG) since it is 
inexpensive, versatile and is currently listed as “generally recognised as safe” (GRAS) 
by FDA. Addition of PEG to the NPs surface (PEGylation) increases the blood 
circulation time, reduces the non-specific binding of proteins Fig. 1.6(b), and reduces 
NPs aggregation, resulting in so called “stealth” behaviour [95]. 
1.4.3 Targeting  
 
One of the factors governing NPs efficiency is their ability to specifically reach to 
their action site (targeting). Targeting of a nanomaterial refers to differential spatial 
localisation of the nanomaterial, which could be achieved through two ways: passive 
targeting or active targeting. Passive targeting could be accomplished by: 
 Direct injection of the nanomaterial into the tumour site, which is helpful 
in case of local cancers such as prostate, head and neck cancers 
developing sufficiently large tumours [21].  
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Figure 1.6: Effect of surface modification on the NP circulating time: (a) uncoated NP, the hydrophobic 
surface of the NP permits the adsorption of opsonin proteins (a2), which in turn facilitate the uptake of the 
NP by the macrophages (a3), and their accumulation in the liver (a4). (b) PEGylated NP, the PEG coating 
reduces the non-specific protein adsorption to the NP surface (b2), increasing the NP circulation time (b3) 
[95]. 
 Enhanced permeability and retention mechanism that was discovered by 
Matsumura and Maeda. [96,97] and is only relevant to oncology 
applications. This mechanism exploits the anatomical difference between 
normal and tumour tissues. Tumour vasculature has endothelium 
discontinuities forming pores with average size ranging between 400-600 
nm [98]. This allows a larger accumulation of circulating nanomaterials 
(with a molecular weight above 50 kDa [20]) in tumour tissues than in 
normal tissues with slower clearance due to lack of effective tumour 
lymphatic drainage [99,100]. The process is schematically represented in 
Fig. 1.7(a) [101]. EPR also occurs in inflammatory diseases, but with 
shorter retention time compared to cancer. EPR effect has been observed 
for a wide range of nanomaterials such as SPIONs, liposomes and 
micelles. EPR is associated with several limitations: (1) In large tumours, 
EPR is absent in the tumour centre, thus causing a decrease of 
nanomaterial accumulation, (2) The tumour tissue has a pressure called 
interstitial fluid pressure (IFP), this pressure is higher in the tumour core, 
diminishing toward the tumour periphery, what it leads to the flow of 
nanomaterials out of the tumour. These problems can be overcome in two 
ways: (a) Enhancing EPR effect with decreasing tumour pressure through  
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co-administration of an adjuvant in addition to nanomaterial injections. 
Adjuvant can be such as vascular endothelial growth factor (VSGF), 
bradykinin, nitric oxide, prostaglandins, and transforming growth factor 
beta (TGFβ) receptor inhibitor. (b) Active targeted nanomaterials. 
Active targeting is relevant to oncology applications and other therapeutic areas. 
This process is achieved by direct conjugation of the nanomaterial to a site-specific 
targeting moiety, as shown in Fig 1.7(b).  
Figure 1.7: Schematic presentation for nanomaterials targeting: (a) passive targeting through enhanced 
permeability and retention and, (b) active targeting [101].  
 
Targeting success depends on choosing the targeting moiety. It should fulfil 
several criteria such as low toxicity, abundance, high affinity and specificity toward 
their receptors at the target site and well suited to chemical modifications by 
conjugation. In addition, in order to avoid the toxicity of non-target tissues, targeted 
nanomaterials should bind to signature molecules that are exclusively expressed by the 
target site (e.g. Prostate-specific membrane antigen (PSMA)). Otherwise undesired 
effects can arise, as it is the case of targeting transferrin [22] and folate receptors 
[102]. These receptors are over-expressed by tumour cells and also are expressed to  
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some degree on many types of non-to-be-targeted cells [15,16] with the result that 
toxic off-target effects cannot be totally eliminated.  
The targeting moiety could be antibodies [23] and their molecular fragments 
[103], proteins [22] or protein-like molecules, nucleic acid ligand (including aptamer 
[24]) and small molecules such as vitamins [104], peptides [105] and carbohydrates 
[106]. 
Conjugating the targeting moiety to the nanomaterial increases the localisation of 
the nanomaterial inside target cells. Park et al. showed that antibody- targeted 
liposomes (Anti-HER2 immunoliposomes containing doxorubicin) have a higher anti-
tumour effect in compared with non-targeted counterparts (Liposomes with 
doxorubicin) [107]. Few years later, Kirpotin et al. disclosed that both targeted and 
non-targeted liposomes are similarly accumulated in the tumour tissue, and the 
enhanced anti-tumour effect of the targeted liposomes is due to their localisation in 
tumour cells, whereas, the non-targeted liposomes are in extracellular stroma or within 
macrophages [108]. 
 Recently, the attention of scientists has geared toward the subcellular organelles 
targeting, as the efficiency of nanomaterials could depend on their localisation in a 
certain organelle. This is the case of gene delivery, in which the nanomaterial 
containing oligonucleotides as a cargo should be targeted to specific cells, breach the 
plasma membrane, escape from the endolysosomal compartements in order to avoid 
the cargo degradation under acidic conditions and then internalise to the nucleus 
through the nuclear pore with the help of a nanomaterial surface conjugated peptide 
called nuclear localising signal (NLS). 
Many technological trends for effective organelle targeting are emerging, such as 
those for targeted delivery to the nucleus [109,110], mitochondria [111], cytosol [112] 
and endosome/lysosome [113]. 
1.4.4 Reporter nanomaterial   
 
The development of an efficient targeted nanomaterial does not entitle a positive 
confirmation of the site-specific delivery. Moreover, tracking the nanomaterials inside    
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the cell is mandatory to explore the nanomaterial localisation in the subcellular 
organelles and their use for molecular imaging and biosensing. 
Nanomaterials by themselves can possess properties that facilitate their detection 
in vivo or in vitro such as fluorescent, optical or magnetic properties as in the case of 
quantum dots, gold nanoparticles or magnetic nanoparticles, respectively. However, 
several types of nanomaterials do not possess these previously mentioned properties, 
lacking therefore a way of detection. That is the case of polymeric nanoparticles, 
ceramic nanoparticles, liposomes, etc. Thus, conjugating the nanomaterial to a 
fluorescent probe is recommended. Fluorescent probes can be either organic such as 
dyes, fluorescent proteins and intrinsic fluorophores or inorganic such as lanthanides 
and QDs. Organic-based fluorescent dyes are widely used in research and diagnostic 
applications. However, they are associated with many disadvantages, such as 
fluorescence bleaching, the requirement of coloured matched lasers, etc. Fluorescent 
nanomaterials (e.g. QDs) can overcome all these disadvantages improving the 
fluorescent probes utility in the clinical diagnosis [114,115]. However, they can have 
high toxicity. Several criteria must be taken into account during the selection of the 
fluorescent probe, such as low toxicity, biodegradability, high photostability, high and 
spectrally narrow absorption and emission cross sections and ultrasensitive detection. 
Fluorescent-SPIONs are considered as dual reporter nanoparticles, where they 
could be detected through two ways, MRI and fluorescence, as shown in a study 
carried out by Lee et al. In this study they evaluate the stem cell labelling by 
fluorescent-SPIONs (in vitro) using MRI and fluorescent microscopy. In addition they 
showed the ability of fluorescent-SPIONs to track labelled human mesenchymal stem 
cells in vivo through fluorescent and MR imaging [116]. 
1.4.5 Monodispersity  
 
Monodispersity means the state of uniformity. A monodispersed nanomaterial 
solution means that all nanomaterials in that solution have a narrow distribution of 
sizes. The main challenge faced by chemists during nanomaterials synthesis is  
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controlling the polydispersity that has many adverse effects at different levels: (i) At 
the biological level, it can affect the nanomaterial breaching ability, since the size and 
the size distribution are important in case of plasma membrane breaching and the 
passage through pores such as nuclear pores. Therefore, controlling the polydispersity 
is crucial; otherwise different batches of the same nanomaterial might display different 
behaviour inside the cell. (ii) At the physical level, it could affect the quantum effects 
of the nanomaterial that are size-dependent. For instance, (a) a tight control of 
nanomaterial size and a narrow distribution of sizes are mandatory to obtain a very 
efficient fluorescent probes capable of emitting narrow light in a very wide range of 
wavelengths [14]; (b) the magnetic properties of MNP are affected by the size 
distribution [117]. 
1.4.6 Nanomaterial physicochemical properties  
1.4.6.1 Size  
 
During the nanomaterial synthesis several factors could affect the nanomaterial 
size such as reactant concentrations, reaction temperature and solvent conditions [2]. 
Moreover, it is evident that nanomaterial size is completely depending on the surface 
charge and the suspending medium conditions (e.g. pH, ionic strength, organic 
molecules). For instance, the nanomaterial size in the blood increases due to protein 
adsorption and formation of protein corona, as mentioned by Dobrovolskaia et al. 
[118]. Therefore, characterisation of the nanomaterial in its relevant solution is 
mandatory. 
The size of the nanomaterial has an impact on: (i) The nanomaterial 
biodistribution and circulation half-life time upon in vivo administration. Several 
studies proved those nanomaterials with sizes less than 5 nm are rapidly cleared from 
the circulation through extravasation or renal clearance [119] whereas nanomaterials 
with sizes larger than 200 nm are sequestered by the spleen as results of mechanical 
filtration and removal by reticuloendothelial system (RES) [97]. Therefore, 
nanomaterials with sizes ranging from 10-100 nm are optimal for long blood 
circulation time upon intravenous injection [120]. (ii) The nanomaterial toxicity, as the  
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size enables the nanomaterials to reach places where larger materials cannot enter, 
thus modifying nanomaterial toxicity. (iii) The cellular uptake rate of nanomaterials, 
as each cell has its own optimum size for higher nanomaterial uptake. (iv) The 
internalisation mechanism and consequently the subcellular fate of the nanomaterials 
(detailed discussions on the internalisation mechanisms and their implication for 
nanomaterial uptake are given in chapter 3).  
1.4.6.2 Shape 
 
Several studies have demonstrated the effect of the shape on the nanomaterial 
cellular uptake and biodistribution. For instance, it has been showed that the spherical 
shaped nanomaterials are taken up by cells better than rod shaped ones; which is 
explained by the greater time needed for membrane wrapping of elongated 
nanomaterials [121]. 
Other studies showed that long filamentous nanomaterials have long blood 
circulation half-life time in compared with short filamentous and spherical shaped 
counterparts [122]. These results are not absolute since they depend on other factors, 
such as nanomaterial size, charge, surface coating, etc. Therefore, scientists developed 
a technique called particle replication in non-wetting template (PRINT) in order to 
study the effect of the shape independently of the other factors. 
1.4.6.3 Charge 
 
The nanomaterial surface charge is the major factor that contributes to the 
nanomaterial cellular uptake, biodistibution and toxicity. Studies have showed that 
charged nanomaterials are taken up better by the cells than their neutral counterparts. 
However, charged nanomaterials have short circulation half-life time due to the non-
specific protein adsorption and clearance by RES. Positively-charged nanomaterials 
have a wide popularity in nanomedical applications due to their efficient cellular 
internalisation and endosomal escape, but their toxic and immunogenic effect is a 
subject of controversy [91]. 
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1.5 Nanotoxicity  
Since the ancient times, human beings and environment have been exposed to 
natural nanomaterials (e.g. viruses, forest fires, etc.). Over the years, this exposure has 
increased due to the unintentional or intentional anthropogenic activities. The great 
advance in nanotechnology at the industrial, biological and medical levels is one of the 
major anthropogenic sources of exposure. In addition, the nanomaterial involvement 
in biomedical application such as MRI, optical imaging, drug delivery, etc., has also to 
be taken into account. Nowadays, more than 1000 consumer products containing 
nanomaterials are available on the market such as sunscreens, dental bonding, paints, 
textile, computer chips, cell phones, etc. Also, nanomaterials are involved in 
environmental nano-remediation. These vast applications are due to the unique 
physicochemical properties of nanomaterials. However, the same properties that make 
the nanomaterials useful in many applications also have a negative impact on human 
and environment. Nanomaterials gain access into human body through dermal 
exposure, inhalation, gastrointestinal or injection. 
Several studies showed that nanomaterials induce damages to the subcellular 
organelles such as mitochondria [123] and nucleus [124]. Other studies showed that 
nanomaterials have the ability to alter the blood coagulation pathway [125], induce 
platelet aggregation [125] or cause haemolysis [126]. Moreover, several studies 
showed that nanomaterials in direct contact with cell surface may lead to: (i) 
formation of reactive oxygen species (ROS) resulting in oxidative stress and 
inflammation [6]; (ii) lipid peroxidation, resulting in cell damage [127], and (iii) 
up/down regulation for genes, resulting in cell dysfunction [128]. Therefore, several 
nanomaterials have been reported as cytotoxic [129,130], neurotoxic [131,132], 
haemotoxic [133,134], genotoxic [135,136], ecotoxic [137,138] or bactericidal [139]. 
Based on the foregoing, full attention must be given to the safety and 
nanotoxicological issues for the new synthesised nanomaterials. Therefore, 
nanotoxicology is considered an important issue for study and will occupy a major 
part of this thesis. 
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1.6 Purpose of the thesis 
The main rationale of the thesis is to study the toxicological behaviour of our 
polymer based superparamagnetic iron oxide nanoparticles in vitro and in vivo, in 
order to introduce them in the market as a therapeutic tool (agents for hyperthermia) or 
as a diagnostic tool (MRI contrast agents). 
Being this thesis the first one in the group aimed to investigate the toxicity and 
biodistribution behaviour of the magnetic nanoparticles and their stable suspension in 
phosphate buffered saline (in the following called bioferrofluids), i will make rather 
extensive introductions to each chapter. Experiments, however, will concentrate on 
specific goals, as natural time limitations of a thesis precludes more comprehensive 
approaches. In the following i will describe the general characterisation of the 
bioferrofluids utilised and will list the specific objectives of the thesis. In each chapter 
specific goals will also be provided. 
1.6.1 Bioferrofluids description 
 
Our bioferrofluids consist on maghemite/polymer composite beads dispersed in 
phosphate buffered saline at pH 7.40. Each bead consists on several maghemite (ɣ-
Fe2O3) nanoparticles embedded within a hydrophobic poly(4-vinylpyridine) (P4VP) 
polymer, and covered with a shell of hydrophilic chains of APEG(200). Samples used 
in this work have a fraction of PEG chains functionalised with carboxylate groups 
(APEG(1000)-COO-) that allows the conjugation of antibodies, peptides, fluorescent 
dye, pharmaceutical agent, etc. In fact, one of the samples used in this work contains a 
fraction of PEG chains functionalised with fluorescein molecules attached covalently 
to the end of the chains. These fluorescent nanoparticles are used in chapter 3. The 
maghemite/polymer composite bead structure is schematically shown in Fig 1.8. 
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Figure 1.8: Schematic illustration of the maghemite/polymer composite bead structure. 
1.6.2 Specific goals of the thesis  
 
This aim will be achieved through several studies. In this thesis we have 
accomplished some of them such as:  
1) Cytotoxicity studies (the content of chapter 2), which aim to study the 
effect of nanoparticle size and cell type on nanoparticles toxicity.  
2) Nano-bio interface studies (the content of chapter 3), which aim to give 
an explanation for the results of the previous chapter through studying the 
effect of nanoparticle size and cell type on the cellular uptake rate and 
endocytosis mechanism. 
3) Haematotoxicity studies (the content of chapter 4), which aim to study the 
effect of nanoparticle and its compositions on the coagulation process, 
blood cell count and haemolysis in vitro as these nanoparticles are 
designed for iv injection. 
4) Evaluation of SPIONs as a MRI contrast agent and biodistribution and  
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toxicity studies in vivo (the content of chapter 5), which aim to study the 
relaxivity of the less toxic nanoparticles in vitro in compared to 
commercialised contrast agent “Endorem®”, studying the biodistribution 
of the less toxic nanoparticles in vivo using MRI and histological studies 
for their toxic effects in organs. 
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Chapter 2 
In vitro cytotoxicity studies of 
superparamagnetic iron oxide 
nanoparticles 
2.1 Introduction  
With the great advances in nanotechnology at the industrial, biological and 
medical levels, human beings and their environment frequently become exposed to 
nanomaterials [1]. The same unique physicochemical properties that make 
nanomaterials attractive for applications could also cause harm when nanomaterials 
interact with biological systems and environment [2]. Therefore, exposure risks, 
toxicity mechanisms and route of entry need to be well understood. Based on that, a 
new branch of science known as “nanotoxicology” has emerged. Nanotoxicology is 
different than classical toxicology; while in classical toxicology the factor for 
considering the dose-effect relationship is the mass/concentration, in nanotoxicology 
several other factors are involved in addition, such as size, shape, surface area and 
surface modification [3]. 
2.1.1 A brief example about nanohazards: Learning from the past is setting out the 
future 
 
This section shows how negligence in taking preventive measures can lead to 
lives loss, and it should be a lesson to be learned amid the vast introduction of 
nanomaterials in the market. 
The story began with two toxic substances from peacetime technologies that 
emerged above all others in terms of death casualties: quartz and asbestos. The   
 
 
 
 
42   Chapter 2.  Cytotoxicity studies 
 
toxicity caused by the inhalation of fine particles of these two substances was 
recognised in the eighteenth century and at the end of nineteenth century, respectively 
Therefore, understanding the toxicity mechanism of these substances was a 
subject that drew the attention of the concerned industries and scientists. 
Unfortunately, appropriate epidemiological research to associate exposure and effect 
was long overdue, while applying preventive measures were not introduced, and 
workers died and still continue doing it nowadays. Therefore, we must be alert; it is 
not necessary to understand mechanisms before taking strides to prevent an 
occupational or environmental disease [4]. 
In the twentieth century, the impact of the air pollution on the public health has 
garnered immense attention; especially after a series of disasters that cost in lives lost, 
such as the 1930 Meuse Valley fog in Belgium, the 1948 Donora smog in 
Pennsylvania and the infamous London smog of 5-9th December 1952 that 
contributed to at least 4,000 deaths in its duration Fig. 2.1. These deaths were due to 
lung disease and acute cardiac failure, with or without obvious cardio-vascular 
pathology. Studies showed that no single agent was considered to be at the origin of 
the severe respiratory symptoms and death; however it was a combination of 
contaminants, especially irritant contaminants derived from combustion of coal and its 
products what were considered as the mainly responsibles for death [5].   
Figure 2.1: Headers of press coverage from Guardian Journal on London's smog disaster [10].  
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After the London’s smog, United Kingdom (UK) had set an example of the 
effective regulation to reduce pollution through “Clean Air Acts” in 1956. In 1968 
Lawther et al. demonstrated that over half of the particles in London smog were less 
than 100 nm in diameter; however, these crucial results were ignored for 25 years [4]. 
The toxicological effects of airborne ultrafine particles (UFPs or PM0.1 are a fraction 
of ambient particulate matter (PM) with a diameter less than 0.1 µm [6]) have been 
addressed in several studies [6–9]. 
2.1.2 Nanotoxicology  
 
Epidemiological and toxicological studies with airborne UFPs can be considered 
as the origin of the nanotoxicology field [2]. Nanotoxicology refers to the study of the 
interactions of nanomaterials with biological systems, with emphasis on elucidating 
the relationships between each nanomaterial physicochemical properties and the 
induction of toxic responses [11], Therefore, this type of studies helps to design new 
nanomaterials with lower adverse effects on health. Nanotoxicology is considered an 
interdisciplinary branch of science that needs the collaboration of toxicology, 
materials science, medicine and molecular biology to reach appropriate risk 
assessments (benefits/side effects evaluation). Nanotoxicology encompasses many 
items of study such as routes of exposure, targets of nanomaterials, biodistribution, 
physicochemical properties, molecular determinant, genotoxicity, and regulatory 
issues Fig. 2.2. As detailed below, this chapter will focus on the cytotoxicity of the 
magnetic nanoparticles and their bioferrofluids whose biocompatibility is studied in 
this Thesis. 
2.1.2.1 Routes of exposure to nanomaterials  
 
The term “exposure to nanomaterials” is not a neoteric one, as humans have been 
exposed to nanomaterials during their evolutionary phases. However, this exposure 
has increased to a great extent due to several anthropogenic sources such as the 
industry evolution, combustion-based engine transportation and finally the 
nanotechnology developments [13]. Paradigms of natural and anthropogenic sources 
of nanomaterials are summarised in Table 2.1. 
 
 
 
 
44   Chapter 2.  Cytotoxicity studies 
 
Figure 2.2: Complex array of issues surrounding toxicity of nanomaterials [12].   
Table 2.1: Paradigms of natural and anthropogenic sources of nanomaterials [2]. 
 
The exposure of the population to nanomaterials can be either (a) indirect, as a 
result of environmental contaminations with nanomaterials, coming from natural 
phenomena, nano-remediation or spillage of nanomaterials during industrial process, 
etc. or  (b) direct, as occupational exposure in workplaces, exposure from medical or 
consumer products, etc. [3].Nanomaterials are internalised into the human body via 
inhalation, ingestion, dermal exposure and injection (e.g. intravenous, subcutaneous, 
intraperitoneal or intramuscular) as in case of diagnostic/therapeutic nanomaterials, 
their nano-size enables them to deposit in several organs or translocate from their   
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 original site of entry to other sites in the body [14], causing toxic effects such as in 
case of inhaled nanomaterials though occupational exposure, air pollution or medical 
treatment Fig. 2.3. A number of investigators have discovered the toxicity of several 
nanomaterials in various organs [6,15–20]. 
 
Figure 2.3: Schematic representation of nanomaterials translocation from the lung to regional lymph 
nodes and blood circulation and then their accumulation in various secondary organs of the body, AM is 
alveolar macrophages [21].  
2.1.2.2 Toxicological mechanisms of nanomaterials 
 
Here we will explain the general mechanisms responsible for the cytotoxicity 
using examples related to SPIONs, as these are the nanoparticles that we are interested 
in.  
Iron is an important element that plays a significant role in cell physiology, as it is 
responsible for cell growth and multiplication in view of its role in DNA synthesis 
[22]. According to that, IONPs were initially considered to be a non-cytotoxic, as they 
are biodegradable releasing ferric ion, which can enter to the iron pool and participate  
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in normal iron metabolism. However, several studies showed that small IONPs might 
cause toxic effect as they can reach high local concentrations within the cells and 
become more difficult to be cleared from the body [23].   
2.1.2.2.1 Physicochemical properties dependent toxicity  
 
In fact, nanomaterials physicochemical properties, uptake and toxicity are three 
axes related to each other. Nano-sized materials are considered more toxic than larger 
size ones of the same material [8,20], however, a study carried out by Karlsson et al. 
showed that not in all cases the nano-sized materials are toxic in compared to micro-
sized ones of the same material [24], this study was consistent with a study carried out 
by Warheit et al. [25]. The “nano” size enables the nanomaterials to reach places 
where the larger materials cannot enter, such as nucleus [26] or transfer across the 
placental barrier from pregnant mice to pups [27]. The “nano” size with its 
corresponding high surface to volume ratio increases the biological reactivity of the 
nanomaterial due to different interactions with the cell and its components [1]. This 
increased biological reactivity could be desirable (e.g. antioxidant activity) or 
undesirable (e.g. toxicity, induction of oxidative stress or of cellular dysfunction) [2]. 
Mahmoudi et al. illustrated the effect of the surface coating, the hydrodynamic 
diameter and shape of SPIONs on the cell toxicity. Their results showed that coated 
SPIONs are less toxic than uncoated ones, the lower toxicity is achieved by increasing 
the hydrodynamic diameter, and finally the toxicity of SPIONs at the same 
concentration is increased as cells interact with nanobeads, nanoworms and 
nanosphere [28]. The relation between toxicity and nanomaterial surface charge has 
been reported in several studies illustrating that charged nanomaterials are more toxic 
than neutral charged ones [29,30]. Chemical composition is another factor that could 
affect the cytotoxicity. A study carried out Karlsson et al. , showed that both Fe2O3 
and Fe3O4 have less toxic effect on cultured cells independently on their size (micro or 
nano). In contrast, other metal oxides such as nano-sized CuO is more toxic than 
micro-sized CuO due to the high surface reactivity [24]. 
2.1.2.2.2 Molecular actions dependent toxicity  
 
Nanomaterials can cause cell toxicity through several mechanisms such as:
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Oxidative stress: Oxidative stress is a state that reflects the imbalance between 
the production of reactive oxygen species and the ability of the cell to detoxify or 
repair it. ROS species can be subdivided into two groups: radical ROS (such as 
superoxide anion (O2•-), hydroxyl radical (OH•)), and non-radical ROS (such as 
hydrogen peroxide (H2O2)). Under normal conditions, ROS are produced by the cells 
as a consequence of aerobic metabolism [31]. Cells can tolerate a small and transient 
increase in ROS by an antioxidant defence mechanism.  
The antioxidant mechanism can be divided into (a) primary defence mechanism, 
which includes several enzymes such as superoxide dismutase, catalase, glutathione 
peroxidase and reductase, and (b) secondary defence mechanism, that is carried out 
through reduction of glutathione (GSH) [32]. Under normal conditions, more than 
95% of glutathione in cells exists in the reduced form (GSH). Reduced levels of GSH 
will lead to a decrease of the cell capacity to clean ROS and, therefore, to allow 
oxidative stress.  
On the other hand, cells exposed to an environmental stress (such as pathogen or 
heat) induce a high level of ROS in response. If this high level of ROS persists for 
long time and cells fail to tolerate it, oxidative stress will be enhanced, resulting in 
oxidation of proteins, lipids (lipid peroxidation) and DNA (DNA strand breaks), as 
well as it will give rise to apoptosis or necrosis. Oxidations of protein and DNA have 
been shown to play a key role in the development of cancer, arteriosclerosis, arthritis 
and neurodegenerative disorders [33].  
Nanomaterials favour the formation of ROS when exposed to light, ultraviolet 
(UV) light or acidic environment (e.g. lysosomes) or as a result of interaction with 
cellular components (e.g. mitochondria, redox-active proteins such as NADPH 
oxidase or cell surface receptors), possible mechanisms for ROS production by 
nanomaterials are shown in Fig. 2.4 [1,23]. 
Oxidative stress induced by nanomaterials enhances inflammation through 
upregulation of redox-sensitive transcription factors, including nuclear factor kappa B 
(NF-KB), and activated protein 1 (AP-1) [34]. 
In the case of SPIONs, ROS are induced as a consequence of their degradation in   
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the lysosomes, Fig 2.4(a), with the consequent release of ferrous ions. These free ions 
can cross the mitochondrial membrane to induce ROS through Fenton reaction 
(Equation 2.1) [35].  
H2O2+ Fe2+ -- Fe3++OH-+ OH•             (Equation 2.1) 
Figure 2.4: Schematic illustration of the different mechanisms of ROS induction by the nanomaterials (a) 
existence of nanomaterial under harsh acidic conditions (e.g lysosomes) induces ROS, as a result of 
coating surface reactivity, metal surface exposure to acidic environment or due to leached ions (Fe2+, 
Cd2+), (b) interaction of nanomaterials  with mitochondria, causing mitochondria dysfunction, (c) 
interaction of nanomaterials with redox active protein such as NADPH oxidase, stimulating production of 
high amount of ROS in immune system cells, (d) interaction of nanomaterial with surface receptors, 
activating the intracellular signalling pathways, leading to expression of stress response genes which up-
regulate ROS [23].    
Up to date, the link between ROS induction by SPIONs and cell toxicity remains 
unclear. Some studies show that IONP have the ability of ROS induction and 
subsequently cell damage [36], while others show that they have peroxidise-like 
activity which can diminish the cellular ROS levels [37–40]. The level of induced 
ROS depends on the total amount of surface area of internalised IONPs, and the 
stability of the coating against the intracellular degradation, for instance, citrate-coated 
IONPs have a much faster maximal ROS induction (4h) compared to dextran- or lipid-
coated IONPs [41]. 
Cytoskeleton defect: The cytoskeleton is composed of three types of filamentous 
proteins: microfilaments (actin filaments), intermediate filaments and microtubules. 
Cytoskeleton plays an important role inside the cells, as it affects to cell shape,  
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motility, division, adhesion and connection with its environment.  Furthermore, there 
is a relationship between cytoskeleton and endocytosis mechanism, as endocytosis 
develops through the reorganisation of the cytoskeleton. Therefore, the high demands 
imposed by the nanomaterials on the cellular endocytosis mechanism can affect the 
cytoskeleton network [42,43]. The association between the cytotoxicity of SPIONs 
through disruption of the cytoskeleton network and nanomaterial internalisation and 
their intracellular localisation has been described in several studies. Gupta et al. 
illustrated the relationship between the cytoskeleton deformation and the surface 
modification (coating) of SPIONs [42]. Other studies illustrate the relationship 
between the uncoated SPIONs internalisation by endocytosis and their intracellular 
localisation and cytoskeleton disorganisation [44]. Soenen et al. showed that the high 
intracellular concentration of nanoparticles transiently affects actin cytoskeleton and 
subsequently cell proliferation [45]; in another study Soenen et al. suggest that the 
mere physical presence of high level of IONPs enclosed in the lysosomes, typically 
located in the perinuclear region, diminishes the protein expression and strictly hinders 
the cytoskeleton network [46]. 
Genotoxicity and intracellular signalling alteration: Nanomaterials can induce 
genotoxic effects and alteration in the intracellular signalling pathways through two 
mechanisms:  (i) Primary genotoxicity, which is related to the direct exposure to the 
nanomaterial such as: (a) the “nano” size enables the nanomaterial to penetrate the 
nucleus and directly bind to the DNA [26,47], (b) the localisation of large number of 
nanomaterials confined in lysosomes in the perinuclear region can prevent the cellular 
transcription and translation machinery [46], and (c) leaking of metal ions from 
lysosomes containing nanomaterials can alter protein expression through mRNA 
degradation. (ii) Secondary genotoxixity, which is the result of nanomaterial-cell 
interactions and releasing of other factors such as ROS. High level of ROS induced by 
nanomaterials can directly mediate DNA damage through single or double strand 
breaks. ROS can also alter gene expression and unregulate several transcription 
factors, such as the activation of redox-sensitive transcription factors, including NF-
KB [48]. So far, the relationship between SPIONs and induction of genotoxicity is still 
ambiguous. Several studies show that SPIONs have no genotoxic effect [49], neither 
affect stem cell proliferation [50] and gene expression patterns. In contrast, other  
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studies show that SPIONs can induce genotoxic effects and inhibit stem cell 
differentiation [51].  
2.1.3 Cytotoxicity evaluation tests  
 
Many biomedical applications require the in vitro exposure of cultured cells to 
nanomaterials prior to in vivo translocation. Although in vitro studies allow simpler, 
faster and more cost-efficient assessment of defined toxicity endpoints, they do not 
reflect the real behaviour of nanomaterials in vivo. Therefore, validation and 
complementation with in vivo experiments are mandatory [11].  
Up to date, a real conclusion about in vitro toxicity of nanomaterials remains 
ambiguous. This is due to a great variety in: (1) types of nanomaterials, (2) 
nanomaterial manufacturing methods, (3) nanomaterial physicochemical properties, 
(4) coating agent, (5) type of cell culture used, (6) variation in experiment conditions 
(incubation time and concentration), (7) type of assay used and (8) possible 
interference of the nanomaterial with the assay readout. Therefore, a direct comparison 
between results obtained from different studies is out of the question [23].  
The assessment of nanomaterials cytotoxicity is based on several in vitro assays 
established for hazard characterisation of chemicals; however, nanomaterials are 
completely different and may interfere with the commonly used assays either through 
interaction with the assay components due to their high surface to volume ratio and the 
high adsorption capacity, or through interfering with the detection system due to their 
optical properties [52,53]. 
Several assays are used to investigate different aspects of nanomaterials cytotoxicity 
in vitro. (1) Cell viability assays, including determination of mitochondrial activity 
using MTT assay, assessing cell membrane integrity using lactate dehydrogenase 
(LDH), trypan blue or propidium iodide assay, determination of intracellular esterase 
activity using Calcein AM assay, detection of intact lysosomes using neutral red assay 
and detection of apoptosis using fluorescent Annexin V or Caspase substrates 
detection assay. Obviously, a comparison between the results from one assay with 
others is impossible as they measure different parameters. (2) Stress 
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response assays, including detection of ROS; detection of any possible secondary 
effects in case of significant ROS induction, such as lipid or protein peroxidation, 
cytoplasmic calcium levels, cytoplasmic redox state (GSH detection) or DNA defects. 
(3) Detection of inflammatory response by measuring inflammatory markers such as 
the chemokine interleukin-8 (IL-8), or tumour necrosis factor α (TNF-α), IL-6, or IL-
1β [52].  
2.2 Objectives 
The aim of this chapter is to study the toxicological behaviour of our 
bioferrofluids in vitro through studying their effects on cell viability using lactate 
dehydrogenase test and the Acridine orange/Ethidium bromide assay, defining the 
type of cell death (apoptosis or necrosis) using DNA fragmentation assay and 
detection of Caspase- 3 activity, investigating their ability to induce oxidative stress 
by measuring the carbonyl content and glutathione (GSH) detection, and finally, 
detection of inflammasome activation by measuring interleukin 1β. 
In vivo toxicity studies of our bioferrofluids will be discussed in chapter 5.  
2.3 Materials and methods 
2.3.1 Bioferrofluid preparation and characterisation 
 
Bioferrofluids preparation and characterisation methods are the same as described 
in Annex I.  The preparation compositions of maghemite (ɣ-Fe2O3) nanoparticles in a 
poly(4-vinylpyridine) matrix are summarised in Table 2.2. 
2.3.2 Cytotoxicity studies  
 
All cytotoxicity experiments were performed at the laboratorio de toxicología 
molecular, Facultad de veterinaria- Universidad de Zaragoza, under the supervision 
of Professor Victor Sorribas.  
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Table 2.2: Composition of maghemite–P4VP nanocomposites preparation for 
different samples.   
Sample P4VP 
(g/L) 
1M FeBr3  
(mL ) 
1M FeBr2 
(mL ) 
Fe/pyridine 
mol ratio 
Fe2+/ Fe3+ 
mol ratio 
Fe2O3  
wt % 
R1 0.80 1.27 0.64 0.25 0.50 16.00 
R2 0.80 2.54 1.27 0.50 0.50 27.60 
R3 0.80 3.81 1.90 0.75 0.50 36.30 
R4 0.80 5.08 2.54 1.00 0.50 43.20 
R7 0.80 4.23 3.39 1.00 0.80 43.20 
R8 0.80 4.01 3.61 1.00 0.90 43.20 
 
2.3.2.1 Cell culture 
 
Opossum Kidney (OK) cells were grown in 75 cm2 NunclonTM Flask as described 
in ref. [54], in Dulbecco’s Modified Eagle’s Medium (DMEM/F12) (Gibco-Life 
Technologies, Paisley, UK) supplemented with 10% fetal calf serum (FCS), 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. 
Primary cultures of rat aortic vascular smooth muscle cells (VSMC) were cultured in 
75 cm2 NunclonTM Flask as described in ref. [55], in Minimal Eagle’s Medium (MEM) 
(Gibco-Life Technologies, Paisley, UK) supplemented as for OK cells.  
Both cell lines were incubated in a 5% CO2 incubator (lab Line) at 37 ºC with 
culture medium changes every second day until they became confluent. Cells were 
then washed twice with phosphate buffered saline (PBS), trypsinised with Trypsin-
EDTA 1X (Life Technologies) and re-suspended in their appropriate cell culture 
medium. Cells were then ready to be used in other assays. The cells were passaged in 
a split ratio of 1:5 and 1:3 for OK and VSMC respectively. Cell passages were 
between 55-57 and 6 for OK and VSMC respectively. 
2.3.2.2 Cell viability assays 
2.3.2.2.1 The lactate dehydrogenase assay 
Test principle: LDH assay is a colorimetric assay based on the reduction of  
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 yellow tetrazolium salt INT to a red formazan.  
Upon membrane damage, significant amounts of LDH are released from the 
cytosol of damaged cells. The LDH activity is measured in the cell culture supernatant 
using a Cytotoxicity Detection kit (Roche, Mannheim, Germany). The reaction is 
occurred in two steps: in the first step the released LDH reduces NAD+ to NADH+H+ 
by oxidation of lactate to pyruvate. In the second step the catalyst (diaphorase) 
transfers H/H+ from NADH+H+ to the yellow tetrazolium salt INT, which is reduced 
to red formazan Fig. 2.5 [56]. 
Figure 2.5: LDH activity detection reaction.  
Method: For the determination of cytosolic lactate dehydrogenase leakage, both 
cell lines were grown in 24-well plates, as described in ref. [55], until they became 
confluent. Cells were made quiescent for 24 hours previous to the treatments with 
bioferrofluids by incubating them in culture medium containing 0.5 % FCS. After 24 
hours, the supernatants were aspirated out, cells were washed twice with PBS. Then, 
both cell lines were treated with 0.5 % FCS culture medium containing different 
dilutions (0, 10-1, 10-2, 10-3, 10-4, 10-5 and 10-6) of bioferrofluids (R1, R2, R3, R4, R7 
and R8). Cells treated with detergent 0.5% triton X-100 were considered as positive 
control Aliquots were taken from cell supernatant at different time points (0, 1, 2, 3, 4 
and 5 days) followed by centrifugation at 4ºC. Then, they were processed to measure
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the LDH activity using Cytotoxicity Detection kit with the help of DTX-880 
multimode detector system (Beckman Coulter, Indianapolis IN, USA) at 450 nm 
absorbance. Percentage of cell death was determined with respect to the maximal 
activity/absorbance obtained by positive control. The dose-response curves were 
plotted as the log Fe2O3 g/L versus the percentage of total LDH activity. The mean 
lethal concentration (LC50) was determined by non-linear regression equation using 
GraphPad Prism 5.0 software (San Diego, CA, USA).  
2.3.2.2.2 Acridine Orange/Ethidium Bromide (AO/EB) assay 
 
For microscopic evaluation of cell death, fluorescent light microscopy with 
differential uptake of fluorescent DNA binding dyes (AO/EB staining) was used.  
Test principle: Acridine orange (AO) is a nucleic acid selective fluorescent dye 
that penetrates all cells and binds to DNA and RNA, making them fluorescence green 
and red, respectively. In contrast, Ethidium Bromide (EB) is only taken up by cells 
when the cytoplasmic membrane integrity is lost and stains the nucleus red. EB 
emission dominates over AO, therefore, live cells have a normal green nucleus, early 
apoptotic cells have bright green nucleus with condensed or fragmented chromatin, 
late apoptotic cells display condensed and fragmented red chromatin, and cells that 
have died from direct necrosis have a structurally normal red nucleus. 
Method: OK cells were seeded in 8 chamber slides (BD Falcon, Erembodegem, 
Belgium), and grown in their appropriate culture medium. After overnight growth, the 
supernatants were aspirated out and the cells were treated with aliquots of 0% FCS 
culture medium containing different concentrations (0, 0.007, 0.01, 0.02 g/L Fe2O3) of 
bioferrofluids (R1 and R8) for 24 hours. After 24 hours, the supernatants were 
aspirated out and the cells were washed twice with PBS, stained with acridine orange 
plus ethidium bromide in PBS as described in ref. [57,58]. The slides were mounted 
and examined rapidly under Axiovert 200M fluorescence microscopy (Carl Zeiss, 
Jena, Germany) after excitation at 495 nm. Green and red fluorescence were detected 
simultaneously using a dual band pass filter for emission at 530 nm and 610 nm. Phase 
contrast images of cells have been taken as well. 
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2.3.2.3 Apoptosis Assays  
2.3.2.3.1 DNA fragmentation  
 
Apoptosis or program cell death plays an important role in the natural renewal of 
cells, as well as in several different disease states. During apoptosis, cells undergo 
many morphological and biochemical changes different to necrosis. One of the 
biochemical changes is the fragmentation of the nuclear DNA, producing fragments 
with length varying between 180 to 200bp.  
In order to examine the bioferrofluids ability to induce apoptosis, 
deoxynucleotidyl transferase- dUTP nick end labelling (TUNEL) fluorescent assay 
was used. 
Test principle: TUNEL assay is based on the incorporation of modified dUTP 
(e.g. fluorescein-dUTP) by the enzyme terminal deoxynucleotidyl transferase (TdT) at 
the 3’-OH ends of fragmented DNA. The modifications of dUTP are flurophores or 
small molecules, called haptens.  
Method: OK cells were seeded in 8 chamber slides and grown in their 
appropriate culture medium. After overnight growth, the supernatants were aspirated 
out and the cells were treated with aliquots of 0% FCS culture medium containing 
different concentrations (0, 0.007, 0.01, 0.02 g/L Fe2O3) of bioferrofluids (R1 and R8) 
for 24 hours. After 24 hours, the supernatants were aspirated out and the cells were 
washed twice with PBS. The cells were processed for TUNEL assay under the 
protocol instructions supplied with Click-iT TUNEL Alexa fluor-488 kit (Molecular 
Probes-Life Technologies, Paisley, UK), cells treated with DNase I were considered as 
Positive control. The slides were examined under the Axiovert 200M fluorescence 
microscopy at excitation filter of 470 ± 20 and emission filter of 525 ± 25. Phase 
contrast images of cells have been taken as well. 
2.3.2.3.2 Caspase- 3 Assay  
 
Members of the caspase family proteases (especially activated caspase-3) are  
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considered to be crucial mediators for the complex biochemical events associated with 
apoptosis. Therefore, apoptosis was also evaluated fluorometrically by measuring the 
activity of caspase-3, which is one of the most commonly used apoptosis assays. The 
cystein protease Caspase-3 is produced as a zymogen in the cytosol that is activated by 
cleavage into active caspase-3. Activated caspase-3 has substrate specificity for the 
amino acid sequence Asp-Glu-Val-Asp (DEVD) and cleaves several proteins leading 
to apoptosis. 
Test principle: In case of apoptosis, the elevated level of activated caspase-3 
produced can be detected using EnzChek® Caspase-3 Assay kit #2 (Molecular 
Probes). Activated caspase-3 detection method is based on measuring the cleavage of 
caspase-3 substrate (DEVD) that is linked to a flourophore (Rhodamine 110), the 
flourophore absorbs or emits light when it is separated from the substrate.  
Method: OK cells were seeded in 57 cm2 Petri dishes, grown in their appropriate 
culture medium until they became confluent.  The supernatants were aspirated out and 
the cells were treated with aliquots of 0% FCS culture medium containing different 
concentrations (0, 0.007, 0.01, 0.02 g/L Fe2O3) of R1 and R8 bioferrofluids for 24 
hours. After incubation, the supernatants were aspirated out, followed by cellular wash 
with PBS thrice. The cells were processed for (a) protein determination using BCATM 
protein assay kit (Thermo scientific) and (b) caspase-3 detection under the protocol 
instructions supplied with EnzChek® Caspase-3 Assay kit #2. The fluorescence was 
measured with the help of DTX-880 multimode detector system at excitation/emission 
filters of 496/520 nm. This experiment was repeated 3 times in duplicate. The Mann-
Whitney test was used for the statistical analysis of the experimental data. The results 
are presented as mean ± standard error of mean (SEM). Statistical significance was p 
< 0.05. 
2.3.2.4 Oxidative stress 
2.3.2.4.1 Carbonyl content measurement  
 
There is a debate over the IONPs and their ability to produce ROS. Many studies 
stated that IONPs have oxidative capabilities [36], while others stated that IONPs have
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 peroxidase-like activity [38]. Here we investigated the oxidative capabilities of our 
bioferrofluids by measuring the carbonyl content of the oxidised proteins. 
Proteins are one of the major targets of ROS. Upon oxidation, carbonyl groups 
(aldehydes and ketones) are introduced into protein side chains by a site-specific 
mechanism. The OxyELISA™ Oxidized Protein Quantitation Kit (Merck Millipore, 
Billerica, MA, USA) was used for sensitive immunodetection of these carbonyl 
groups. 
Test principle: The test is based on direct Enzyme-linked immunosorbent assay 
(ELISA), in which protein samples are immobilised to a 96-well microlitre plate by 
passive absorption. The carbonyl groups in the protein side chains are then derivatised 
to 2,4-dinitrophenylhydrazone (DNP-hydrazone) by reaction with 2,4-
dinitrophenylhydrazine (DNPH). The DNP-derivatised proteins are then incubated 
with a mouse monoclonal antibody (conjugated to horseradish peroxidase enzyme 
(HRP)) specific to the DNP moiety. Subsequent incubation with the enzyme substrate 
3,3’,5,5’-Tetramethylbenzidine (TMB) results in a coloured product which can be 
quantified using an spectrophotometer at 450 nm of absorbance.  
Method: OK cells were grown in 6-well plate until they became confluent; 
supernatants were then aspirated out and the cells were treated with aliquots of 0% 
FCS culture medium containing different concentrations (0, 0.0005, 0.001, 0.002, 
0.005, 0.007, 0.01, 0.02 g/L Fe2O3) of R1 bioferrofluid for 24 hours. As a positive 
control, cells were incubated with 1 mM H2O2 for 30 minutes. All samples were 
processed and analysed following the protocol instructions supplied with 
OxyELISA™ Oxidized Protein Quantitation Kit. The absorbance was measured with 
the help of DTX-880 multimode detector system at 450 nm. This experiment was 
repeated 3 times in duplicate. The Mann-Whitney test was used for the statistical 
analysis of the experimental data. The results are presented as mean ± SEM. Statistical 
significance was p < 0.05. 
2.3.2.4.2 Thiol tracker 
 
Glutathione, one of the important antioxidant compounds existing inside the cells. 
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In the absence of ROS, Glutathione exists in its reduced form (GSH) and can be 
detected through special dyes that react with its reduced thiol group (-SH). 
Test principle: test is based on using a dye that reacts with reduced thiols in 
intact cells.  
Method: OK cells were seeded in 8 chamber slides, and grown in their 
appropriate culture medium. After overnight growth, the supernatants were aspirated 
out and the cells were treated with aliquots of 0% FCS culture medium containing 
different concentrations (0, 0.007, 0.01, 0.02 g/L Fe2O3) of bioferrofluids (R1 and R8) 
for 24 hours. After 24 hours, the supernatants were aspirated out and the cells were 
washed twice with PBS. The cells were processed following the protocol instructions 
supplied with ThiolTracker™ Violet Kit (Molecular Probes). The slides were 
examined under the Axiovert 200M fluorescence microscopy at excitation/emission 
filters of 405/526 nm. In addition, GSH has been detected fluorometrically for cells 
grown in black 96-well plate (Fluoronunc, Thermo Nunc, Roskilde, Denmark), and 
treated with bioferrofluids as previously described. GSH was determined using 
ThiolTracker™ Violet kit and a DTX-880 fluorometer at excitation filter of 405 nm 
and emission filter of 526 nm. This experiment was repeated 3 times in triplicate. The 
statistical analysis of experimental data utilised the Mann-Whitney test. The results are 
presented as mean ± SEM. Statistical significance was p < 0.05. 
2.3.2.5 Inflammasome activation 
 
Inflammasome is a multiprotein complex, which participates in the production of 
the pro-inflammatory cytokines Il-1β and IL-18. The best characterised inflammasome 
is NLRP3 inflammasome, which consists of the NLR protein NLRP3, the adapter 
ASC and pro-caspase-1. Activation of the inflammasome can be triggered by several 
stimuli such as ROS, lysosomal damage, etc., resulting in release of active caspase-1, 
which in turn activates the conversion of pro-IL-1β and pro-IL-18 to active IL-1β and 
active IL-18. 
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2.3.2.5.1 Interleukin 1β measurement 
    
IL-1β is a member of IL-1 cytokine family and an important mediator of the 
inflammatory response. 
Test principle:  The test is based on sandwich ELISA, in which an antibody 
specific for rat IL-1β has been coated onto the wells of the microliter strips provided 
with Rat IL-1β ELISA kit (Life Technologies), was incubated with the samples. The 
first incubation allows the binding of the IL-1β to the immobilised antibody, after 
incubation and wash, a second antibody specific for Rat IL-1β is added. After a second 
incubation and removal of the excess of second antibody, an enzyme (Streptavidin-
Peroxidase) is added, which in turn bind to the second antibody. After a third 
incubation and washing to remove all the unbound enzyme, a substrate solution is 
added, which is acted upon by the bound enzyme to produce colour. The colour 
intensity is directly proportional to IL-1β concentration in the original samples. 
Method: OK cells were seeded in 24-well plate, until they became confluent, the 
supernatants were then aspirated out and the cells were treated with aliquots of 0% 
FCS culture medium containing different concentrations (0, 0.007, 0.02 g/L Fe2O3) of 
R1 and R8 bioferrofluids for 24 hours. The supernatants were collected and then 
processed for IL-1β measurement following the manufacturer instructions supplied 
with Rat IL-1β ELISA kit. The absorbance was measured with the help of DTX-880 
multimode detector system at 450 nm. This experiment was repeated 2 times in 
duplicate. The statistical analysis of experimental data utilised the Mann-Whitney test. 
The results are presented as mean ± SEM. Statistical significance was p < 0.05. 
2.3.2.5.2 LysoTracker  
 
Lysosomes are the cellular compartments that can play an important role during 
the endocytosis. Their role in the bioferrofluids internalisation has been tested using 
lysoTracker.  
.
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Test principle: This test is based on the selective accumulation of fluorescent 
acidotropic probes (consisting of fluorophore linked to weak base) in cellular 
compartments with low internal pH.  
Method: OK cells were seeded in 8 chamber slides, after overnight growth. The 
supernatants were aspirated out and the cells were treated with aliquots of 0% FCS 
culture medium containing 0.02 g/L Fe2O3 of bioferrofluids (R1 and R8) for 24 hours. 
The cells were processed following the instructions of LysoTracker DND-99 kit 
(Molecular Probes). Cells were mounted with ProLong Gold antifade reagent with 
4’,6-diamidino-2-phenylindole, DAPI, (Molecular Probes).  Slides were investigated 
under the Axiovert 200M fluorescence microscope equipped with ApoTome. Red 
fluorescence was detected using the long pass filter at 546 ± 6 nm and emission at 590 
nm and DAPI excited using the long pass filter at 436 ± 10 nm, and emission at 480 ± 
20 nm.  
2.4 Results  
2.4.1 Bioferrofluids characterisation  
 
Atomic absorption in a plasma spectrometer was used to determine the iron 
contents of bioferrofluid stock samples used in this work. Concentrations of iron 
contents are summarised in Table 2.3.  
The samples were characterised by DLS. Results showed a single population of 
particles with a log-normal distribution of hydrodynamic diameters Fig. 2.6. The plots 
do not show any population of small particles corresponding to isolated maghemite 
nanoparticles, which according to TEM have sizes below 16 nm, or to empty polymer 
beads that have a hydrodynamic size of 16 nm, as shown in Table 2.3. Therefore, it 
can be safely assumed that the suspension is just composed of a single population of 
maghemite/polymer composite beads. The average hydrodynamic diameter (DH) of 
the beads increases rapidly with the iron oxide/polymer and Fe(II)/Fe(III) ratios (Table 
2.2). The average DH is ranging between 51 to 112 nm Table 2.3. Measurements of 
zeta potential of the nanoparticles suspension for all samples yielded average values
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close to zero.  
Figure 2.6: Distribution of hydrodynamic diameters in bioferrofluid samples from DLS measurements.  
TEM observations do not show separated composite beads as observed in DLS 
Fig. 2.7. Instead, the polymer appears as a continuous film embedding the maghemite 
nanoparticles. Chloride and phosphate salts used in the preparation of the PBS 
particles suspensions are usually grouped in bags, whereas maghemite nanoparticles 
are uniformly distributed throughout the film. Most of maghemite nanoparticles are 
rounded, however, a small amount of other minor particle populations, such as thin 
maghemite rods and larger elongated particles was observed, probably made of 
goethite according to extra reflections that are occasionally observed in the electron 
diffraction (ED) patterns. The size of maghemite nanoparticles in the samples 
increases regularly from 4 nm (sample R1) to 15 nm (sample R8) in relation to the 
Fe/P4VP and Fe(II)/Fe(III) ratios used in the preparation Table 2.2. The size 
distribution analysis for the maghemite nanoparticles is shown in Fig. 2.8. 
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Table 2.3: Bioferrofluids characterisation. 
 
 
 
 
 
aHydrodynamic diameter; bPolydispersity index as obtained from DLS; cMaghemite nanoparticle diameter from TEM images; dNumber of 
composite beads per litre of suspension.
Sample [P4VP-g-APEG]3 
(g/L) 
[Fe2O3] 
(g/L) 
DH(nm )a PDIb DP(nm)c SD(nm) N/Ld x 
1018 
blank 26.7 0 16 0.30    
R1 20.3 1.5 51 0.22 4.1 0.7 2.09 
R2 22.5 4.2 76 0.21 7.4 1.2 0.90 
R3 20.9 4.8 82 0.16 9.4 1.7 0.56 
R4 24.6 7.4 79 0.15 12.1 2.8 0.74 
R7 19.1 5.5 104 0.13 13.3 2.6 0.24 
R8 19.5 5.4 112 0.10 14.4 4.6 0.19 
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The whole composition of the maghemite/polymer composite beads does not 
appear clearly by cryo-TEM Fig. 2.9A. Images showed maghemite nanoparticles are 
uniformly distributed in the solidified water matrix, surrounded by an area with a 
slight contrast over the background, which may correspond to the P4VP polymer that 
has a higher packing density than PEG polymer due to its hydrophobic character.  
Figure 2.7: TEM images of maghemite magnetic nanoparticles in bioferrofluids (a) R1, (b) R2, (c) R3, 
(d) R4, (e) R7, and (f) R8. 
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Figure 2.8:  Size distribution analysis of spherical maghemite magnetic nanoparticles (a) R1, (b) R2, (c) 
R3, (d) R4, (e) R7, and (f) R8.  
However, the presence of PEG polymer is not revealed due to a low contrast 
difference between the polymer and the water matrix. Nevertheless, the contour of the 
whole composite beads becomes apparent after surface functionalisation with 
antibodies Fig. 9B, or thermometric lanthanide complexes Fig. 9C. It is observed that 
the beads have an oval shape and contain the maghemite nanoparticles in the interior.   
The nanoparticles i study here in this work, however, are the basic ones without 
antibodies and lanthanides functionalisations. The reason for it stays in part on time 
constraints and, also, because these kind of functionalised nanoparticles where 
developed when this thesis was with its last steps. 
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Figure 2.9:  Cryo-TEM images of sample R8 (A), the sample R8 after conjugation with an antibody (B) 
or lanthanide complexes (C). Inserts show the detailed composition of the composite bead.  
2.4.2 Cell Viability assay 
2.4.2.1 LDH assay  
 
The cytotoxicity of these bioferrofluids was assayed in two cell lines representing 
epithelial (OK cells) and mesenchymal (VSMC) origins. Cytotoxicity was first 
evaluated as total cell death, according to the intracellular LDH released to the 
incubation medium, as a function of dose and time of treatment. 
LDH experiment has been carried out for all samples of bioferrofluids with 
several dilutions (0, 10-1, 10-2, 10-3, 10-4, 10-5 and 10-6) in VSMC and OK cells at 
different time points (0, 1, 2, 3, 4 and 5 days). Obtained cytotoxicity data in both cell 
lines showed the classical sigmoidal dose-response curves when plotted as a 
logarithmic function of iron oxide concentration (Fe2O3 g/L) Fig. 2.10. After 1 day of 
treatment, VSMC showed to be sensitive (higher toxicity response) to all samples of 
bioferrofluids (R1, R2, R3, R4, R7 and R8) Fig. 2.10(a). In contrast, OK cells showed 
to be more sensitive to R1 (smaller size) in respect to other samples (R2, R3, R4, R7  
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 and R8) that show lower toxicity compared to R1 Fig. 2.10(b). Fitting the data to a 
sigmoidal equation by non-linear regression provided values of LC50 for each sample 
that were in the range of 7-16 mg/L Fe2O3 and 10-20 mg/L Fe2O3 for VSMC and OK 
cells respectively after 1 day of treatment. 
Figure 2.10: LDH activity after 1 day of treatment for all samples of bioferrofluids in both VSMC (a) and 
OK cells (b).  
The experiment was carried out during 5 successive days with the determination 
of LC50 for all bioferrofluids samples in both cell lines, as shown in Fig. 2.11. The 
data are summarised in Tables 2.4 and 2.5 for VSMC and OK cells respectively. The 
LC50 values for VSMC are smaller than for OK cells, and LC50 values decrease with 
the time in both cell lines. 
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Figure 2.11: Variation of LC50 (as g/L Fe2O3) with time for all samples of bioferrofluids in VSMC (a) 
and OK cells (b).  
Table 2.4. LC50 (as mg/L Fe2O3) values for all samples of bioferrofluids in VSMC 
 
 
 
 
 
Table 2.5. LC50 (as mg/L Fe2O3) values for all samples of bioferrofluids in OK cells. 
 
 
 
 
 Day 1 Day 2 Day 3 Day 4 Day 5 
R1 6.89 5.11 3.70 2.73 1.55 
R2 8.63 5.93 4.86 3.68 2.29 
R4 9.44 6.72 5.37 3.93 2.50 
R3 10.58 7.54 6.13 4.65 3.11 
R7 13.50 8.41 6.65 5.39 3.45 
R8 15.54 10.59 7.67 6.11 4.71 
 Day 1 Day 2 Day 3 Day 4 Day 5 
R1 9.60 4.36 3.49 2.86 2.78 
R2 11.53 8.72 6.33 4.20 3.57 
R4 14.31 10.81 7.73 6.17 4.04 
R3 15.67 12.11 9.36 7.61 5.04 
R7 18.49 14.01 10.79 9.18 7.26 
R8 20.11 15.60 13.17 10.31 8.87 
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Toxicity was also analysed as a function of compositional and structural 
parameters of bioferrofluids. When the LC50 values after 1 day of treatment were 
plotted against the maghemite nanoparticle diameters, the bead hydrodynamic 
diameters and the iron oxide content indicated in Table 2.3, the relationships were 
linear in both cell lines Fig. 2.12(a), (b) and (c). The slopes of the regressions lines 
were positive, apparently meaning that toxicity decreases with the increasing of the 
diameters as well as of the iron oxide content in both cell lines.  
Figure 2.12: Linear correlation between LC50 (as g/L Fe2O3) after 1 day treatment and maghemite 
nanoparticles diameters (a), bead hydrodynamic diameters (b), iron oxide content (c), number of beads 
per litre bioferrofluids (d) and polymer/ iron oxide content ratio (e) for all samples of bioferrofluids in 
VSMC and OK cells.  
In contrast, when the same LC50 values were plotted against the number of beads 
per litre of suspension and the ratio of the organic component (P4VP-g-APEG) and 
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iron oxide content in both cell lines (Table 2.3), the relationships were linear in both 
OK and VSMC and the slopes of the regression lines were negative, indicating that the 
toxicity is directly proportional to these two factors in both cell lines, as shown in Fig. 
2.12(d) and (e). 
In order to confirm the relationship between the DH and the cytotoxicity on OK 
cells, a fixed concentration of iron oxide (0.02 g/L Fe2O3) from each sample (R1, R2, 
R3, R4, R7 and R8) was incubated with OK cells for 1 day. LDH activity was 
analysed and the results showed an inverse relationship between the hydrodynamic 
diameter and the cell toxicity, as shown in Fig. 2.13. 
 
 
 
 
 
 
 
Figure 2.13: Effect of bead hydrodynamic diameter on the cytotoxicity of OK cell after 1 day of 
treatment. 
 
2.4.2.2. Acridine Orange/Ethidium Bromide assay 
 
Cytotoxicity was confirmed by microscopy using both phase contrast and double 
staining with AO/EB. Fig. 2.14 shows OK cells treated for 24 hours with R1 
bioferrofluids at concentrations lower, similar and higher than the estimated LC50. 
Dead cells are red stained with EB, while live cells allow only the entrance of AO and 
therefore fluorescence green with a faint red staining in cytoplasm corresponding to 
RNA and lysosomes. Phase contrast illumination of the cells suggests a necrotic type 
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 of cell death with no evidence of apoptosis. Identical findings were obtained with R8 
bioferrofluids as shown in Fig. 2.15. 
Figure 2.14: Confocal micrographs of AO/EB stained OK cells treated with different concentrations of 
R1 bioferrofluids for 24 hours. Faint red/orange spotty staining in Control corresponds to the intercalation 
of AO in RNA and lysosomal staining. Scale bar: 100 µm. 
Figure 2.15: Confocal micrographs of AO/EB stained OK cells treated with different concentrations of 
R8 bioferrofluids for 24 hours. Faint red/orange spotty staining in Control corresponds to the intercalation 
of AO in RNA and lysosomal staining. Scale bar: 100 µm. 
 
2.4.3 Apoptosis assay  
 
Even if morphology of the cells did not indicate evidence of apoptosis as 
previously shown in AO/EB assay, two different methods were used to confirm this 
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point based on the detection of both early and late apoptotic events.  
2.4.3.1 DNA fragmentation (late apoptotic event) 
 
OK cells treated with different concentrations of R1 bioferrofluids showed 
absence of DNA fragmentation, which is indicated as a black field with no 
fluorescence after using a fluorescent TUNEL assay. However, positive control, as 
corresponds to DNase I treated cells, was fluorescent green, as shown in Fig. 2.16. 
Identical findings were obtained with R8 bioferrofluids, as shown in Fig. 2.17. Phase 
contrast images were taken to confirm the presence of the cells.   
Figure 2.16: Confocal micrographs of fluorescent TUNEL stained OK cells treated with different 
concentrations of R1 bioferrofluids for 24 hours. Positive control is DNase I treated OK cells. Scale bar: 
100 µm. 
 
Figure 2.17: Confocal micrographs of fluorescent TUNEL stained OK cells treated with different 
concentrations of R8 bioferrofluids for 24 hours. Positive control is DNase I treated OK cells. Scale bar: 
100 µm. 
 
 
 
 
 
72   Chapter 2.  Cytotoxicity studies 
 
2.4.3.2 Caspase-3 activity detection (early apoptotic event) 
 
A fluorescent caspase-3 assay was carried out in OK cells treated with different 
concentrations of R1 and R8 bioferrofluids for 24 hours. Results showed no 
significant change in caspase-3 level compared to the control (untreated OK cells) Fig. 
2.18, resulting in no evidence of apoptosis detected. Data corresponding to caspase-3 
activity detection are analysed using Mann-Whitney test and are summarised in Table 
2.6. 
Figure 2.18: Caspase-3 activity detection in OK cells treated with different concentrations of R1 and R8 
bioferrofluids for 24 hours. Values represent mean ± SEM (n=6).  
Table 2.6. Statistical analysis data for caspase-3 activity detection in OK cells treated 
with different concentrations of R1 and R8 bioferrofluids for 24 hours (n=6).  
[Fe2O3] 
g/L 
R1 bioferrofluids R8 bioferrofluids 
Caspase-3 activity 
Mean ± SD 
(µM caspase/µg protein) 
P 
(Mann-
Whitney) 
Caspase-3 activity 
Mean ± SD 
(µM caspase/µg protein) 
P 
(Mann-
Whitney) 
0 0.0186 ± 0.003 - 0.0186 ± 0.003 - 
0.007 0.0159 ± 0.003 0.1797 0.0179 ± 0.003 0.8182 
0.01 0.0164 ± 0.004 0.4848 0.0185 ± 0.005 0.9372 
0.02 0.0146 ± 0.005 0.1320 0.0151 ± 0.004 0.1320 
 
2.4.4 Oxidative stress  
2.4.4.1 Carbonyl content measurement 
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In order to ascertain the toxicity mechanism induced by the NPs, oxidative stress 
was determined by measuring the carbonyl content in a protein lysate from OK cells 
treated with different concentrations of R1 for 24 hours. Results showed no significant 
change in carbonyl content level as compared to the untreated cells (negative control), 
as shown in Fig.2.19. Data corresponding to measurements of carbonyl content were 
analysed using Mann-Whitney test and results are summarised in Table 2.7. 
Figure 2.19: Determination of carbonyl content in protein lysate from OK cells treated with different 
concentrations of R1 bioferrofluids for 24 hours. Positive control is cells treated with 1mM H2O2 for 30 
minutes. Values represent mean ± SEM (n=6), and (*) indicates significant differences between positive 
control and negative control. 
Table 2.7. Statistical analysis data corresponding to measurements of carbonyl 
content in a protein lysate from OK cells treated with different concentrations of R1 
bioferrofluids for 24 hours (n=6).  
[Fe2O3] g/L R1 bioferrofluids 
Carbonyl content 
(Mean ± SD) 
(nmol carbonyls/mg protein) 
P 
(Mann-
Whitney) 
Negative control 3.76 ± 0.25 - 
Positive control 7.41 ± 0.76 0.0048 
0.0005 3.99 ± 0.22 0.1262 
0.001 4.05 ± 0.14 0.1262 
0.002 4.16 ± 0.56 0.1262 
0.005 4.32 ± 0.60 0.1262 
0.007 4.02 ± 0.31 0.0641 
0.01 4.06 ± 0.20 0.2273 
0.02 3.84 ± 0.12 0.9358 
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 2.4.4.2 Thiol tracker 
 
The existence of oxidative stress was also determined by measuring the 
abundance of reduced glutathione in OK cells treated with different concentrations of 
bioferrofluids (R1 and R8) for 24 hours. Thiol tracker was used for both, visualisation 
under fluorescence microscopy and quantification in fluorometer. Results showed no 
existence of any change in the concentration of reduced thiol content upon 
bioferrofluids treatment either visually Fig. 2.20 or fluorometrically Fig. 2.21, 
suggesting the absence of oxidative stress.  Data corresponding to GSH measurement 
were analysed using Mann-Whitney test and are summarised in Table 2.8. 
Figure 2.20: Confocal micrographs of Thiol tracker stained OK cells treated with different concentrations 
of R1 and R8 bioferrofluids for 24 hours. Scale bar: 100 µm. 
 
Table 2.8. Statistical analysis data for GSH measurement in OK cells treated with 
different concentrations of R1 and R8 bioferrofluids for 24 hours (n=9).  
[Fe2O3] 
g/L 
R1 bioferrofluids R8 bioferrofluids 
GSH measurement 
Mean ± SD 
(GSH %) 
P 
(Mann-
Whitney) 
GSH measurement 
Mean ± SD 
(GSH %) 
P 
(Mann-
Whitney) 
0 100.00 ± 24.71 - 100.00 ± 24.71 - 
0.007 128.69 ± 30.01 0.0712 99.07 ± 19.53 0.7577 
0.01 118.95 ± 24.91 0.2105 130.05 ± 30.68 0.0549 
0.02 122.20 ± 27.83 0.1416 113.45 ± 26.16 0.3510 
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Figure 2.21: Quantitative fluorometric measurement of reduced glutathione in OK cells treated with 
different concentrations of R1 and R8 bioferrofluids for 24 hours. Values represent mean ± SEM (n=9).    
 
2.4.5 Inflammasome activation  
2.4.5.1 IL-1β measurement  
 
We checked the possibility of inflammasome activation as a likely toxic response 
that could be involved in cell death. With this purpose, IL-1β level was measured in 
cell culture medium of OK cells treated with different concentrations of R1 and R8 
bioferrofluids for 24 hours. Results showed a significant increase in IL-1β level at 
concentration 0.02 g/L Fe2O3 of R1 bioferrofluids, while R8 did not, as shown in Fig. 
2.22. Data corresponding to IL-1β measurement were analysed using Mann-Whitney 
test and are summarised in Table 2.9. 
Table 2.9. Statistical analysis data for IL-1β level measurement in cell culture 
medium of OK cells treated with different concentrations of R1 and R8 
bioferrofluids for 24 hours (n=4). 
 
[Fe2O3] 
g/L 
R1 bioferrofluids R8 bioferrofluids 
IL-1β measurement 
Mean ± SD 
(% IL-1β expression) 
P 
(Mann-
Whitney) 
IL-1β measurement 
Mean ± SD 
(% IL-1β expression) 
P 
(Mann-
Whitney) 
0 100.00 ± 8.71 - 100.00 ± 8.71 - 
0.007 110.88 ± 5.74 0.1143 109.59 ± 5.41 0.1143 
0.02 499.22 ± 48.61 0.0286 110.88 ± 2.18 0.0571 
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Figure 2.22: Quantitative IL-1β level measurement in cell culture medium of OK cells treated with 
different concentrations of R1 and R8 bioferrofluids for 24 hours. Values represent mean ± SEM (n=4), 
and (*) indicates significant differences between R1 treated OK cells and negative control. 
2.4.5.2 LysoTracker  
 
Finally, we also visually checked the abundance of the lysosomes as a possible target 
of internalised NPs, because a malfunctioning of these organelles could explain the 
sudden cell necrosis. Thus, OK cells were treated with R1 and R8 bioferrofluids at 
concentration 0.02 g/L Fe2O3, for 24 hours. Lysosomes visualisation with a 
LysoTracker revealed that after treatment with 0.02 g/L Fe2O3 of either R1 or R8, OK 
cells showed an increased fluorescence, as shown in Fig.2.23. As a result, we 
investigated the fate of NPs in the cell as well as the internalisation mechanism, which 
are the contents of the next chapter. 
Figure 2.23: Fluorescent labelling of OK cell lysosomes (red) with a LysoTracker before (a) and after 
treatment with 0.02 g/L Fe2O3 of R1 (b) and R8 (c) bioferrofluids. Blue is DAPI staining of nuclei. Scale 
bar: 20 µm. 
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2.5 Discussion and conclusions 
In general, a biomedical performance, however promising, would be of little 
significance without a good biocompatibility that must join with efficient cellular 
uptake. Therefore, the main aim of this chapter is to study the toxicity of our 
bioferrofluids in vitro.  
Generally, SPIONs were considered as non-toxic, as iron is involved in many 
cellular functions, but their unique physicochemical properties would impose toxicity. 
Our concern about the toxicity starts from the choosing of the core, our synthetic 
strategy guarantees a precipitation of maghemite nanoparticles only. Several studies 
showed that maghemite nanoparticles have lower toxicity as compared to magnetite 
nanoparticles. The reason is that magnetite is a mixture of FeO and Fe2O3, which is 
not stable and undergoes oxidation to form maghemite (equation 2.2), releasing free 
Fe2+ ions that can penetrate the nucleus membrane causing DNA damage or penetrate 
the mitochondrial membrane producing ROS through Fenton reaction (equation 2.1), 
which in turn causes DNA damage (genotoxicity) [24,59]. 
Fe3O4+ 2H+------ γ Fe2O3+Fe2++H2O  (Equation 2.2) 
Cell viability results showed cell type-dependent toxicity, as bioferrofluids are 
more toxic in VSMC than OK cells Fig. 2.10. Other authors have emphasised the 
crucial role of cell type on the toxicity response to nanoparticles [60,61]. Difference in 
toxicity response between both cell lines to the nanoparticles could be related to the 
internalised amount of nanoparticles inside both cell lines. VSMC take up more 
nanoparticles as compared to OK cells, as shown in Fig. 3.10. Several studies illustrate 
the relationship between toxicity, uptake and intracellular localisation of the 
nanoparticles inside the cells, as higher uptake rates are usually linked to greater 
biological effects. In addition, the mere presence of nanoparticles enclosed in the 
lysosmes causes toxicity, as they reach a high local concentration that exceed LC50, 
which may lead to sudden death [23,61,62]. A study carried out by  Soenen et al. 
illustrated that the intracellular localisation and intracellular concentration of 
nanoparticles inside the cell maybe consider the cause of cellular stress that is 
manifested itself as a reduction in cell proliferation, transit increase in ROS production 
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and alteration in actin cytoskeleton in murine 3T3 fibroblasts cells treated with 
positively charged magnetoliposomes [45]. Our mean lethal concentrations are lower 
than previously reported values. However, taking into account the great variability in 
methodology, experimental condition, nanoparticle characterisation, concentrations, 
etc., a comparison of the results is out of question [63,64]. LC50 values were decreased 
with time in both cell lines Fig. 2.11 indicating that the toxicity is due to accumulative 
effect.  
There are several factors influencing the cell toxicity of nanoparticles, such as 
nanoparticle composition, oxidative state of iron in SPIONs, coating, shape, surface 
charge, core size, hydrodynamic size, among others [28,35,36]. With respect to the 
nanoparticles composition, our results show that in both cell lines the toxicity 
increases by increasing the polymer/iron ratio, Fig. 2.12(e). This is in contradiction 
with a study carried out by Mahmoudi et al. indicating the inverse relationship 
between toxicity and polymer/iron ratio [28]. Interestingly, the toxicity and uptake of 
nanoparticles were depending on the oxidative state of iron (Fe2+ or Fe3+), our results 
showed that by increasing Fe2+/Fe3+ ratio (Table 2.2) the toxicity and uptake decreased 
in both cell lines. 
Similar to other preparations, our nanoparticles are surrounded by a PEG coating 
in order to reduce the interactions with cell membrane and consequently reduce 
internalisation rate and toxicity [65,66]. These effects are proportional to the 
percentage of PEG chains on the surface [67] and the molecular weight of PEG [68]. 
Yu et al. showed that uncoated IONPs induced more than 6 fold increase in cell death 
as compared to dextran or PEG coated ones [69]. 
Toxicity is also strongly affected by surface charge, studies show that positively 
charged NPs are internalised more in cells, and consequently toxicity is also higher 
[70,71]. However, controlling the number of positive charge could achieve higher 
uptake with lower toxicity [72]. Samples used in the present work can be considered 
as neutral or slightly positive, according to Z-potential measurements. Therefore, no 
toxicity should be expected from surface charge.  The mechanism of cell death could  
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be related to the surface charge. A study carried out by Schaeublin et al., shows that 
positively charged gold nanoparticles cause apoptosis, while neutral ones cause 
necrosis in HaCat cells [29]. 
Beside all the previously mentioned factors that affect the NPs toxicity, a size-
dependent toxicity was also observed in both cell lines, see Fig. 2.12(a), (b), which is 
clearer in case of OK cells, see Fig. 2.13. Toxicity decreases as maghemite core size 
and bead hydrodynamic size increase, which will be explained in the next chapter by a 
lower uptake observed in larger nanoparticles sizes, as shown in Fig 3.9(a). A similar 
finding was observed by Mahmoudi et.al. who observed a decrease in the cellular 
toxicity of PVA coated SPIONs by increasing the hydrodynamic diameters, due to 
lower uptake [28]. In addition, cell death seems to be concentration dependent, as 
indicated by the linear correlations shown in Fig. 2.12(c), and inversely proportional 
to the total number of nanoparticles (total surface area) Fig. 2.12(d). 
The subsequent studies have been focused on OK cells only, as the preliminary in 
vivo studies indicated accumulation of nanoparticles in kidney.  
Exposure to SPIONs has been associated with apoptosis [35]. In this work we 
show that our SPIONs cause necrotic cell death, which is indicated by absence of the 
common apoptotic markers: DNA fragmentation, see Figs. 2.16 and 2.17, and caspase-
3, see Fig. 2.18. 
The relationship between SPIONs and ROS induction is not clear. Some studies 
show the ability of SPIONs to induce ROS [36], others show their peroxidase-like 
activity [40]. ROS can cause cell death through either apoptosis or necrosis, then, the 
link between ROS and induction of toxic effect is not clear and seems to be somehow 
cell type-dependent [73]. ROS induction by nanoparticles depends on several factors 
such as coating stability, the amount of total surface area of internalised IONPs and 
also the time of incubation [41,74]. After 24 hours of incubation with R1 
bioferrofluids our bioferrofluids did not show any significant changes in carbonyl 
contents level in OK cells, see Fig. 2.19. There may be two explanations supporting 
this result. First, the incubation time maybe inadequate, as in this study we measured 
the carbonyl content level after 24 hours of incubation. Arbab et al. showed that ROS  
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induction by SPIONs reaches its highest level after 24 hours of incubations and 
returns to normal after 72 hours [75]. However, Stroh et al. showed that ROS 
induction by SPIONs reaches its highest level after 90 minutes of incubations and 
disappears after 24 hours of incubation [41]. All these studies are depending on the 
coat stability of the nanoparticles as well as other experimental factors (e.g. cell type). 
Therefore, assessing the carbonyl content in time interval is mandatory. A second 
explanation can be in the higher stability of our coating (P4VP-g-APEG). Our 
maghemite nanoparticles are embedded within P4VP that is stable at acidic pH and 
then coated with PEG. The degradation resistance of P4VP under acidic pH protects 
the IONPs from degradation in the lysosmes. This explains the persistence of our 
nanoparticles as intact over a period of 30 days post injection in vivo without any toxic 
effect (chapter 5) and well as the non-oxidative stress induction. Stability of the coat 
and ROS induction have been the centre of several studies. Soenen et al. showed that 
the endosomal localisation of different coated SPIONs results in nanoparticles 
degradation and release of free ions that generate ROS. Thus, citrate coated SPIONs 
showed faster maximal ROS induction (4h) compared to other SPIONs coated with 
dextran or lipid [76]. Carbonyl content level results were confirmed by the normal 
level of GSH in nanoparticles treated cells, as shown in Figs. 2.20 and 2.21. 
Many nanomaterials have been reported to induce inflammation as a consequence of 
an elevated level of ROS or as a consequence of nanomaterial binding and activation 
of cell surface receptors, see Fig. 2.4(d). This leads to the activation of NF-KB, which 
in turns activates inflammatory genes, including genes encoding the pro-inflammatory 
cytokines: TNFα, IL-6 and IL-1β [34,77,78]. The pro-IL-1β is converted to activate 
IL-1β with the help of Caspase-1, which results from inflammasome activation. Our 
nanoparticles produced an elevated level of IL-1β at higher concentration (0.02 g/L 
Fe2O3) of R1, see Fig. 2.22, demonstrating the inverse relationship between 
nanoparticle size and induction of inflammatory effect. Similar results have been 
observed by Yang et al. using silver nanoparticles [78]. 
Activation of the inflammasome occurs through several stimuli, one of them being the 
lysosomal damage. For this reason we have carried out an assay to elucidate the   
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interrelationship between NPs and lysosome. Our results showed that the fate of 
nanoparticles seems to be their storage into the lysosomes, see Fig. 2.23. Then, when 
the experimental in vitro conditions lead to a massive internalisation and accumulation 
into lysosomes, a sudden disorder of this organelle seems to take place and necrosis of 
the cell arises, as shown in Figs. 2.14 and 2.15. We do not have a direct evidence for 
the occurrence of this mechanism, however, the accumulation of the nanoparticles in 
the lysosomes and the increased abundance of these organelles in the cells, see Fig. 
2.23, points out to this possibility. Soenen et al. also suggested this possibility as the 
abundance of lysosomes in the perinuclear region could impede protein transcription, 
and also cause disruption in the cytoskeleton [46].   
From all above we can conclude that our bioferrofluids toxicity is depending on 
several factors such as cell type, maghemite nanoparticle size, bead hydrodynamic 
size, polymer/iron ratio, Fe2+/Fe3+ ratio, concentration, total nanoparticles number , 
coating and charge. Nanoparticles cause cell death through necrosis with no evidence 
of ROS production after 24 hours of incubation in OK cells, small size nanoparticles 
(sample R1) have an inflammatory effect arising from inflammasome activation and 
the larger nanoparticles that having higher iron oxide loading (sample R8) are 
preferred for further work due to their lower toxicity in compared to other sizes. 
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Chapter 3  
Studies at the nano-bio interface level: 
uptake, subcellular localisation and 
endocytosis 
 
3.1 Introduction  
Since the in vivo delivery of the nanomaterials ends with cellular internalisation, 
studies pertaining to the nano-bio interface are of utmost importance. Good 
understanding of nanomaterial-cell interactions will, (a) disclose valuable information 
related to some nanomaterial implications, such as toxicity, (b) determine the 
intracellular fate of the nanomaterial, (c) help to design an efficient drug delivery 
system capable of escaping from unfavourable cellular conditions, e.g. lysosomes, (d) 
improve the subcellular targeting research area in the near future [1,2]. 
3.1.1 Nano-bio interface 
The journey of the nanomaterials internalisation into the cells starts when the 
nanomaterials come in contact with the plasma cell membrane. At this moment two 
different worlds (synthetic and biological) are merged, generating what is called nano-
bio interface which can be defined as “the interface between the nanomaterials and the 
biological systems (proteins, membranes, phospholipids, endocytic vesicles, 
organelles, DNA and biological fluids) that includes the dynamic physicochemical 
interactions, kinetics and thermodynamic exchanges between nanomaterials surfaces 
and biological systems surfaces” [3]. 
Nano-bio interface encompasses three dynamic interacting components as  
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depicted in Fig. 3.1: (a) the nanomaterial surface, which is affected by the 
nanomaterial physicochemical properties, (b) the solid-liquid interface, including the 
changes occurring when the nanomaterial interacts with components in the 
surrounding medium, (c) the interactions between the solid-liquid interface and the 
biological system [3].  
Let us explain each of these components in more detail.  
Figure 3.1: Schematic representation of the nano-bio interface [3]. 
3.1.1.1 The Nanomaterial 
 
The nanomaterial internalisation into the cell following the nanomaterial-cell 
interaction is affected by many factors. Some of these factors are related to the 
nanomaterial physicochemical properties such as:  
 The shape: Several studies have demonstrated the shape effect on the cellular 
uptake of the nanomaterial, for instance, Chithrani et al. studied the shape 
effect on gold nanoparticles uptake. Results indicated that spherical 
nanoparticles of sizes 74 and 14 nm were taken up 500% and 375% more than 
rod shaped nanoparticles of 74x14 nm size, respectively. This could be 
 
 
 
 
3.1. Introduction 91 
 
explained on the basis that the elongated ones require more time for 
membrane wrapping [4]. Studying the effect of the shape on cellular uptake is 
complex and not well understood, since many other factors such as charge and 
size could influence. Therefore, a new technology known as PRINT is 
recommended to study the effect of the shape independent of other 
nanomaterial physicochemical properties [1,5]. 
 The size: Several studies have illustrated the effect of size on nanomaterial 
cellular uptake. For instance, Huang et al. studied the effect of the size on the 
cellular uptake using Polyvinylpyrrolidone (PVP) coated IONPs with different 
hydrodynamic diameters (32, 71, 102 and 118 nm) in macrophage cells. 
Results indicated that the higher uptake occurred at a nanoparticle size of 102 
nm, which is considered as an optimum size for cellular uptake [6]. Another 
example is shown by Chithrani et al. They studied the uptake of gold 
nanoparticles with different sizes (14, 50 and 74 nm) in Hela cells. Results 
indicated that the 50 nm particle size is an optimal size for efficient 
nanoparticles uptake in Hela cells [4]. This study is consistent with a study 
carried out by Lu et al. In their work they studied the uptake of mesoporous 
silica nanoparticles with a size range of 30 to 280 nm in Hela cells. Results 
showed that 50 nm particle size is considered as an optimum size for efficient 
nanoparticles uptake in Hela cells [7].  
 The charge:  Surface charge is considered the most important parameter that is 
involved in the interactions of the nanomaterials with the biological 
membranes [8]. Accordingly, the nanomaterial net surface charge strongly 
determines its ability for internalisation into the cell [9,10]. Several studies 
showed that positively charged nanomaterials are taken up better by the cells 
than negatively or neutrally charged nanomaterials. For instance, Cengelli et 
al. stated that positively charged SPIONs functionalised with amino polyvinyl 
alcohol (PVA) are taken up by isolated brain-derived endothelial and 
microglial cells at a much higher level than negatively charged and neutral 
ones [10]. Villanueva et al. studied the uptake of IONPs functionalised with 
differently charged carbohydrates in Hela cells. Results showed no 
intracellular uptake for neutral nanoparticles. However, the negatively charged 
ones showed uptake and toxicity depending on the coating nature, while the 
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positively charged nanoparticles showed higher uptake with no toxicity [9]. 
These results require to be verified in terms of toxicity as they contradict other 
studies in the literature. As they depend on many other factors explained 
before, not all the studies are easy to compare. There is a strong correlation 
between the amount of the charge and the internalisation into the cell. Lorenz 
et al. showed the direct correlation between the amount of amino groups on 
the nanoparticle surface and the uptake by Hela cells. However, this relation 
was not clear for mesenchymal stem cells (MSC) which may be affected by 
other factors, such as nanoparticle size [11]. Not only the amount of the 
surface charge affects the nanomaterial-cell interaction but also the ligand 
arrangement on the nanomaterial surface, as stated by Verma et al. [12]. 
Although, the positively charged nanomaterials exhibit efficient 
internalisation into the cells, they have toxic effect due to severe pore 
formation in the plasma cell membrane [13]. Also they are immunogenic [14], 
quickly cleared from the circulation by RES and observed to agglomerate with 
erythrocytes and other blood components in vivo [15,16].  
3.1.1.2 Interactions between the nanomaterial and the surrounding médium 
 
According to several factors of the medium in which the nanomaterials exist, such 
as ionic strength, pH and the presence of large organic molecules (e.g. proteins), 
nanomaterials acquire new physicochemical properties, which in turns affect the 
nanomaterial-cell interaction and subsequently to the nanomaterial internalisation and 
its dispersion stability.  
3.1.1.2.1 The effect of ionic strength and pH on the nanomaterial dispersion stability  
 
Ionic strength and pH are considered important parameters that control the 
stability of the nanomaterial dispersion. Ionic strength influences the dispersion 
stability by changing the electrical double layer thickness, while the pH can affect the 
stability by altering the zeta potential. Increasing the ionic strength or bring the pH to 
the nanomaterial isoelectric point will enhance the agglomeration and disrupt the 
nanomaterial dispersion stability [17]. Jiang et al. studied the effect of ionic strength 
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and pH on the state of dispersion using 15 nm titanium oxide (TiO2) nanoparticles. 
Increasing the ionic strength was associated with 50 fold increase in the hydrodynamic 
size, while changing the pH was associated with change in the hydrodynamic size and 
the surface charge [17]. Many of these newly acquired nanomaterial properties 
determine the forces that operate at the nanomaterial- medium interface Fig. 3.2. 
These forces include long-range forces arising from attractive van de Waals and 
repulsive electrostatic double layer interaction, plus short-range forces arising from 
charge, steric, depletion and solvent interactions [18]. In addition, changing the 
nanomaterial physicochemical properties will affect on the nanomaterial 
internalisation rate.  
Figure 3.2: Demonstration of the forces involved in the interactions between nanomaterials [3]. 
3.1.1.2.2 Protein corona  
 
When nanomaterials are introduced into biological fluids (blood, plasma or 
interstitial fluids), they are exposed to be coated with proteins forming nanomaterial-
protein corona complexes. Protein concentration and nanomaterial physicochemical 
properties (size, charge, coatings, hydrophobicity, etc.) determine which proteins 
should interact with the nanomaterial and subsequently facilitate nanomaterial 
internalisation into the cell [19,20]. Albumin, immunoglobulins, complement proteins, 
fibrinogen and apolipoproteins have been identified as the proteins developing the 
strongest bonds to carbon nanotubes, iron oxide nanoparticles, liposomes and  
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polymeric nanoparticles surfaces [21]. 
The binding between the nanomaterial and protein has a mutual effect on both of 
them: 
(i) Effect of the nanomaterial-protein corona complex on the nanomaterial: 
The nanomaterial acquires new physicochemical properties upon protein 
corona formation. Dobrovolskaia et al. studied the effect of the plasma 
proteins on the nanoparticle size and charge, and on the dispersion 
stability. The hydrodynamic size of 30 and 50 nm gold nanoparticles 
increased by 50 upon incubation with the plasma proteins as measured by 
DLS, and confirmed by other techniques such as TEM and atomic force 
microscopy (AFM), while the charge decreased. Such increase in size and 
decrease in surface charge can affect to nanoparticles uptake by the cells.  
Ultraviolet-visible (UV-Vis) studies proved that the protein corona 
stabilises the nanoparticles from aggregation [22]. In addition, formation 
of nanomaterial-protein corona complex affects to the nanomaterial 
biodistribution and clearance, as described in previous chapters. 
(ii) Effect of the nanomaterial-protein corona complex on the proteins: As a 
result of nanomaterial-protein corona complex formation, proteins could 
undergo conformational changes resulting in activation [23], loss of 
function as enzymatic activity [24] and fibrillation [25].  
3.1.1.3 Interactions between the nanomaterial and the biological system (Cellular 
uptake) 
 
After the first interactions of the nanomaterial with biological medium, which can 
induce many changes and alterations in the nanomaterial physicochemical properties, 
as described in the previous section, finally the nanomaterial reaches the biological 
cell membrane. The interactions between the nanomaterials and biological membranes 
are not straightforward due to the complexity of both systems. The complexity of the 
plasma cell membrane arises from its selective permeability, flexibility and 
heterogeneity, while for the nanomaterial is due to its acquired physicochemical 
properties [3]. Several factors are controlling the nanomaterial uptake by the cells,  
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such as the nanomaterial physicochemical properties (explained in section 3.1.1.1), 
cell type [26], cell density [26] and nanomaterial concentration.  
Nanomaterial surface ligands (antibodies, proteins, chemical moieties, metallic 
sites, polymers or surface functionalities) are the responsible to form the first link 
between the nanomaterial and the plasma cell membrane, resulting in internalisation of 
the nanomaterial inside the cell by either non-endocytic or endocytic routes of 
delivery, as depicted in Fig. 3.3 [3]. 
Figure 3.3: Schematic representation of nanomaterial-cell membrane interaction mechanisms that are 
responsible for nanomaterial internalisation. The parameters controlling the non-endocytic routes are 
marked by asterisks. In contrast, the endocytic route is controlled by specific ligand-receptor interactions 
[3]. 
3.1.1.3.1 Non-endocytic routes of delivery  
 
The non-endocytic pathways are considered efficient tools for gene delivery, 
since they transport genes directly to the cytoplasm, bypassing the harshness 
conditions associated with the endocytic pathway such as the lysosomal degradation 
[27]. This direct penetration of the cell membrane is controlled by the nanomaterial 
surface properties (e.g. charge, hydrophobicity and roughness) which form non-
specific attractive forces to the cell membrane [3].  
3.1.1.3.2 Endocytic routes of delivery  
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Endocytosis is a complex process with multiple mechanisms by which cells 
transport extracellular and plasma membrane-bound entities into the cell interior. 
Altogether, these mechanisms have to control the entry into the cell in a coordinated 
and specific manner and they play a crucial role in many cellular processes [28,29]. 
According to the mechanism of internalisation, macromolecules such as nanomaterials 
pass through different environments inside the cells that vary in harshness due to 
enzymatic or chemical conditions. In addition, these mechanisms define the fate of the 
nanomaterials inside the cell and their subcellular localisation [1]. The endocytosis 
mechanisms categorise as a) phagocytosis or b) pinocytosis Fig. 3.4.  
Figure 3.4: Different categories of endocytosis mechanisms [30]. 
a) Phagocytosis (cell eating): This mechanism is restricted to specialised 
mammalian cells, including macrophages, monocytes and neutrophils. The  
function of the mechanism is to engulf large pathogens or debris [30]. 
b) Pinocytosis (cell drinking): This mechanism is observed in all types of cells. 
The function of the mechanism is to internalise fluid surrounding cell [1,31]. 
Pinocytosis includes a handful of mechanisms distinguished by size and 
encapsulating vesicles composition as shown in Fig. 3.4: 
I. Macropinocytosis: In this mechanism, membrane protrusions are formed 
to collapse onto and fuse with the plasma membrane in order to transport 
vesicles of microns in size. This mechanism is interesting due to its 
avoidance of lysosomal degradation [1,30]. 
II. Micropinocytosis: This mechanism is including the remaining 
mechanisms of pinocytosis that are responsible for the internalisation of 
nanomaterials with sizes ranging from tens to hundreds of nanometers [1]. 
 Clathrin-mediated endocytosis (CME): CME is the best studied  
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mechanism and was believed for long time to be the only 
mechanism of endocytosis [31]. CME occurs in all types of 
mammalian cells, transporting essential nutrients such as low-
density lipoprotein (LDL) and iron-laden transferrin (Tfn) into 
cells through their binding to specific receptors, for that CME is 
considered as a highly selective internalisation mechanism 
[32,33]. After the formation of ligand-receptor complex, a variety 
of proteins including cytosolic proteins called clathrins, diffuse 
into the plasma membrane in order to shape a coated pit around 
the substance to be transferred. Then, it is invaginated and 
pinched off to form endocytic vesicles of sizes around 120 nm. 
This process is dynamin-dependent [34]. CME ends with 
lysosomal degradation which could be: a) harmful for the 
nanomaterials that could not resist these harsh conditions and lack 
the way to escape from the endosomal compartements [27], b) 
beneficial for pH-sensitive delivery system, bypassing 
cytoplasmic drug resistance mechanisms [35,36].  
 Caveolae-mediated endocytosis: Caveolae are flask-shaped 
invaginations of the plasma membrane coated with caveolin-1, 
their size ranges from 50 to 80 nm [30,31]. Up to date, no studies 
have demonstrated the presence of caveolae able to uptake 
nanomaterials larger than 100 nm [31]. Caveolae mediates the 
internalisation of Simian virus 40 (SV40) and cholera toxin. 
However, other studies showed their internalisation by other 
endocytosis mechanisms [37,38]. This pathway facilitate the 
internalisation of the nanomaterial without lysosomal degradation 
to Golgi apparatus and endoplasmic reticulum [1].  
  Clathrin and caveolin-independent endocytosis: Caveolae is 
considered as a type of lipid raft, other types of lipid raft are small 
in size (40-50 nm) and diffused freely on the plasma membrane. 
These small rafts can be internalised within any endocytic vesicle. 
For example, non aggregates cholera toxins bind to rafts 
associated with glycolipid and internalised by clathrin-coated 
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vesicles [30].  
Currently, many methods are used to study the endocytosis mechanism of a given 
nanomaterial in a certain cell type, such as:  
a) Pharmacological inhibitors, as methyl-β-cyclodextrin (mβCD), Genistein, 
Cytochalasin D, potassium depletion, etc. This method is not efficient, since 
some inhibitors are non-specific, and may inhibit more than one mechanism. 
In addition, other inhibitors have a side-effect on cell physiology [31].  
b) Cell expressing muted proteins and the use of siRNA. These methods have 
disadvantages due to their side-effect on cell physiology. Therefore, the best 
way to study the endocytosis mechanism is try to combine several 
methodologies [31].  
c) Intracellular localisation of nanomaterials, using markers for cellular 
structures such as Lysotracker, early endosome antigen 1 (EAA1), Caveolin, 
etc. Measuring the colocalisation is helpful but it should be kept in mind the 
reasons that cause the false colocalisation depending on the way of detection 
[31].  
3.2 Objectives  
The aim of this chapter is to understand the origin of the cytotoxicity caused by 
our bioferrofluids described in the previous chapter. This will be achieved through 
several studies at the nano-bio interface level such as: studying the cellular uptake and 
the uptake kinetics of NPs with exploring the effect of size, cell type, NPs 
concentrations and time of incubation, determination of the NPs subcellular 
localisation and finally determination of the endocytotic mechanism by which the NPs 
are internalised into the cell.  
3.3 Materials and methods 
3.3.1 Bioferrofluids preparation and characterisation  
The preparation and characterisation methods of the bioferrofluids used in this 
chapter are described in Annex I.  Their preparation conditions are summarised in 
Table 3.1.  
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Table 3.1: Preparation conditions of maghemite polymer nanocomposites for 
different samples.     
 
 
3.3.2 Study of the cellular uptake and the corresponding kinetic behaviour  
3.3.2.1 Qualitative determination of uptake using fluorescent nanoparticles 
 
Opossum Kidney cells and vascular smooth muscle cells were seeded in 8 
chamber slides (BD Falcon, Erembodegem, Belgium), and grown in their appropriate 
culture medium. After overnight growth of both cell lines, the supernatants were 
aspirated out and the cells were treated with 0.007 g/L Fe2O3 of fluorescein-labelled 
R8 nanoparticles (with 112 nm of hydrodynamic diameter) in serum free medium at 
different time points (4, 8, 12 and 24 hours). After treatment, the supernatants were 
aspirated out followed by cellular wash for 3 times with pre-warmed PBS. Cells were 
fixed with 3% (w/v) paraformaldehyde in PBS for 10 minutes at room temperature, 
followed by 3 times wash with PBS. After that, they were mounted and observed 
under Axiovert 200M fluorescence microscope equipped with ApoTome (Carl Zeiss, 
Jena, Germany) with excitation at 470 ± 20 nm and detection with a band pass filter at 
525 ± 25 nm. 
3.3.2.2 Quantitative iron detection  
 
Both cell lines (OK and VSMC) were seeded in 6-well plastic plates and grown in 
their appropriate culture medium. When confluent, the culture medium was aspirated 
out and the cells were treated with different concentrations (0, 0.001, 0.003, 0.007, 
0.01 g/L Fe2O3) of R1` and R8` bioferrofluids with, respectively, 84 nm and 163 nm 
of hydrodynamic diameter, in serum free culture medium for 24 hours. Some samples 
were treated with 0.007 g/L Fe2O3 of R8` bioferrofluids at time intervals of 0, 4, 8, 12 
and 24 hours. After incubation, the cells were washed several times with PBS, 
trypsinised, and centrifuged at 4°C for 10 minutes at 1600 rpm. The supernatant was 
Sample P4VP 
(g/L) 
1M FeBr3  
(mL ) 
1M FeBr2 
(mL ) 
Fe/pyridine 
mol ratio 
Fe2+/ Fe3+ 
mol ratio 
R1` 1.4 2.22 1.11 0.25 0.50 
R8` 2.4 12.03 10.83 1.00 0.90 
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discarded and the pellet was re-suspended in 400 μL Milli-Q water, using a syringe 
and a 25G needle. Two aliquots of 25 μL of this suspension were taken to determine 
the protein content, using a BCA TM Protein Assay Kit. The remaining 350 μL of this 
suspension was used to determine the iron content by atomic absorption. With this 
purpose, the suspensions were placed in Teflon tubes and left for 24 hours at 80°C to 
dryness. After that, 1 mL of highly purified HNO3 (>69.0%) was added, and then the 
samples were digested using a microwave digestor (MVS-2 Berghof). Samples were 
cooled and then diluted to 5 mL with Milli-Q water. Iron content was determined by 
graphite furnace atomic absorption spectroscopy (Varian SpectrAA with Zeeman 
corrector).  
3.3.3 Subcellular localisation  
3.3.3.1 Immunocytology  
 
Both cell lines (OK and VSMC) were seeded in 8 chamber slides and grown in 
their appropriate culture medium. After overnight growth, the supernatants were 
aspirated out and the cells were treated with 0.007 g/L Fe2O3 of fluorescein-labelled 
R8 nanoparticles in serum free medium for 24 hours. After 24 hours, the supernatants 
were aspirated out and the cells were washed 3 times with cold PBS, fixed with 3% 
(w/v) paraformaldehyde in PBS for 10 minutes and washed 3 times with cold PBS. 
They were then incubated with 20 mM glycine in PBS for 10 minutes, washed again 3 
times with cold PBS, permeabilised with 0.1% (w/v) saponin in PBS for 30 minutes, 
washed again and incubated with the primary antibodies for 1 hour at room 
temperature. For the endoplasmic reticulum and early endosomes detection, an anti-
Derlin-1 (Sigma) antibody and an anti-EEA1 antibody (Santa Cruz Biotechnology 
Inc., Dallas, Texas, USA) were used respectively. After that, the cells were washed 3 
times with PBS and then incubated for 30 minutes in the dark with the corresponding 
Alexa fluorescent secondary antibody, followed by 3 times wash with PBS. Cells were 
mounted with Prolong®Gold antifade reagent with DAPI (Life Technologies, USA). 
For co-localisation, an Axiovert 200M fluorescence microscope equipped with 
ApoTome for structured illumination and Axiovision software were used. Slides were 
excited at 470 ± 20 nm and green fluorescence was detected with a band pass filter at 
525 ± 25 nm. Red fluorescence was excited using the long pass filter at 546 ± 6 nm  
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and emission at 590 nm, and DAPI was excited using the long pass filter at 436 ± 10 
nm and emission at 480 ± 20 nm. Superimposition of green, red and blue fluorescence 
generated the final merged image. 
3.3.3.2 Trackers (Lyso- and Mito- trackers)  
 
Both cell lines (OK and VSMC) were seeded in 8 chamber slides, and grown in 
their appropriate culture medium. After overnight growth, the supernatants were 
aspirated out and the cells were treated with 0.007 g/L Fe2O3 of fluorescein-labelled 
R8 nanoparticles in serum free medium for 24 hours. After 24 hours, the supernatants 
were aspirated out and the cells were washed 3 times with PBS. For visualisation of 
the endo-lysosomal compartments, cells were incubated with 75 nM of LysoTracker® 
Red DND-99 (Life Technologies) for 2 hours at 37 ºC, following the manufacturer 
instructions. After this, the cells were washed with PBS, fixed with 3% (w/v) 
paraformaldehyde in PBS for 10 minutes, washed again three times, and mounted for 
microscopy. For mitochondria, cells were incubated with 200 nM of 
MitoTracker®Red CMXRos (Life Technologies) for 45 minutes at 37 ºC and then 
they were processed as for Lysotracker. The slides are ready for observation under 
Axiovert 200M fluorescence microscope equipped with ApoTome. Axiovision 
software was used. Slides were excited at 470 ± 20 nm, and green fluorescence was 
detected with a band pass filter at 525 ± 25 nm. Red fluorescence was excited using 
the long pass filter at 546 ± 6 nm and emission at 590 nm, and DAPI was excited 
using the long pass filter at 436 ± 10 nm and emission at 480 ± 20 nm. 
Superimposition of green, red and blue fluorescence generated the final merged 
image. 
3.3.4 Study of endocytosis mechanism  
3.3.4.1 Potassium depletion 
 
Opossum Kidney cells, were seeded in 8 chamber slides and grown as previously 
described. Cells were washed once with potassium-free buffer (in mM, 140 NaCl, 20 
Hepes pH 7.4, 1 CaCl2, 1 MgCl2, and 5.55 D-glucose) followed by a wash with 
hypotonic buffer (potassium-free buffer diluted with water 1:1). After three additional  
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washes with potassium-free buffer, cells were then incubated for 4 hours with 0.007 
g/L Fe2O3 of fluorescein-labelled R8 nanoparticles in potassium-free buffer. As a 
positive control, different wells of OK cells were treated as above with a potassium-
containing buffer and incubated with the same fluorescein-labelled R8 nanoparticles 
concentration and time in potassium-containing buffer. After incubation, the cells 
were washed, fixed and mounted as explained above and observed with Axiovert 
200M fluorescence microscopy. Slides were excited at 470 ± 20 nm and green 
fluorescence was detected with a band pass filter at 525 ± 25 nm, DAPI excited using 
the long pass filter at 436 ± 10 nm and emission at 480 ± 20 nm.  
3.3.4.2 Chlorpromazine inhibitor 
 
After cell growth in 8 chamber slides as described previously, OK cells were 
incubated with 10 μg/mL chlorpromazine (Sigma) for 1 hour in serum free culture 
medium at 37 ºC. Subsequently, cells were incubated with 0.007 g/L Fe2O3 of 
fluorescein-labelled R8 nanoparticles and chlorpromazine for 4 hours. As a positive 
control, cells were treated with transferrin from human serum conjugated with Alexa 
fluor®594 (Life Technologies) at a concentration of 50 μg/mL. After incubation, cells 
were washed, fixed, mounted and observed under Axiovert 200M fluorescence 
microscopy. Slides were excited at 470 ± 20 nm and green fluorescence was detected 
with a band pass filter at 525 ± 25 nm. Red fluorescence was excited using the long 
pass filter at 546 ± 6 nm and emission at 590 nm, and DAPI was excited using the 
long pass filter at 436 ± 10 nm and emission at 480 ± 20 nm.  
3.4 Results  
3.4.1 Bioferrofluids characterisation  
 
The iron contents of bioferrofluid stock samples were determined by atomic 
absorption in a plasma spectrometer. Concentrations of iron contents are 1.8, 8.1 and 
8.1 g/L Fe2O3 for R1` bioferrofluids, R8` bioferrofluids and fluorescein-labelled R8 
nanoparticles (FR8) respectively. 
The samples were characterised by TEM and DLS and the results are shown in 
Figs. 3.5, 3.6 and 3.7. Most of the nanoparticles are spherical and quite homogeneous 
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in size as shown in Fig. 3.5. The size distribution analysis for the maghemite magnetic 
nanoparticles is shown in Fig. 3.6. The core size (mean ± SD) is 4.40 ± 0.86 and 13.08 
± 2.33 for R1` and R8` bioferrofluids respectively, the core size of FR8 is similar to 
that of R8`.  
DLS observations for each sample showed a single population of particles as 
represented in Fig. 3.7. The average hydrodynamic diameter for each sample is 84, 
163 and 112 for R1` bioferrofluids, R8` bioferrofluids and FR8 respectively. 
Measurements of zeta potential of the nanoparticles suspension for all samples yielded 
average values close to zero.  
Figure 3.5: TEM images of maghemite magnetic nanoparticles in bioferrofluids (a) R1`, (b) R8`. 
Figure 3.6:  Size distribution analysis of spherical maghemite magnetic nanoparticles (a) R1`, (b) R8`.  
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Figure 3.7: Distribution of hydrodynamic diameters in bioferrofluid samples from DLS measurements.  
3.4.2 Study of the cellular uptake and the corresponding kinetic behaviour 
 
Nanoparticles internalisation into VSMC and OK cells was studied by two ways: 
qualitatively using fluorescein-labelled NPs and quantitatively using non-fluorescent 
NPs and atomic absorption.   
3.4.2.1 Qualitative determination of uptake using fluorescent nanoparticles 
 
Both cell lines (OK and VSMC) were treated with a non-toxic dose (0.007 g/L 
Fe2O3) of FR8 for 4, 8, 12 and 24 hours and visualised under fluorescence microscope. 
A significant amount of fluorescence was observed after 4 hours of incubation, which 
increased by increasing the incubation time up to 24 hours in both cell lines. FR8 
showed a perinuclear dotted pattern of staining in both OK and VSMC Fig. 3.8. In the 
case of VSMC, nanoparticles were surrounded completely the nuclei (Fig. 3.8, lower 
panel), while inside OK cells the nanoparticles were located laterally to the nuclei 
(Fig. 3.8, upper panel), most likely as a consequence of the epithelial origin and 
differentiation of the cells.  
 
 
 
 
3.4. Results 105 
 
Figure 3.8: Internalisation of fluorescein-labelled R8 nanoparticles in OK and VSMC at different time 
points of incubation. Upper panel is OK cells after (a) 4, (b) 8, (c) 12 and (d) 24 hours of incubation, 
lower panel is VSMC after (e) 4, (f) 8, (g) 12 and (h) 24 hours of incubation. Scale bar: 20 µm. 
3.4.2.2 Quantitative iron detection  
 
In order to check whether the NPs were internalised into the cells and the detected 
fluorescence was not an artifact of fluorescent NP decomposition, quantitative 
determination of iron content inside the cells using atomic absorption was carried out.  
In this section, we also explore the effects of nanoparticle size, nanoparticle 
concentration and cell type on the nanoparticle uptake. Both cell lines (OK and 
VSMC) were treated with different concentrations of R1`and R8` bioferrofluids for 24 
hours. Results corresponding to OK cells evidence the effect of the nanoparticle size 
on cellular uptake, since the cell capacity to internalise R1` (84 nm) is much higher as 
compared to R8` (163 nm) as shown in Fig. 3.9(a). In the R1` uptake curve a 
concentration dependent uptake is observed, since the increase in the concentration of 
the nanoparticles is accompanied by an increase in their cellular uptake. The curve 
nearly reaches the saturation above the concentration of 0.007 g/L Fe2O3. On the other 
hand, in the R8` uptake curve, the concentration increase of the nanoparticles is 
accompanied with an increase in the cellular uptake until a concentration of 0.007 g/L 
Fe2O3. After this value the uptake slightly decreases at a concentration of 0.01 g/L 
Fe2O3. In case of VSMC, the effect of nanoparticle size on cellular uptake is 
summarised in Fig. 3.9(b). For R1` and R8` uptake curves, a concentration dependent 
uptake is also observed, since the increase in the concentration of the nanoparticles is
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accompanied by an increase in the cellular uptake. VSMC did not reach the saturation 
state upon treatment with different nanoparticles concentrations up to 0.01 g/L Fe2O3. 
Figure 3.9: Quantitative iron detection for OK cells (a) and VSMC (b), after incubation with different 
concentrations of R1` and R8` bioferrofluids for 24 hours. Values represent mean ± SEM (n=6).  
 
The effect of cell type on the nanoparticles uptake is clearly showed in Fig. 3.10, 
where VSMC are taken up more R1` Fig. 3.10(a) and R8` Fig. 3.10(b) as compared to 
OK cells. It is therefore evident that the difference in uptake rates could explain the 
greater toxicity of these NPs in VSMC than in OK cells as shown in previous chapter 
For the quantitative evaluation of the uptake kinetics, we performed a time-course 
assay of non-fluorescent NPs uptake in VSMC and OK cells. Cells were incubated 
with R8` at concentration 0.007 g/L Fe2O3 for different time periods. The results 
showed an increase in the uptake with time, where nanoparticles uptake was observed  
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to be more rapid in the first 4 hours of incubation in OK cells, as shown in Fig. 
3.11(a), which reached to the higher uptake at 12 hours of incubation. In the case of 
VSMC, a steady increase in the uptake with time was observed and the cell did not 
reach the saturation even after 24 hours of incubation, as shown in Fig. 3.11(b). These 
results are consistent with those obtained in section 3.4.2.1 using fluorescein-labelled 
R8 nanoparticles. 
Figure 3.10: Effect of cell type on the nanoparticles uptake. Both cell lines (OK and VSMC) were 
incubated with different concentrations of R1` (a) and R8` (b) bioferrofluids for 24 hours. Values 
represent mean ± SEM (n=6). 
3.4.3 Subcellular localisation  
 
Studying the subcellular fate of the nanomaterial inside the cell helps to give an 
idea about the endocytosis mechanism, as well as monitoring the localisation of drug 
delivery nanomaterials. The subcellular localisation was investigated in both cell lines  
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Figure 3.11: Time dependent uptake of R8` bioferrofluids in OK cells (a) and VSMC (b). Values 
represent mean ± SEM (n=6).  
 
(OK and VSMC) treated with a non-toxic dose of FR8 for 24 hours. Different 
antibodies and trackers were used and images were taken with the help of a 
fluorescence microscope equipped with ApoTome. Results showed that fluorescein-
labelled nanoparticles were not found in the endoplasmic reticulum, Fig. 3.12, the 
early endosomes, Fig. 3.13, or in the mitochondria, Fig. 3.14, as manifested by the 
absence of co-localisations with the corresponding antibodies or trackers. However, 
positive co-localisation indicated by yellow pixel in the merge image was observed in 
the endo-lysosomal compartments (Lysosomes and late endosomes) after 24 hours of 
exposure to fluorescein-labelled nanoparticles, as shown in Fig. 3.15. 
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Figure 3.12: Nanoparticles subcellular localisation using an endoplasmic reticulum marker (Anti-Derlin 
Ab). Cells were treated with fluorescein-labelled R8 nanoparticles at 0.007 g/L Fe2O3 for 24 hours. 
Samples were examined under fluorescence microscope equipped with ApoTome. The higher panel is 
OK cells with fluorescein-labelled R8 in green and DAPI in blue (a), Anti-Derlin Ab in red and DAPI in 
blue (b), and the merge image (c).  The lower Panel is VSMC with fluorescein-labelled R8 in green and 
DAPI in blue (d), Anti-Derlin Ab in red and DAPI in blue (e), and the merge image (f). Scale bar: 20 µm. 
Figure 3.13: Nanoparticles subcellular localisation using an early endosome marker (Anti-EEA1 Ab). 
Cells were treated with fluorescein-labelled R8 nanoparticles at 0.007 g/L Fe2O3 for 24 hours. Samples 
were examined under fluorescence microscope equipped with ApoTome. The higher panel is OK cells 
with fluorescein-labelled R8 in green and DAPI in blue (a), Anti- EEA1 Ab in red and DAPI in blue (b), 
and the merge image (c). The lower Panel is VSMC with fluorescein-labelled R8 in green and DAPI in 
blue (d), Anti- EEA1 Ab in red and DAPI in blue (e), and the merge image (f). Scale bar: 20 µm. 
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Figure 3.14: Nanoparticles subcellular localisation using MitoTracker®Red CMXRos. Cells were treated 
with fluorescein-labelled R8 nanoparticles at 0.007 g/L Fe2O3 for 24 hours. Samples were examined 
under fluorescence microscope equipped with ApoTome. The higher panel is OK cells with fluorescein-
labelled R8in green and DAPI in blue (a), MitoTracker in red and DAPI in blue (b), and the merge image 
(c). The lower Panel is VSMC with fluorescein-labelled R8 in green and DAPI in blue (d), MitoTracker 
in red and DAPI in blue (e), and the merge image (f). Scale bar: 20 µm. 
Figure 3.15: Subcellular localisation of nanoparticles using LysoTracker® Red DND-99. Cells were 
treated with fluorescein-labelled R8 nanoparticles at 0.007 g/L Fe2O3 for 24 hours. Samples were 
examined under fluorescence microscope equipped with ApoTome. The higher panel is OK cells with 
fluorescein-labelled R8 in green and DAPI in blue (a), LysoTracker in red and DAPI in blue (b), and the 
merge image (c). The lower Panel is VSMC with fluorescein-labelled R8 in green and DAPI in blue (d), 
LysoTracker in red and DAPI in blue (e), and the merge image (f). Scale bar: 20 µm. 
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3.4.4 Study of endocytosis mechanism 
 
There are several methods that can be used to study the endocytosis mechanism of 
a given nanomaterial in a certain cell type. A method based in pharmacological 
inhibitors has been used in this work.  
3.4.4.1 Potassium depletion 
 
Potassium depletion of cells removes the clathrin-coated pits from the cell 
membrane and therefore it specifically prevents this pinocytotic mechanism. OK cells 
were washed with potassium free buffer followed by washing with hypotonic solution 
and then incubated for 4 hours with potassium free buffer containing 0.007 g/L Fe2O3 
fluorescein-labelled R8 nanoparticles. Results showed inhibition in the nanoparticles 
internalisation due to potassium depletion exposure as shown in Fig. 3.16. Therefore, 
this result suggests that nanoparticles are internalised following a clathrin-dependent 
endocytosis route. 
Figure 3.16: Effect of Potassium depletion on the nanoparticles internalisation by OK cells. (a) Positive 
control cells (b) Potassium depletion treated cells. Scale bar: 20 µm. 
3.4.4.2 Chlorpromazine inhibitor  
In order to confirm that our nanoparticles internalised through clathrin-mediated 
endocytois, another inhibitor of clathrin-coated pit formation, like chlorpromazine, 
was used. OK cells were incubated for 1 hour at 37ºC with 10 µg/ml chlorpromazine, 
followed by incubation with 0.007g/L Fe2O3 fluorescein-labelled R8 nanoparticles and 
chlorpromazine for 4 hours. The concentration of the inhibitor was adjusted using 
transferrin, which is considered a ligand exclusively internalised via the clathrin 
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coated pit pathway. Results showed that nanoparticle internalisation was completely 
inhibited upon chlorpromazine treatment, as shown in Fig. 3.17. Similar results were 
obtained using fluorescent transferrin as a positive control. These results confirm that 
a clathrin-mediated endocytosis route is the responsible for the nanoparticle uptake. 
Figure 3.17: Effect of chlorpromazine on nanoparticles uptake by OK cells. (a) cells incubated with 
transferrin; (b) cells incubated with transferrin and chlorpromazine; (c) cells incubated with fluorescein-
labelled R8; (d) cells incubated with fluorescein-labelled R8  and chlorpromazine. Scale bar: 20 µm. 
3.5 Discussion and conclusions 
The ability of the nanomaterials to breach the plasma cell membrane is 
considering as a crucial factor for their efficacy in biomedical applications. Hence, 
studies pertaining to nanomaterial cellular uptake are of utmost importance. 
Fluorescent microscope confers the way to visualise the nanomaterials 
distribution inside the cell. This work has been centred to visualise the internalisation 
of fluorescein-labelled R8 nanoparticles (112 nm) in two cell lines (OK and VSMC). 
The nanoparticles were not detected after 2 hours of incubation (data not shown), but 
were evident after 4 hours of incubation and their internalisation increased in a time 
dependent manner, as shown in Fig. 3.8. These results were confirmed by quantitative 
measurements of the cellular iron content using acidic digestion method and atomic 
absorption spectroscopy, as depicted in Fig. 3.11. It was evident not only a time 
dependent internalisation, but also a cell type dependent internalisation. Thus, OK 
cells were reached their higher uptake concentration at 12 hours, as indicated in Fig.   
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3.11(a), while VSMC did not reach the saturation state up to 24 hours of incubation, as 
shown in Fig. 3.11(b). This could be explained by different saturation capacity 
between both cell lines. These kinetic uptake results are consistent with other studies 
[6,39–41].  
Many factors, such as nanomaterial concentration, nanomaterial physicochemical 
properties, cell type, and others, influence nanomaterial uptake by the cells. In this 
work, we studied the effect of NPs concentration, NPs size and cell type on the NPs 
uptake. A concentration dependent uptake was reported for both VSMC and OK cells 
treated with R1 and R8 bioferrofluids, as shown in Fig. 3.9. However, in OK cells 
treated with R8 a slight decrease in the curve was noticed at the concentration 0.01 g/L 
Fe2O3, see Fig. 3.9(a), but this decrease could be neglected due to the large error bars. 
This finding is in agreement with previous studies [6,39,42].  
The size dependent uptake was conspicuous in each cell line (OK or VSMC), 
since R1` (84 nm) internalised into the cells better than R8` (163 nm), as shown in Fig. 
3.9. The internalised R1` was 1.78 and 1.30 folds of R8` in OK cells and VSMC 
incubated with a concentration of 0.007 g/L Fe2O3, respectively. This could explain 
the higher toxic effects associated with R1 as compared with R8 in both cell lines. The 
pronounced internalisation difference between R1` and R8` could be explained by the 
influence on their respective uptake due to different endocytosis mechanisms. The size 
effect on cellular uptake has been of previous concerns [4,7]. For instance, Huang et 
al. studied the uptake of positively charged PVP-IONPs in mouse macrophage cells 
using a series of samples with Dp = 8, 23, 37, 65 nm and corresponding hydrodynamic 
sizes DH = 32, 71, 102 and 118 nm, results showed a maximum of iron mass uptake 
per cell for a size of Dp =37 nm and DH=102 as compared with other ones, indicating 
that DH=102 nm is an optimal size for the macrophages uptake [6]. 
In another study on immortalised human T cells, internalisation of dextran coated 
aminated IONPs having similar core sizes (Dp = 6.1, 5.6 and 6.5 nm) but different 
hydrodynamic sizes (DH = 33, 53, 107 nm) and different IO loading (numbers of 
cores: 1.9, 5.2, 11.3), it was found that NPs were substantially uptaken only after a  
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certain degree of amination and that internalisation rate was considerably higher (one 
order of magnitude) for DH = 107 nm nanoparticles [43].. Thus, both studies found a 
maximum internalisation rate for a hydrodynamic size somewhat above 100 nm. On 
the other hand, a comparison of cellular uptake of IONPs with Dp = 5 and 30 nm using 
porcine aortic endothelial cells, before and after coating with dextran or PEG, showed 
higher iron uptake for 5 nm NPs than 30 nm NPs when coated with dextran and the 
reverse for uncoated or PEG coated NPs [44]. Unluckily, it is difficult to extract 
conclusions from these results because data on aggregation and hydrodynamic 
diameters are missing. In our work, surprisingly, both Dp and DH have shown a direct 
impact on cell mortality and cell internalisation 
The cell type dependence of nanoparticles uptake was indicated in Fig. 3.10. At a 
concentration of 0.007 g/L Fe2O3, a 1.71 fold increases in the R1` uptake was detected 
for VSMC as compared to OK cells (see Fig. 3.10(a)), while 2.33 fold increases in the 
R8` uptake was detected for VSMC as compared to OK cells (see Fig. 3.10(b)). This 
different behaviour is due to different cell physiology, which might explain the high 
sensitivity of VSMC toward the nanoparticles (R1 and R8) comparing with OK cells. 
These results are in agreement with several previous studies [26,45,46]. 
Several mechanisms are responsible for the nanomaterial internalisation into the 
cells; each mechanism differs from the other in its components as well as in the 
internalisation route. During the internalisation, nanomaterials are exposed to different 
environments and conditions that vary in its harshness; this could be favourable or 
unfavourable to the nanomaterial depending on its purpose of use as well as on its 
properties. Hence, good understanding of the nanomaterial internalisation mechanisms 
and the factors affecting it will help to define the subcellular fate of the nanomaterial 
inside the cell, as well as improve the designing of an efficient drug delivery carrier.  
Fluorescein-labelled R8 nanoparticles were tracked in four different cellular 
organelles (endoplasmic reticulum, early endosomes, mitochondria and endo-
lysosomal compartments) in both cell lines (OK and VSMC) using fluorescent 
antibodies and trackers with the help of fluorescent microscope equipped with 
ApoTome. Fluorescein-labelled nanoparticles were not found in the endoplasmic 
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reticulum, early endosomes, mitochondria or the nucleus, as shown in Fig. 3.12, 3.13 
and 3.14. They are, however, observed inside the endo-lysosomal compartments 
(lysosomes and late endosomes) after 24 hours of incubation in both cell lines (OK 
and VSMC), as shown in Fig. 3.15. These results are in agreement with previous 
studies [39,45–47]. 
The existence of FR8 in the endo-lysosomal compartments suggests that the 
mechanism responsible of the nanoparticle internalisation is a clathrin-dependent 
endocytosis one. In order to confirm the endocytosis mechanism, pharmacological 
inhibitors (potassium depletion and chlorpromazine) were used. Potassium depletion 
of the cell blocks clathrin-dependent endocytosis by removing clathrin from the 
membrane, while chlorpromazine blocks this route by inhibiting Rho GTPase. 
Complete inhibition of FR8 internalisation was detected in OK cells upon potassium 
depletion treatment as well as chlorpromazine treatment, as shown in Figs. 3.16 and 
3.17, indicating that clathrin-dependent endocytosis is the responsible route for the 
internalisation of FR8. These results are consistent with other previous studies 
[48,49].Mores studies are required, in order to reveal the R1 endocytosis mechanism, 
to give an explanation of the size dependent internalisation.  
Then, we can conclude that nanoparticles internalisation is dependent on many 
factors such as, incubation time, nanoparticles concentration, nanoparticles size and 
cell type. The obtained results give explanations for the caused toxicity by R1 in 
compared with R8 in both cell lines, as well as, explanations of the high sensitivity of 
VSMC toward the nanoparticles compared with OK cells. Fluorescein-labelled R8 
nanoparticles are accumulated in the endo-lysosomal compartments after 24 hours of 
incubation with OK and VSMC cells, which should be confirmed by further 
experiments as electron microscopy techniques. Clathrin-dependent endocytosis is 
responsible for internalisation of FR8 in OK cells. Further studies should be carried 
out with R1, in order to investigate its endocytic route of internalisation. 
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Chapter 4  
In vitro haemocompatibility studies of 
superparamagnetic iron oxide 
nanoparticles 
4.1 Introduction  
Haemostasis is a very important protective physiological process that maintains 
blood in a fluid state under normal conditions. It responds to blood vessel injury by 
rapid formation of blood clot (thrombus), followed by thrombus dissolution 
(fibrinolysis) and damaged vessel repairs [1]. Human beings are frequently exposed to 
natural and anthropogenic nanomaterials. As a result, it became evident that airborne 
nanomaterials have a thrombogenic effect as a result of pulmonary exposure [2–4]. 
Similarly, medically applied nanomaterials can stimulate blood clotting by the 
coagulation pathways activation or by inducing platelet aggregation [5]. More 
interestingly, some reported results show that they can behave as either pro-coagulant 
or hypo-coagulant agents depending on size [6], coating material [7–10], charge 
[11,12] and the material composition [13].  
Despite the importance and coverage of biomedical applications of metal oxides, 
not many studies have been focused on the toxicological behaviour of these materials 
in blood. Thus, Ostomel et al. have investigated the haemostatic response due to 
surface charges of a variety of metal oxide particles which did not include SPIONs 
[11], Li et al. have investigated the influence of nano-TiO2 on erythrocyte [14] and 
Singh et al. have investigated the disturbance in iron homeostasis caused by SPIONs 
[15]. 
As detailed below, this chapter will focus on the haemocompatibility of bioferrofluids. 
As they are developed for intravenous administration, the assurance they will not 
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cause any toxicity to blood components when injected is an important issue that 
should be taken into consideration, especially for a successful development of these 
nanoparticles. The evaluation of the haemostatic behaviour of nanomaterials is carried 
out by a set of studies such as the study of the nanomaterials effect on the coagulation 
process, of their toxicity to blood components and of their haemolytic effect. These 
studies are explained in details in the next paragraphs.  
4.1.1 Studies for nanomaterial toxicity in blood  
Blood coagulation studies: Several methods have been used to investigate the 
effects of the nanomaterials on the coagulation process. They include global tests 
(prothrombin time (PT), activated partial thromboplastin time (aPTT) and fibrinogen), 
thrombus – elastography, platelets aggregation and degradation products of fibrinogen 
and fibrin. Recently, a detailed description of methods has been published [16], which 
focuses on the global plasma coagulation tests (PT, aPTT and fibrinogen) and platelet 
aggregation. Some studies have evaluated the compatibility of nanomaterials with the 
blood coagulation system in vivo in mice [8], rats [17] and rabbits [18], while most of 
the authors have carried them out only in vitro [6–8]. 
Haemolysis studies: The nano-size and the unique physicochemical properties of 
the nanomaterials can cause haemolysis by acting on the membrane of red blood cells 
[19]. Therefore, in vitro biocompatibility studies should also include evidence of 
haemolysis. Several studies have revealed the effect of the nanomaterials on the blood 
by measuring their haemolytic action in vitro [20]. However, direct results 
interpretation of these studies is complicated due to variability in the experimental 
conditions such as incubation time of blood with the nanomaterials, the wavelength at 
which the haemoglobin is quantified, the centrifugation forces, blood storage time and 
conditions and blood source (human or rabbit) [21].  Nanomaterials could interfere 
with the haemolysis detection assay by several ways. For instance, separation by 
ultracentrifugation of gold nanoparticles of 5 nm size, which are similar to the size of 
haemoglobin, could also precipitate the haemoglobin, resulting in a false-negative 
results. Also, false-negative results could be obtained as in the case of haemoglobin 
adsorption on the nanomaterial surface. In contrast, false-positive results could be 
obtained in the case of metal oxide nanoparticles, since they have the ability to oxidise 
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the haemoglobin. Therefore, modification of the haemolysis detection assay is 
mandatory depending on the type of nanomaterials [22].  
Complete blood count assay: Quantification of leukocytes (white blood cells), 
erythrocytes (red blood cells) and platelets is important to rule out immediate 
cytotoxicity of nanomaterials or contact spontaneous platelets aggregation [5,7]. 
Platelets are very sensitive to contact with biological substances (collagen, adenosine 
diphosphate (ADP), epinephrine) and others, including ristocetin, solid materials and 
high shear stress. When this occurs they tend to produce micro aggregates of platelets 
that are easily detected by modern blood cell counters because they decrease the 
number of platelets and alter the size distribution curve. Nanomaterials can potentially 
damage the cell membrane and even the cytoplasm since they can penetrate inside 
cells. Blood cell counters not only quantify blood cells, but they can also detect 
abnormalities in shape, size and homogeneity. 
In the following we will briefly describe the coagulation process, regulatory 
factors and related test principles. 
4.1.2 Coagulation cascade 
Coagulation process occurs after the injury of blood vessels through two 
processes: a) primary haemostasis, in which, platelets immediately form a plug at the 
injury site by adhering to subendothelial collagen-von Willebrand factor (vWF) via 
their glycoprotein (GP) Ib receptors and b) secondary haemostasis that consists of two 
pathways: i) the extrinsic pathway (initiation pathway) and ii) the intrinsic pathway 
(propagation pathway), both pathways are merged into a common pathway that ended 
with the formation of fibrin strands, which strengthen the platelets plug.  
The coagulation pathways are a series of reactions in a descending way, in which 
an inactive enzyme (zymogen) of serine protease (such as coagulation factor IX, X, 
XI...etc), cofactor (such as FVIII or FV) or transglutaminase (such as FXIII) becomes 
active and then catalyses the next reaction in the cascade. The coagulation factors are 
referred as factor (F), Roman numbers and lowercase “a” in case of active form. 
In 1964, two different groups proposed the coagulation concept as a waterfall/  
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cascade model. This model suggests that the intrinsic pathway is the primary pathway 
that trigger thrombin formation following a vascular damage, while the extrinsic 
pathway is a complementary one by which the thrombin can be formed [23–25]. The 
model was improved by important additions and modifications during the following 
years [26]. Currently, the model underlines the main role of the extrinsic pathway as 
the initiator of thrombin formation and the intrinsic pathway as the amplification or 
propagation pathway, as shown in Fig. 4.1. 
4.1.2.1 Extrinsic pathway (initiation pathway) 
Upon the vascular damage, the tissue factor (TF) -a lipid-dependent 
transmembrane glycoprotein that is present in subendothelial cells and monocytes 
necessary for the initiation of blood coagulation cascade and formation of thrombin- 
becomes exposed to the blood. TF binds to a) the coagulation factor VII that is auto-
cleaved within the complex to FVIIa, or to b) the activated form of the coagulation 
factor VII (FVIIa), since a fraction of coagulation factor VII circulates in blood in its 
active form. The binding between TF and factor VII/VIIa triggers the coagulation by 
converting factors IX and X to their active forms FIXa and FXa, respectively, see Fig. 
4.1. Factors IXa and Xa may remain associated with TF-bearing cells or diffuse to the 
blood and bind to the surface of activated platelets that formed the primary platelets 
plug. Activated platelets have a great potential to bind to the coagulation factors, this 
ability is due to their negatively charged phospholipids [27].  
The formation of thrombin from prothrombin requires the formation of a 
hydrolytic enzyme called “prothrombinas complex” that consists of FXa, 
phospholipids, calcium and the activated form of co-factor V (FVa), as described in 
Fig. 4.1. Factor V is activated by two substances, FXa and thrombin.  The generated 
thrombin -the key enzyme of the coagulation system- initiates several positive 
feedback amplification reactions in order to increase the clot formation. This happens 
through activation of several coagulation factors that are involving in the intrinsic 
pathway as the coagulation factor XI and co-factor VIII, as well as, activation of co-
factor V in the common pathway. Also, thrombin activates the conversion of 
fibrinogen to fibrin and activates the platelets at the injury sites, increasing the 
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phospholipids at their surface [1]. In addition, the formed thrombin activates the 
coagulation factor XIII to FXIIIa that rapidly cross-links fibrin monomers [28]. 
Moreover, thrombin protects the formed clot from solubilisation and proteolysis 
(fibrinolysis) through the activation of thrombin activatable fibrinolysis inhibitor 
(TAFI). Now, TAFI inhibits the conversion of plasminogen to plasmin (the primary 
enzyme of fibrinolysis) by removing the carboxy-terminal lysine residues from fibrin 
surface, because these lysines are important for the binding of fibrinolytic enzymes to 
fibrin [29].  
Figure 4.1: Schematic representation of the coagulation cascade. Coagulation proteins are referred as 
factor (F), Roman numbers and lowercase “a” in case of active form. Green dotted lines represent positive 
feedback amplification reactions, while red dotted lines represent coagulation inhibition reactions. The 
red box includes the proteins that are excluded from the revised coagulation cascade model. The 
efficiency of the extrinsic, intrinsic and common pathways are evaluated by measuring PT, aPTT and 
Thrombin time (TT) respectively.  
4.1.2.2 Intrinsic pathway (propagation pathway) 
The thrombin-activated coagulation factor XI (FXIa) initiates the activation of the 
coagulation factor IX to FIXa. The co-factor VIII circulates bound to the von 
Willebrand factor - vWF is an important protein that is essential for the adhesion of 
platelets at the site of injury to form the primary platelets plug. In addition, after
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platelets activation vWF works along with fibrinogen to mediate platelets-platelets 
interaction permiting clot stabilisation. Also vWF protects FVIII from proteolytic 
degradation in the complex form. Upon thrombin activation, co-factor VIII dissociates 
from vWF and converts to its active form FVIIIa. FVIIIa binds to FIXa, calcium and 
phospholipids in order to form the “tenase complex”, which catalyses the activation of 
the coagulation factor X to FXa, which in turn catalyses the formation of thrombin, as 
described in Fig. 4.1 [30]. 
When blood comes in contact with a negatively charged surface (contact 
activation), a group of proteins including coagulation factor XII, high molecular 
weight kininogen (HK) and prekallikrein (PK), forms a complex leading to the 
activation of the coagulation factor XII to FXIIa. FXIIa catalyses the conversion of 
coagulation factor XI to FXIa and, subsequently, the coagulation cascade is initiated in 
a descending way, as described in Fig. 4.1 [31]. These proteins (HK, PK and FXII) do 
not appear in the revised coagulation cascade, since inherited deficiency of FXII, HK 
or PK is asymptomatic. However, deficiency in the coagulation factor XI exhibits 
haemorrhagic effects [32,33]. 
4.1.2.3 Common pathway 
Both extrinsic and intrinsic pathways are merged in a common pathway, which 
starts with the conversion of the prothrombin to thrombin in a reaction catalysed by 
prothrombinase complex.  
Thrombin catalyses the conversion of fibrinogen to fibrin monomers, through 
cleavage of fibrinopeptides A and B from fibrinogen, which alters the surface charge 
of the molecule. These fibrin monomers are converted to insoluble fibrin polymers 
(fibrin meshwork) by the action of thrombin-activated factor XIII (FXIIIa), which 
forms cross-links between and within the fibrin monomers to generate the insoluble 
fibrin meshwork around platelet aggregates [34]. A portray of the coagulation cascade 
is shown in Fig. 4.2. The final form of the blood clot is shown in Fig. 4.3. 
4.1.2.4 Regulation of blood coagulation by anticoagulant pathways  
In order to prevent any massive coagulation action, the coagulation process is 
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tightly regulated by a number of inhibitors that inhibit the systematic release of 
thrombin and other pro-coagulant proteases. These coagulation inhibitors 
(anticoagulants) are: 
Figure 4.2: A portray of the coagulation cascade. 
  
Figure 4.3: Blood clot structure using coloured 
scanning electron microscope (SEM). It consists of a 
cross-linked fibrin meshwork (white filaments), in 
which erythrocytes (red) are trapped [35] 
.  
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 The tissue factor pathway inhibitor (TFPI). An endogenous anticoagulant 
protein, a serine protease inhibitor, which inhibits further production of 
FXa and FIXa by the TF-FVIIa complex. The inhibition process occurs in 
two steps. First, the TFPI binds to and inactivates FXa; second, TFPI-FXa 
complex binds to and inhibits the TF-FVIIa complex. TFPI circulates in 
the plasma as a complex with plasma lipoproteins (80%) or free 
(uncomplexed) (5-20%). Lipoprotein-associated TFPI has less 
anticoagulant effect than the free TFPI. Free TFPI is released from 
endothelial cells to the circulation after heparin, non-heparin 
glycosaminoglycans, pentosan polysulphate, hypersulphated heparin, 
low-molecular weight heparin and tissue plasminogen activator 
administration [36]. 
 Antithrombin (AT). A serine protease inhibitor, which is stimulated by 
heparin and heparin-like molecules that are present on the surface of the 
intact endothelial cells as heparan sulfate. It inhibits the coagulation by 
inhibiting FXa and thrombin [37,38]. 
 Protein C. A vitamin-K-dependent protein, which is activated on the 
surface of intact endothelial cells by the binding between thrombin (a 
procoagulant and anticoagulant factor) and thrombomodulin (an 
endothelium-bound protein) into activated protein C (APC). APC with 
free protein S (a Vitamin-K-dependent co-factor protein) form a 
membrane bound complex, which can cleave factor Va to FV. Factor V 
acts as an anticoagulant agent that works in synergy with protein S in the 
degradation of FVIIIa to its inactive form (FVIII).  Thus, inhibiting the 
coagulation process [39]. 
  Nitric oxide, prostacyclin and ecto-ADPase. These substances are 
released from the intact endothelium and can cause a decrease in the 
platelets activity [30]. 
 Heparan sulfate. It is a glycosaminoglycan that is attached to the surface 
of intact endothelial cells. It acts as a cofactor for antithrombin.  
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 Tissue-type plasminogen activator (tPA). It is released from the 
endothelial cells and binds to lysine residues expressed on the fibrin 
surface. It catalyses the conversion of plasminogen (plasma protein 
synthesised in the liver) to plasmin. Plasmin proteolytically cleaves fibrin 
into fibrin degradation products and D-dimer (fibrinolysis) [40].  
4.1.3 Coagulation screening tests  
There are several tests used to evaluate the coagulation state in vitro as 
prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen 
and platelets count. The most common tests used are PT and aPTT, while thrombin 
time and fibrinogen test are not considered to be first-line screening tests although 
they are commonly performed. Platelets count should be checked in any case. 
4.1.3.1 Prothrombin Time  
The activity of the extrinsic pathway is evaluated by measuring the prothrombin 
time, an assay that was described in 1935 by Dr. Armand Quick [29]. In this assay 
tissue factor-phospholipid-calcium mixture or thromboplastin is added to platelets-
poor plasma. The most commonly used thromboplastin reagents are those derived 
from rabbit tissue [41]. Elongated PT time could be obtained in case of factors VII, X, 
V deficiencies and prothrombin deficiency as occurred with vitamin K-antagonist [42] 
or severe liver disease [43]. However, normal values of PT are detected in the case of 
haemophilia (factor VIII or factor IX deficiency). Hence, PT value does not reflect the 
coagulation process in vivo [30]. 
4.1.3.2 Activated partial thromboplastin time 
The activity of the intrinsic pathway is evaluated through measuring the activated 
partial thromboplastin time; a modified assay from partial thromboplastin time that 
was discovered by Drs. Langdell, Wagner and Brinkhous in 1953 [29]. In this assay 
non-physiological, negatively charged compounds (e.g., celite, kaolin, or ellagic acid 
suspended in a phospholipid mixture) are added to platelets-poor plasma [44]. 
Presence of such compounds (contact system activator) activates a series of reactions 
in a descending order ended with the formation of thrombin. Prolonged aPTT could be 
obtained in case of factors XII, XI, IX, VIII and V deficiencies, prothrombin 
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deficiency, liver disease, haemophiliaand the presence of anticoagulant agents such as 
heparin, argatroban, bivalirudin and lepirudin.  
4.1.3.3 Thrombin time 
This test is used in order to evaluate the efficiency of the common pathway. It is 
not considered to be a first-line screening test. In this test a bovine or human thrombin 
is added to platelets-poor plasma, which in turns converts fibrinogen into fibrin. The 
time for fibrin clot formation is then recorded. Thrombin time is similar to another 
time called “Reptilase time” (RT) which is more frequently used, but in this test a 
snake venom activator is added instead of thrombin. The thrombin time is sensitive to 
heparin while the reptilase time is not. Elongation of TT is associated with 
amyloidosis, fibrin degradation products, fibrinogen deficiency/abnormality, hypo-
albuminaemia and the presence of inhibitors as heparin [45–47]. 
4.1.3.4 Fibrinogen test  
This test is used to detect abnormal bleeding or coagulation disorder. A high level 
of fibrinogen is associated with several disorders such as inflammation, cardiovascular 
diseases, strokes and cancer. However, low fibrinogen level increases the risk of 
bleeding and it is associated with several disorders such as haemodilution, liver 
diseases and inherited deficiencies (e.g. Hypofibrinogenaemia, afibrinogenaemia and 
dysfibrinogenaemia).  Several methods are used to measure the plasma fibrinogen 
level such as a) Blombäck and Blombäck method, b) clotting rate assay according to 
von Clauss, c) immunoassays, including radial immunodiffusion (RID) according to 
Mancini et al., ELISA or nephelometric, d) total amount of clottable fibrinogen by 
means of turbidimetric assay according to Ellis and Stransky, e) Chromotime System, 
and f) prothrombin time-derived fibrinogen assay on ACL coagulometer [48–50]. 
4.1.3.5 Platelets count  
Platelets count is often a part of complete blood count (CBC) assay. 
Abnormalities in platelets account are associated with bleeding disorders and other 
bone marrow diseases as leukaemia.  
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4.1.4 Haemolysis  
Haemolysis is the breakdown of red blood cells, which leads to the leaking of 
haemoglobin and intracellular ingredients such as potassium into the plasma. 
Haemolysis can lead to life-threatening conditions such as anaemia, jaundice, 
hypertension, arrhythmia and renal failure [51]. Severe haemolysis could be detected 
visually with naked eyes. However, this method is unreliable in case of mild 
haemolysis detection, since the presence of bilirubin in serum may impair the ability 
to detect haemolysis visually, especially in neonatal samples in which elevated 
bilirubin concentration commonly happens. Mild haemolysed samples (serum free 
haemoglobin in the range between 0.3 and 0.6 g/L) could be detected by semi-
quantitative spectrophotometer measurement at wavelength 400-800 nm. Oxygenated 
haemoglobin is detected by two absorption peaks at the wavelengths 540 and 580 nm 
Fig. 4.4 [52]. In general, absorbed haemoglobin peak at 580 nm is preferable because 
it is a bit higher. Significant haemolysis is associated with decreasing in erythrocytes, 
haemoglobin and haematocrit [53].  
Figure 4.4: Light absorption spectra of human fetal and adult oxygenated haemoglobin. Absorptivity is 
expressed in L. mmol -1.cm-1 [52]. 
4.2 Objectives  
The aim of this chapter is to study the in vitro toxicity of our bioferrofluids (P4VP-g-
APEG bioferrofluids) and its components in blood, through investigating their effect 
on the coagulation process by measuring the prothrombin time and activated partial 
thromboplastin time, studying their effect on blood cells through measuring the blood 
cell count and detection of haemolysis by measuring the free haemoglobin. In 
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addition, this chapter explores the effect of surface coating of the nanoparticles on the 
blood haemostasis using two bioferrofluids, one is coated with dimercaptosuccinic 
acid and the other is coated with dimercaptosuccinic acid with short-chain diamine 
PEG.  
4.3 Materials and methods  
4.3.1 P4VP-g-APEG coated bioferrofluids preparation and characterisation 
Bioferrofluids preparation and characterisation methods are the same as described 
in Annex I.  The preparation conditions of the maghemite polymer nanocomposites 
used in this chapter are summarised in Table 4.1.  
Table 4.1: Preparation conditions of maghemite polymer nanocomposites for 
different samples.     
Sample P4VP 
(g/L) 
1M FeBr3  
(mL ) 
1M FeBr2 
(mL ) 
Fe/pyridine 
mol ratio 
Fe2+/ Fe3+ 
mol ratio 
H 0.4 1.584 0.794   
 
The prepared P4VP-g-APEG bioferrofluid was further purified by centrifugation 
at 196.000 G for 30 minutes and re-dispersed in PBS by ultrasounds. The dispersion 
was filtered through a sterile 0.22 µm membrane filter to obtain P4VP-g-APEG 
bioferrofluids.  
4.3.2 DMSA-bioferrofluids and DMSA-PEG-(NH2)2-bioferrofluids preparation and 
characterization 
These bioferrofluids were supplied by Prof. Puerto Morales, from the Instituto de 
Ciencia de Materiales de Madrid, as part of an ongoing collaboration. 
The synthesis was performed in three steps:  1) synthesis of magnetite 
nanoparticles, 2) surface modification with DMSA and 3) PEG conjugation and 
dispersion in water. Magnetite nanoparticles were obtained via thermal decomposition 
of an iron coordination complex as a precursor to ensure nanoparticle homogeneity in  
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size and shape following the method reported by Sun and co-workers [54,55].  Particle 
size and shape were studied using a 200 keV JEOL-2000 FXII microscope.  A drop of 
a dilute magnetic nanoparticle suspension in hexane was placed on a carbon coated 
copper grid and dried at 50 ºC.  Size distribution was determined from TEM 
micrographs through manual measurement of more than 200 particles and data were 
analysed with Gwyddion 3.25 software to obtain the mean size and standard deviation 
by gaussian fitting.  Particles were coated with meso-2,3-dimercaptosuccinic acid 
(DMSA) by a ligand exchange process to remove oleic acid, after which a short-chain 
diamine PEG (PEG-(NH2)2) was covalently bound to the nanoparticle surface via 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) activation of the 
carboxylic acids.  Colloidal properties of 0.5 mM Fe nanoparticle suspensions in water 
were characterised by dynamic light scattering using a Nanosizer ZS (Malvern).  Z-
Average values in intensity at pH 7 were used as the mean hydrodynamic size.  The 
polydispersity degree index was calculated by dividing the standard deviation by the 
mean size.  The Z potential was measured in a 0.01 M KNO3 solution.  Other 
properties of DMSA-bioferrofluids and DMSA-PEG-(NH2)2-bioferrofluids have been 
described in detail in previous publications [56,57]. 
4.3.3 Coagulation studies  
All haemocompatability experiments were performed at the hospital Clinico 
Universitario Lozano Blesa, Zaragoza, under the supervision of Professor Martín 
Gutierrez, Doctor Rosa Cornudella and Doctor José Antonio Moreno.  
4.3.3.1 Control plasma 
Blood samples were obtained from healthy human volunteers. Samples were 
collected in citrate (0.129 M) vacutainer tubes. The samples were centrifuged at 3500 
rpm to obtain platelets-poor plasma (PPP). The plasma was processed for the 
coagulation studies of PT and aPTT, using PT and aPTT HemoSILTM reagents and 
measured by the coagulometer TOP-ACL from IL-Instrumentation. The results were 
within the reference limits (9-14 s. and 23-37 s. respectively). 
4.3.3.2 PPP treated with bioferrofluids 
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PPP samples were mixed with different concentrations of bioferrofluids (P4VP-g-
APEG bioferrofluids, DMSA bioferrofluids and DMSA-PEG-(NH2)2 bioferrofluids) 
and processed for the measurement of PT and aPTT. 
 4.3.3.3 PPP treated with bioferrofluids coating components 
To study the effect of the coating on the coagulation, PPP samples were mixed 
with different concentrations of APEG, P4VP-g-APEG, DMSA, and PEG-(NH2)2and 
processed for the measurement of PT and aPTT.  
 4.3.4 Complete blood counts studies  
4.3.4.1 Control blood 
Blood samples were obtained from healthy human volunteers.  Samples were 
collected in EDTA K3, 1.8 mg/mL vacutainer. The blood samples were processed for 
CBC studies using a Coulter LH 780 analyzer from Beckman Coulter.  
4.3.4.2 Blood treated with bioferrofluids, and coating materials 
Blood samples were mixed with different concentrations of the investigated 
materials (P4VP-g-APEG bioferrofluids, DMSA bioferrofluids, DMSA-PEG-(NH2)2 
bioferrofluids, APEG, P4VP-g-APEG, DMSA, and PEG-(NH2)2) and processed for 
blood cell counting. 
4.3.5 Haemolysis studies  
4.3.5.1 Control blood  
Blood samples were obtained from healthy human volunteers. Samples were 
collected in Lithium heparin 17 UI/mL vacutainer tubes. The plasma free haemoglobin 
was analysed after blood centrifugation at 2500 rpm for 5 minutes using a double 
beam spectrophotometer Analytic Jena –Specord 205 with wavelength range between 
500 – 630 nm. 
4.3.5.2 Blood treated with bioferrofluids 
Whole blood was mixed and incubated with different concentrations of 
bioferrofluids (P4VP-g-APEG bioferrofluids, DMSA bioferrofluids, and DMSA-PEG- 
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(NH2)2 bioferrofluids) for 5 min, then centrifuged at 2500 rpm for 5 min and the 
plasma processed for the measurement of the free haemoglobin. 
4.4 Results  
4.4.1 P4VP-g-APEG bioferrofluids characterisation 
The iron content of bioferrofluid stock sample was determined by atomic 
absorption in a plasma spectrometer. Concentration of iron content is 7.78 g/L Fe2O3. 
The sample has 13.36 g/L of P4VP, 12.03 g/L of APEG(200) and 1.34 g/L of 
APEG(1000)-COO-, and the necessary amounts of phosphate, sodium, potassium and 
chloride ions for a standard PBS solution of pH=7.40 and I = 0.15 M.  
The sample was analysed by TEM and DLS and the results are shown in Figs. 4.5 
and 4.6. TEM images show iron oxide nanoparticles uniformly distributed in a 
continuous polymer film (insert in Fig. 4.5). Most of the iron oxide nanoparticles are 
spherical, as shown in Fig. 4.5. A size distribution analysis for the maghemite 
magnetic nanoparticles is shown in Fig. 4.6(a). The core size (mean ± SD) is 9.1 ± 2.1 
nm.  
Figure 4.5: TEM images of maghemite magnetic nanoparticles in P4VP-g-APEG bioferrofluids. The 
inset shows the sample at lower magnification. 
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DLS observations show a single population of particles with an average 
hydrodynamic diameter of 80 nm, as shown in Fig. 4.6(b). Measurements of zeta 
potential of the nanoparticles suspension yielded average values close to zero.  
The structures of components of the nanoparticles shell are shown in Diagram 1. 
The reaction of P4VP and APEG is a Michael addition involving the acrylate double 
bond and the nitrogen of the pyridine that becomes quaternised and therefore 
positively charged in this way. The structure of the P4VP-g-APEG graft copolymer is 
comb-like. The backbone is a polyethylene chain with pyridine side groups. The 
APEG chains are linked to some of the pyridine groups by N-C bonds between the 
nitrogen of the pyridine and the β-carbon of the acrylate PEG ester, thus hanging 
perpendicular to the copolymer backbone as depicted in Diagram 1. Therefore the N 
of pyridine groups linked to APEG chains are positively charged and the copolymer is 
cationic. 
 
 
Figure 4.6: P4VP-g-APEG bioferrofluids analysis: (a) Size distribution of spherical maghemite magnetic 
nanoparticles; (b) Distribution of hydrodynamic diameters in bioferrofluid sample from DLS 
measurements. 
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Diagram 1: Structure of polymers and copolymers. 
 
4.4.2 DMSA bioferrofluids and DMSA-PEG-(NH2)2 bioferrofluids characterisation 
The iron contents of bioferrofluids stock samples were determined by atomic 
absorption in a plasma spectrometer. Concentrations of iron contents are 5.8 and 1 g/L 
Fe for DMSA bioferrofluids and DMSA-PEG-(NH2)2 bioferrofluids, respectively.  
Magnetite nanoparticles used in this work were obtained via thermal 
decomposition of iron (III) acetylacetonate in 1-octadecene in the presence of oleic 
acid.  Magnetite magnetic nanoparticles are relatively spherical and well dispersed due 
to the presence of oleic acid around the particles Fig. 4.7 (a), with an average core size 
of 7 ± 1 (mean ± SD). A size distribution analysis for the magnetite magnetic 
nanoparticles is shown in Fig. 4.7(b).  
Particles were coated with meso-2,3-dimercaptosuccinic acid after a ligand 
exchange reaction. In order to increase the biocompatibility of the material, 
nanoparticles coated with DMSA were chemically modified with PEG.  Properties of 
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DMSA bioferrofluids and DMSA-PEG-(NH2)2 bioferrofluids have been extensively 
described in refs. [56,57]. 
Figure 4.7: DMSA bioferrofluids and DMSA-PEG-(NH2)2 bioferrofluids characterisation, (a) TEM 
images of magnetite magnetic nanoparticles of ~7 nm oleic acid coated nanoparticles, (b) Size 
distribution histograms of spherical magnetite magnetic nanoparticles.  Red line indicates the Gaussian 
fitting function of TEM particle size data, (c) Hydrodynamic sizes for DMSA bioferrofluids (solid line) 
and DMSA-PEG-(NH2)2 bioferrofluids (dotted line), (d) Evolution of Z-potential as a function of pH,  
DMSA bioferrofluids [●], DMSA-PEG-(NH2)2 bioferrofluids [■]. 
DLS observations showed a monomodal distribution of DMSA coated 
nanoparticles with an average hydrodynamic diameter of 22 nm and polydispersity 
degrees lower than 0.25. After PEG modification, the average hydrodynamic size at 
pH 7 increases from 22 to 27 nm, as shown in Fig. 4.7(c). The surface charge 
decreases from approximately -35 mV for DMSA bioferrofluids samples to values 
between -15 mV for DMSA-PEG-(NH2)2 bioferrofluids, as shown in Fig. 4.7(d). 
4.4.3 Coagulation studies  
4.4.3.1 PPP treated with P4VP-g-APEG bioferrofluids 
PPP were treated with different concentrations of P4VP-g-APEG bioferrofluids 
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ranging from 0.07 g/L Fe2O3 to 0.38 g/L Fe2O3, and processed for the measurement of 
PT and aPTT. PT shows no significant difference with concentrations of 0.12 g/L of 
Fe2O3 and lower. At this concentration, PT value is 10.79 ± 0.70 s which compares 
well with its control value 11.30 ± 0.68 s. At the highest concentrations of P4VP-g-
APEG bioferrofluids, for instance, at concentration 0.38 g/L Fe2O3, PT value is 9.18 ± 
0.40 s, which is slightly shorter than the control value 10.66 ± 0.42 s although within 
our laboratory normal reference range (9-14 s). These results are shown in Fig. 4.8(a).  
 
Figure 4.8: The effect of P4VP-g-APEG bioferrofluids on: (a) the prothrombin time in seconds, (b) the 
activated partial thromboplastin time in seconds. Values represent mean ± SEM (n=10), (*) marks 
significant differences between P4VP-g-APEG bioferrofluids and control.  
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On the other hand, aPTT shows a rapid increase as the P4VP-g-APEG 
bioferrofluids concentration increases. For instance, at concentration 0.07 g/L Fe2O3, 
aPTT value is 34.67 ± 4.52 s, significantly different to the control one, 27.76 ± 2.16 s, 
although within our laboratory normal reference range (23-37 s). In contrast, at 
concentration 0.38 g/L Fe2O3, aPTT value is 64.56  ± 7.21 s, twice the control value of 
31.85 ± 1.48 s. The results are shown in Fig. 4.8(b).   
Data corresponding to PT and aPTT determinations were analysed using Mann-
Whitney test and are summarised in Table 4.2. 
 In order to explore the cause of the aPTT prolongation, PPP treated with the 
higher concentration of bioferrofluids (0.38 g/L Fe2O3) were used for further studies 
such as a) mixture test, in which PPP treated with bioferrofluids were mixed with 
normal plasma (1:1), aPTT measurements showed a prolongation of aPTT value of 
55.30 ± 7.22 s as compared to its control value 31.08 ± 3.08 s (n=4), b) TT 
measurements, results showed normal value of TT 28.24 ± 2.90 s as compared to its 
control value 27.60 ± 3.04 s (n=5) (TT reference limits is 15-28 s.), c) coagulation 
factor measurements, the level of the coagulation factors (VIII, IX, XI, XII) of the 
intrinsic pathway were evaluated and the results showed a reduction in the level of all 
of these coagulation factors to 28%, 15%, 11.9% and 12.7%, respectively (normal 
values are 60-120% for VIII, 70-120% for factors IX, XI and XII). 
Table 4.2: Statistical analysis data for the effect of P4VP-g-APEG bioferrofluids on PT 
and aPTT. The number of samples was 10 for each concentration and the original P4VP-
g-APEG bioferrofluids concentration was 7.78 g/L [Fe2O3]. 
Conc.  
g/L     
PT  
Mean ± SD (s) 
P 
(Mann-
Whitney) 
aPTT  
Mean ± SD (s) 
P 
(Mann-
Whitney) Test Control Test Control 
0.07 10.63 ± 1.07 10.89 ± 0.66 0.3258 34.67 ± 4.52 27.76 ± 2.16 0.0015 
0.08 10.27 ± 0.76 10.61 ± 0.80 0.2730 34.03 ± 3.51 27.01 ± 1.87 0.0004 
0.09 10.94 ± 0.78 11.28 ± 0.66 0.2899 37.02 ± 4.11 27.88 ± 2.11 0.0002 
0.11 10.97 ± 0.82 11.17 ± 0.67 0.4497 37.60 ± 3.88 27.51 ± 1.58 0.0002 
0.12 10.79 ± 0.70 11.30 ± 0.68 0.1306 39.19 ± 4.11 27.42 ± 1.88 0.0002 
0.15 10.16 ± 0.55 10.88 ± 0.69 0.0156 40.54 ± 4.07 29.65 ± 3.16 0.0002 
0.19 9.76 ± 0.35 10.66 ± 0.42 0.0004 46.04 ± 3.96 31.85 ± 1.48 0.0002 
0.25 9.47 ± 0.30 10.66 ± 0.42 0.0002 56.06 ± 11.77 31.85 ± 1.48 0.0002 
0.38 9.18 ± 0.40 10.66 ± 0.42 0.0002 64.56 ± 7.21 31.85 ± 1.48  0.0002 
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4.4.3.2 PPP treated with APEG  
To study the coating effect on the coagulation process, a APEG blank solution 
with the same content of APEG(200) + APEG(1000)-COO- as the one used for the 
coated nanoparticles (13.36 g/L) has been used. This APEG solution was mixed with 
PPP at concentrations of 0.13 and 1.33 g/L. No alteration in the coagulation profile 
has been observed, except the PT at the concentration 1.33 g/L APEG. The PT value 
for the test sample was 12.40 ± 0.69 s, which is slightly different than the control 
value 11.47 ± 0.65 s, although it is within our laboratory normal reference range (9-14 
s). These results are summarised in Fig. 4.9, while statistical analysis data are shown 
in Table 4.3. 
Figure 4.9: The effect of APEG on: (a) prothrombin time, (b) the activated partial thromboplastin time, in 
seconds. Values represent mean ± SEM (n=6), (*) marks significant differences between APEG and 
control. 
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Table 4.3: Statistical analysis data for the effect of APEG on PT and aPTT, the 
number of samples was 6 for each concentration, the original APEG concentration 
was 13.36 g/L. 
Conc. 
g/L 
PT  
Mean ± SD (s) 
P 
(Mann-
Whitney) 
aPTT 
Mean ± SD (s) 
P  
(Mann-
Whitney) Test Control Test Control  
0.13 10.78 ± 0.31 10.88 ± 0.41 0.63 29.17 ± 2.36 29.18 ± 3.07 0.87 
1.33 12.40 ± 0.69 11.47 ± 0.65 0.04 29.35 ± 1.49 29.80 ± 1.47 0.42 
 
4.4.3.3 PPP treated with P4VP-g-APEG 
The P4VP-g-APEG blank sample used in this work was prepared under the same 
conditions and concentrations applied for P4VP-g-APEG bioferrofluids preparations. 
The PT value does not change at concentration of 1.33 g/L (11.78 ± 1.17 s as 
compared to control value 11.47 ± 0.65 s) and becomes shorter than the control value 
at concentration of 0.13 g/L (10.28 ± 0.57 s and 11.30 ± 0.48 s, respectively) and at 
concentration 0.013 g/L (9.98 ± 0.98s and 11.30 ± 0.48s, respectively). However, PT 
values for plasma treated with P4VP-g-APEG is significant lower than the control 
one. However, these values are within our laboratory normal reference range (9-14 s). 
On the contrary, the aPTT shows a large increase at a concentrations of 1.33 and 0.13 
g/L, greater than 120 seconds, the time limit of the equipment. A lower concentration 
of 0.013 g/L still shows significant differences for aPTT value with respect to the 
control one (39.63 ± 11.17 s and 31.45 ± 2.01 s, respectively). The results are shown 
in Fig. 4.10 while statistical analysis data are summarised in Table 4.4. 
Table 4.4: Statistical analysis data for the effect of P4VP-g-APEG copolymer on PT 
and aPTT, the number of samples was 6 for each concentration, the original P4VP-g-
APEG concentration was 13.36 g/L. 
Conc. 
g/L 
PT  
Mean ± SD (s) 
P 
(Mann-
Whitney) 
aPTT 
Mean ± SD (s) 
P 
(Mann-
Whitney) Test Control Test Control 
0.013 9.98 ±  0.98 11.30 ± 0.48 0.04 39.63 ± 11.17 31.45 ± 2.01 0.03 
0.13 10.28 ± 0.57 11.30 ± 0.48 0.02 > 120 31.45 ± 2.01 - 
1.33 11.78 ± 1.17 11.47 ±0.65 0.74 > 120 29.80 ±  1.47 - 
 
4.4.3.4 PPP treated with DMSA bioferrofluids and DMSA-PEG-(NH2)2 bioferrofluids  
PPP were treated with different concentrations of DMSA bioferrofluids ranging 
from 0.048 g/L Fe to 0.29 g/L Fe, and processed for the measurement of PT and aPTT. 
 
 
 
 
4.4. Results   143 
 
PT shows no significant difference, except at concentrations of 0.058 and 0.29 g/L Fe, 
in which the PT values for PPP treated with DMSA bioferrofluids were lower than 
control. However, these values are within our laboratory normal reference range (9-14 
s). These results are shown in Fig. 4.11(a) while statistical analysis data are 
summarised in Table 4.5. On the other hand, aPTT shows a rapid increase as the 
DMSA bioferrofluids concentration increases. For instance, at lower concentration 
0.048 g/L Fe, aPTT value is 40.66 ± 5.23 s, significantly different to the control one 
which is 30.26 ± 2.48 s, and at the higher concentration 0.29 g/L Fe, aPTT value is 
65.58 ± 6.13 s, more than the double value of the control value 27.95 ± 2.35 s. The 
results are shown in Fig. 4.11(b), while statistical analysis data are summarised in 
Table 4.5. 
Figure 4.10: The effect of P4VP-g-APEG on: (a) Prothrombin time, (b) the activated partial 
thromboplastin time, in seconds. Values represent mean ± SEM (n=6), (*) marks significant differences 
between P4VP-g-APEG and control.  
 
 
 
 
144   Chapter 4  Haemocompatibility studies 
 
Table 4.5: Statistical analysis data for the effect of DMSA bioferrofluids on PT and 
aPTT, the number of samples was 6 for each concentration, the original DMSA 
bioferrofluids concentration was 5.8 g/L Fe.       
Conc. 
g/L  
PT  
Mean ± SD (s) 
P 
(Mann-
Whitney) 
aPTT 
Mean ± SD (s) 
P 
(Mann-
Whitney) Test Control Test Control 
0.048 9.35 ± 0.87 9.95 ± 0.96 0.3776 40.66 ± 5.23 30.26 ± 2.48 0.0079 
0.058 9.43 ± 0.49 10.22 ± 0.51 0.0438 41.97 ± 2.29 29.80 ± 3.78 0.0022 
0.073 8.97 ± 0.72 9.83 ± 0.83 0.1320 51.74 ± 6.99 28.93 ± 1.63 0.0080 
0.097 9.64 ± 0.55 10.18 ± 1.11 0.3602 54.15 ± 6.46 29.95 ± 1.90 0.0022 
0.145 9.14 ± 0.81 10.43 ± 0.91 0.0666 55.15 ± 9.56 29.57 ± 3.47 0.0022 
0.290 8.52 ± 0.40 10.22 ± 0.71 0.0050 65.58 ± 6.13 27.95 ± 2.35 0.0050 
 
 
Figure 4.11: The effect of DMSA bioferrofluids on: (a) the prothrombin time, (b) the activated partial 
thromboplastin time, in seconds. Values represent mean ± SEM (n=6), (*) marks significant differences 
between DMSA bioferrofluids and control. 
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In order to explore the cause of the aPTT prolongation, PPP treated with the 
higher concentration of DMSA bioferrofluids (0.29 g/L Fe) were used for further 
studies such as a) mixture test, in which PPP treated with bioferrofluids were mixed 
with normal plasma (1:1), aPTT measurements showed normal aPTT value 33.53 ± 
0.92 s compared to its control value 30.83 ± 0.74 s (n=3), and b) TT measurements, 
where results showed normal value of TT 27.83 ± 2.57 s compared to its control value 
21.83 ± 1.45 s (n=3) (TT reference limits is 15-28 s.).  
In addition, PPP were treated with different concentrations of DMSA-PEG-
(NH2)2 bioferrofluids ranging from 0.048 g/L Fe to 0.29 g/L Fe, and processed for the 
measurement of PT and aPTT. PT shows no significant difference with all 
concentrations Fig 4.12(a), for instance, at high concentration of 0.29 g/L Fe, PT value 
is 11.78 ± 1.95 s, which compares well with its control value 11.13 ± 1.61 s. In 
contrast, aPTT shows significant increase as the DMSA-PEG-(NH2)2 bioferrofluids 
concentration increases, except for concentration 0.058 g/L Fe Fig. 4.12(b). At this 
concentration and other concentrations (0.048 and 0.073 g/L Fe) where a significance 
difference was detected, aPTT values were at the laboratory range (29-37 s). At higher 
concentration of 0.29 g/L Fe, aPTT value is 49.37 ± 8.71 s, more than the control 
value 30.16 ± 2.54 s. The statistical analysis data are summarised in Table 4.6. 
Table 4.6: Statistical analysis data for the effect of DMSA-PEG-(NH2)2 bioferrofluids 
on PT and aPTT, the number of samples was 6 for each concentration, the original 
DMSA-PEG-(NH2)2 bioferrofluids concentration was 1 g/L Fe.       
Conc. 
g/L     
PT  
Mean ± SD (s) 
P 
(Mann-
Whitney) 
aPTT 
Mean ± SD (s) 
P 
(Mann-
Whitney) Test Control Test Control 
0.048 11.13 ± 1.27 11.23 ± 1.34 0.8095 32.80 ± 0.99 29.53 ± 1.64 0.0087 
0.058 9.67 ± 0.74 9.80 ± 0.83 0.6177 33.98 ± 3.61 29.02 ± 4.08 0.0649 
0.073 9.67 ± 1.16 9.75 ± 1.04 0.9360 36.32 ± 2.95 30.52 ± 1.99 0.0079 
0.097 10.58 ± 2.35 10.75 ± 2.33 0.8092 40.90 ± 1.92 28.33 ± 2.57 0.0022 
0.145 12.2 ± 2.56 11.95 ± 2.49 0.6879 53.23 ± 9.46 29.40 ± 3.31 0.0286 
0.290 11.78 ± 1.95 11.13 ± 1.61 0.7483 49.37± 8.71 30.16 ± 2.54 0.0022 
 
In order to explore the cause of the aPTT prolongation, PPP treated with the 
higher concentration of DMSA-PEG-(NH2)2 bioferrofluids (0.29 g/L Fe) were used for 
further studies, such as a) mixture test, in which PPP treated with theses bioferrofluids 
were mixed with normal plasma (1:1), aPTT measurements showed normal aPTT 
value 33.40 ± 1.73 s compared to its control value 29.33 ± 2.60 s (n=3), b) TT 
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measurements, results showed normal value of TT 28.37 ± 1.59 s compared to its 
control value 24.03 ± 0.50 s (n=3) (TT reference limits is 15-28 s.). 
Figure 4.12: The effect of DMSA-PEG-(NH2)2 bioferrofluids on: (a) the prothrombin time, (b) the 
activated partial thromboplastin time, in seconds. Values represent mean ± SEM (n=6), (*) marks 
significant differences between DMSA-PEG-(NH2)2 bioferrofluids and control.  
A comparison between DMSA-PEG-(NH2)2 bioferrofluids, DMSA bioferrofluids 
and P4VP-g-APEG bioferrofluids on their effect on PT and aPTT is shown in Fig. 
4.13 and data summarised in Table 4.7. In the case of PT, a significant difference 
between test and control values appears in some concentrations. These values are 
within our laboratory normal reference range (9-14 s). In the case of aPTT, however, 
the aPTT values for plasma treated with DMSA-PEG-(NH2)2 bioferrofluids or P4VP- 
g-APEG bioferrofluids at concentrations 0.05, 0.06 and 0.07 g/L Fe, are significantly  
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different to the control values, they are within our laboratory normal reference range 
(23-37 s),  In contrast, the aPTT value for plasma treated with DMSA bioferrofluids at 
these concentrations (0.05, 0.06 and 0.07 g/L Fe) is significantly different than the 
control and out of laboratory normal reference range. 
Figure 4.13: The effect of DMSA-PEG-(NH2)2 bioferrofluids, DMSA bioferrofluids and P4VP-g-APEG 
bioferrofluids on: (a) the prothrombin time, (b) the activated partial thromboplastin time, in seconds. 
Values represent mean ± SEM, (* and **) marks significant differences (>0.0001 and <0.0001 
respectively) between bioferrofluids and control.  
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Table 4.7: Statistical analysis data for the effect of DMSA-PEG-(NH2)2 bioferrofluids, 
DMSA bioferrofluids and P4VP-g-APEG bioferrofluids on PT and aPTT, the number of 
samples was 22, 6, 6 and 10 for control, DMSA-PEG-(NH2)2 bioferrofluids, DMSA 
bioferrofluids and  P4VP-g-APEG bioferrofluids, respectively. 
PT 
Mean ± SD (s) 
Conc. 
g/L 
Control DMSA-PEG-
(NH2)2 
bioferrofluids 
Unpaired 
t-test 
DMSA 
bioferrofluids 
Unpaired 
t-test 
P4VP-g-PEG 
bioferrofluids 
Unpaired 
t-test 
0.05 10.70±1.04 11.13 ± 1.27 0.4264 9.35 ± 0.87 0.0066 10.60 ± 1.07 0.8104 
0.06 10.30±0.78 9.67 ± 0.74 0.0974 9.43 ± 0.49 0.0192 10.30 ± 0.76 0.9685 
0.07 10.40±1.05 9.67 ± 1.16 0.1416 8.97 ± 0.72 0.0041 11.00 ± 0.82 0.1545 
0.1 10.70±1.37 10.58 ± 2.35 0.9241 9.64 ± 0.55 0.1218 10.20 ± 0.55 0.2837 
0.3 10.70±0.97 11.78 ± 1.95 0.0578 8.52 ± 0.40 <0.0001 9.20 ± 0.40 <0.0001 
aPTT 
Mean ± SD (s) 
Conc. 
g/L 
Control DMSA-PEG-
(NH2)2 
bioferrofluids 
Unpaired 
t-test 
DMSA 
bioferrofluids 
Unpaired 
t-test 
P4VP-g-PEG 
bioferrofluids 
Unpaired 
t-test 
0.05 28.90±2.89 32.80 ± 0.99 0.0004 40.66  ±5.23 <0.0001 34.70 ± 4.52 <0.0001 
0.06 28.30±3.23 33.98 ± 3.61 0.001 41.97 ± 2.29 <0.0001 34.00 ± 3.51 <0.0001 
0.07 28.60±2.03 36.32 ± 2.95 <0.0001 51.74 ± 7.00 <0.0001 37.60 ± 3.88 <0.0001 
0.1 29.40±2.68 40.90 ± 1.92 <0.0001 54.15 ± 6.46 <0.0001 40.50 ± 4.07 <0.0001 
0.3 30.30±2.55 49.37 ± 8.71 <0.0001 65.58 ± 6.13 <0.0001 64.60 ± 7.21 <0.0001 
4.4.3.5 PPP treated with DMSA and PEG-(NH2)2 
The DMSA and PEG-(NH2)2 blank samples used in this work were prepared 
under the same conditions and concentrations applied for DMSA bioferrofluids and 
DMSA-PEG-(NH2)2 bioferrofluids preparations. PPP was mixed with different 
concentrations (0.01 and 0.1 g/L) of DMSA. Results show no significance difference 
with respect to those obtained in PT and aPTT, as shown in Fig. 4.14. Data are 
summerised in Table 4.8. 
PT and aPTT results did not show any significance difference between PPP mixed 
with different concentrations (0.01 and 0.1 g/L) of PEG-(NH2)2 and control, results are 
shown in Fig. 4.15, while the statistical analysis data are summarised in Table 4.9.
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Table 4.8: Statistical analysis data for the effect of DMSA on PT and aPTT, the 
number of samples was 6 for each concentration, the original DMSA concentration 
was 1 g/L.       
 
 
Figure 4.14: The effect of DMSA on: (a) the prothrombin time, (b) the activated partial thromboplastin 
time, in seconds. Values represent mean ± SEM (n=6). 
 
 
 
Conc.   
g/L   
PT  
Mean ± SD (s) 
P 
(Mann-
Whitney) 
aPTT  
Mean ± SD (s) 
P 
(Mann-
Whitney) Test Control Test Control 
0.01 10.97 ± 1.19 11.00 ± 1.11 1.0000 28.38 ± 1.68 28.43 ± 1.82 1.0000 
0.10 11.25 ± 0.78 10.78 ± 0.74 0.2946 29.95 ± 3.10 30.00 ± 3.45 0.8726 
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Table 4.9: Statistical analysis data for the effect of PEG-(NH2)2 on PT and aPTT, the 
number of samples was 6 for each concentration, the original PEG-(NH2)2  
concentration was 1 g/L.       
 
Figure 4.15: The effect of PEG-(NH2)2 on: (a) the prothrombin time, (b) the activated partial 
thromboplastin time, in seconds. Values represent mean ± SEM (n=6). 
4.4.4 Complete blood counts studies 
4.4.4.1 Blood treated with P4VP-g-APEG bioferrofluids  
Whole blood was treated with different concentrations (0.07 and 0.7 g/L Fe2O3) of 
P4VP-g-APEG bioferrofluids, and processed for CBC measurements. No significant 
differences were detected in CBC between control and treated blood with P4VP-g- 
 
Conc.   
g/L   
PT  
Mean ± SD (s) 
P 
(Mann-
Whitney) 
aPTT  
Mean ± SD (s) 
P 
(Mann-
Whitney) Test Control Test Control 
0.01 11.15± 1.12 11.08 ± 1.11 0.8721 29.97 ± 1.70 30.22 ± 2.39 1.0000 
0.10 11.22 ± 0.90 10.78 ± 0.74 0.4217 28.10 ± 3.20 30.00 ± 3.45 0.3939 
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APEG bioferrofluids in both concentrations, as well as no significant difference in 
haemoglobin and haematocrit were either observed. The spectrophotometric study of 
haemoglobin in plasma demonstrates the absence of haemolysis for concentration 0.07 
g/L Fe2O3. For a concentration of 0.7 g/L Fe2O3, the high concentration of particles 
interfere the spectrophotometric measurements; however, naked eye inspection does 
not indicate haemolysis. Altogether these data show the safety of nanoparticles in 
relation to erythrocytes. Platelets and leukocytes do not show significant differences 
between the control sample and the two concentrations tested, neither the instrument 
shows flags indicating morphologic alterations and aggregates in any of the studied 
cell series, demonstrating the safety of nanoparticles on these two cell lines. The only 
haematological abnormality is in the coagulation tests, with an unexpected increase of 
aPTT, discussed in detail later. Statistical analysis data are summarised in Table 4.10 
and results are shown in Fig. 4.16.  
Table 4.10: Statistical analysis data for the effect of P4VP-g-APEG bioferrofluids on 
CBC, the number of samples was 4 for each concentration, the original P4VP-g-
APEG bioferrofluids  concentration was 7.78 g/L [Fe2O3]. 
P4VP-g-APEG bioferrofluids 
Conc. 
g/L 
CBC  
Mean ± SD 
P 
(Mann-
Whitney) 
Test Control  
Erythrocytes (106/µL) 
0.07 4.69 ± 0.36 4.61 ± 0.30 0.77 
0.7 4.65 ± 0.31  4.66 ± 0.27 >0.99 
Leukocytes (103/µL) 
0.07 6.79 ± 2.21  6.88 ± 2.21 0.77 
0.7 6.13 ± 2.28  6.28 ± 2.20 >0.99 
Platelets (103/µL) 
0.07 176.25 ± 34.72  180.25 ± 34.22 0.77 
0.7 180.95 ± 26.48  193.50 ± 25.72 0.38 
Haemoglobin (g/dL) 
0.07 14.39 ± 1.04 14.23 ± 0.91 0.88 
0.7 14.22 ± 1.13 14.00 ± 0.95 0.56 
Haematocrit (%) 
0.07 42.70 ± 2.09 41.80 ± 1.32 0.38 
0.7 40.92 ± 2.97 40.68 ± 1.81 0.77 
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Figure 4.16: The effect of P4VP-g-APEG bioferrofluids   on: (a) Erythrocytes, (b) Leukocytes, (c) 
Platelets, (d) Haemoglobin and (e) Haematocrit. Values represent mean ± SEM (n=4).  
 
4.4.4.2 Blood treated with APEG and with P4VP-g-APEG 
The CBC (erythrocytes, leukocytes, platelets, Haemoglobin and Haematocrit), 
corresponding to blood treated with APEG shows a minor difference with control 
sample only for erythrocytes, haemoglobin and haematocrit at concentration 0.13 g/L 
(P = 0.04). The CBC corresponding to blood treated with P4VP-g-APEG at 
concentrations 0.13 and 1.33 g/L did not show in either case significant difference 
from control blood. The results are shown in Figs. 4.17 and 4.18, while statistical 
analysis data are shown in Table 4.11. 
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Figure 4.17: The effect of APEG on: (a) Erythrocytes, (b) Leukocytes, (c) Platelets, (d) Haemoglobin and 
(e) Haematocrit. Values represent mean ± SEM (n=3), (*) marks significant differences between APEG 
and control.  
Table 4.11: Statistical analysis data for the effect of APEG and P4VP-g-APEG on 
CBC, the number of samples was 3 for each concentration, the original APEG and 
P4VP-g-APEG concentration was 13.36 g/L.  
 APEG P4VP-g-APEG 
Conc. 
g/L 
CBC  
Mean ± SD P (Mann-
Whitney) 
CBC 
Mean ± SD P (Mann-
Whitney)  
Test  
 
Control  
 
Test  
 
Control 
Erythrocytes (106/µL) 
0.13 5.04 ± 0.28 4.38 ± 0.16 0.04 5.19 ± 0.44 4.96 ± 0.65 0.51 
1.33 4.33 ± 0.12 4.33 ± 0.10 0.82 5.16 ± 0.41 5.11 ± 0.41 0.51 
Leukocytes (103/µL) 
0.13 8.76 ± 2.52 8.67 ± 1.90 0.82 7.61 ± 1.99 7.43 ± 2.72 0.82 
1.33 8.25 ± 2.63 8.27 ± 2.54 >0.99 5.50 ± 0.90 5.57 ± 0.83 0.51 
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Continue Table 4.11: Statistical analysis data for the effect of APEG and P4VP-g-
APEG on CBC, the number of samples was 3 for each concentration, the original 
APEG and P4VP-g-APEG concentration was 13.36 g/L.  
 APEG P4VP-g-APEG 
Conc. 
g/L 
CBC  
Mean ± SD P (Mann-
Whitney) 
CBC 
Mean ± SD P (Mann-
Whitney)  
Test  
 
Control  
 
Test  
 
Control 
Platelets (103/µL) 
0.13 324.50 ± 107.72 319.33 ±117.86 0.82 230.48 ± 46.71 228.80 ± 47.34 0.92 
1.33 311.30 ± 98.58 316.00±121.52 0.82 229.24 ± 40.71 228.80 ± 47.34 0.83 
Haemoglobin (g/dL) 
0.13 15.11 ± 0.61 12.70 ± 1.28 0.04 15.08 ± 0.99 14.93 ± 1.69 0.82 
1.33 12.32 ± 0.98 12.43 ± 0.98 0.82 14.92 ± 1.40 15.07 ± 1.46 0.82 
Haematocrit (%) 
0.13 43.71 ± 2.93 37.77 ± 3.62 0.04 47.47 ± 2.96 44.43 ± 4.25 0.27 
1.33 38.28 ± 3.34 37.77 ± 3.62 0.51 45.72 ± 4.65 44.30 ± 4.48 0.51 
 
4.4.4.3 Blood treated with DMSA bioferrofluids and with DMSA-PEG-(NH2)2 
bioferrofluids 
Whole blood was treated with different concentrations (0.05 and 0.1 g/L Fe) of 
DMSA bioferrofluids and DMSA PEG-(NH2)2 bioferrofluids, and processed for CBC 
measurements. The CBC (erythrocytes, leukocytes, platelets, haemoglobin and 
haematocrit) results did not show significant differences between control samples and 
blood treated with both bioferrofluids at both concentrations. Results are shown in 
Figs. 4.19 and 4.20, while statistical analysis data are summarised in Tables 4.12 and 
4.13. No significant difference in haemoglobin and haematocrit were either observed. 
The spectrophotometric study of haemoglobin in plasma demonstrates the absence of 
haemolysis for both bioferrofluids at these concentrations (0.05 and 0.1 g/L Fe). 
Altogether these data show the safety of nanoparticles in relation to erythrocytes. 
Platelets and leukocytes do not show significant differences between the control 
sample and the two concentrations tested of both bioferrofluids neither the instrument 
shows flags indicating morphologic alterations and aggregates in any of the studied 
cell series, demonstrating the safety of nanoparticles on these two cell lines. Normal 
morphology of cells was also confirmed by optical microscope for stained blood films, 
as shown in Fig. 4.21. 
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Figure 4.18: The effect of P4VP-g-APEG on: (a) Erythrocytes, (b) Leukocytes, (c) Platelets, (d) 
Haemoglobin and (e) Haematocrit. Values represent mean ± SEM (n=3).   
Table 4.12: Statistical analysis data for the effect of DMSA bioferrofluids on CBC, 
the number of samples was 6 for each concentration, the original DMSA 
bioferrofluids concentration was 5.8 g/L Fe. 
DMSA bioferrofluids  
Conc. 
g/L 
CBC  
Mean ± SD 
P 
(Mann-
Whitney) 
Test Control  
Erythrocytes (106/µL) 
0.05 4.87 ± 0.39  4.49 ± 0.33 0.2403 
0.1 4.88 ± 0.36 4.49 ± 0.33 0.0649 
Leukocytes (103/µL) 
0.05 6.77 ± 1.04 6.78 ± 0.99 0.9361 
0.1 7.39 ± 0.94 6.78 ± 0.99 0.3776 
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Continue Table 4.12: Statistical analysis data for the effect of DMSA bioferrofluids 
on CBC, the number of samples was 6 for each concentration, the original DMSA 
bioferrofluids concentration was 5.8 g/L Fe. 
DMSA bioferrofluids  
Conc. 
g/L 
CBC  
Mean ± SD 
P 
(Mann-
Whitney) 
Test Control  
Platelets (103/µL) 
0.05 213.50 ± 47.91  220.83 ± 42.08 0.5887 
0.1 243.47 ± 42.59  220.83 ± 42.08 0.3939 
Haemoglobin (g/dL) 
0.05 14.98 ± 1.03 13.58 ± 0.74 0.0651 
0.1 14.70 ± 0.82 13.58 ± 0.74 0.0651 
Haematocrit (%) 
0.05 44.29 ± 3.05 40.97 ± 2.57 0.5887 
0.1 44.15 ± 2.52 40.97 ± 2.57 0.3939 
 
 
Table 4.13: Statistical analysis data for the effect of DMSA PEG-(NH2)2 
bioferrofluids on CBC, the number of samples was 6 for each concentration, the 
original DMSA PEG-(NH2)2 bioferrofluids concentration was 1 g/L Fe. 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMSA PEG-(NH2)2 bioferrofluids 
Conc. 
g/L 
CBC  
Mean ± SD 
P 
(Mann-Whitney) 
Test Control  
Erythrocytes (106/µL) 
0.05 4.66 ± 0.44 4.64 ± 0.43 0.8182 
0.1 4.64 ± 0.44  4.64 ± 0.43 0.9372 
Leukocytes (103/µL) 
0.05 7.46 ± 1.44 7.40 ± 1.52 0.8182 
0.1 7.21 ± 1.85  7.40 ± 1.52 1.0000 
Platelets (103/µL) 
0.05 194.78 ± 39.96  205.00 ± 40.12 0.5887 
0.1 195.07 ± 37.18 205.00 ± 40.12 0.5887 
Haemoglobin (g/dL) 
0.05 14.30 ± 1.44 14.08 ± 1.44 0.3776 
0.1 14.14 ± 1.39 14.08 ± 1.44 0.9361 
Haematocrit (%) 
0.05 42.42 ± 3.77 42.07 ± 3.70 0.8182 
0.1 42.11 ± 3.86 42.07 ± 3.70 1.000 
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Figure 4.19: The effect of DMSA bioferrofluids  on: (a) Erythrocytes, (b) Leukocytes, (c) Platelets, (d) 
Haemoglobin and (e) Haematocrit. Values represent mean ± SEM (n=6). 
 
4.4.4.4 Blood treated with DMSA and with PEG-(NH2)2  
Whole blood was treated with different concentrations (0.01 and 0.1 g/L) of 
DMSA and PEG-(NH2)2, and processed for CBC measurements. The CBC 
(erythrocytes, leukocytes, platelets, Haemoglobin and haematocrit) results did not 
show significant differences at both concentrations for blood treated with both 
materials and control. Results are shown in Figs. 4.22 and 4.23, while statistical 
analysis data are summarised in Tables 4.14 and 4.15 
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Figure 4.20: The effect of DMSA-PEG-(NH2)2 bioferrofluids on: (a) Erythrocytes, (b) Leukocytes, (c) 
Platelets, (d) Haemoglobin and (e) Haematocrit. Values represent mean ± SEM (n=6). 
Figure 4.21: Stained films of untreated blood (a, b), and treated blood with DMSA bioferrofluids (upper 
panel) and DMSA-PEG-(NH2)2 bioferrofluids (lower panel) at concentrations 0.05 g/L Fe (b, e) and 0.1 
g/L Fe (c, f).  
 
 
 
 
 
4.4. Results   159 
 
Table 4.14: Statistical analysis data for the effect of DMSA on CBC, the number of samples 
was 4 for each concentration, the original DMSA concentration was 1 g/L. 
DMSA 
Conc. 
g/L 
CBC  
Mean ± SD 
P 
(Mann-
Whitney) 
Test Control  
Erythrocytes (106/µL) 
0.01 4.38 ± 0.19 4.28 ± 0.22 0.4857 
0.1 4.26 ± 0.15 4.28 ± 0.22 0.8857 
Leukocytes (103/µL) 
0.01 7.02 ± 0.74 7.28 ± 0.39 0.6857 
0.1 7.10 ± 0.43 7.28 ± 0.39 0.6857 
Platelets (103/µL) 
0.01 248.71 ± 76.03 270.75 ± 76.57 0.4857 
0.1 246.13 ± 69.07 270.75 ± 76.57 0.4857 
Hemoglobin (g/dL) 
0.01 13.96 ± 0.73 13.33 ± 0.66 0.3429 
0.1 13.56 ± 0.37 13.33 ± 0.66 0.5614 
Hematocrit (%) 
0.01 41.18 ± 1.70 40.33 ± 1.72 0.3429 
0.1 40.26 ± 1.04 40.33 ± 1.72 0.8857 
Table 4.15: Statistical analysis data for the effect of PEG-(NH2)2 on CBC, the number of 
samples was 4 for each concentration, the original PEG-(NH2)2 concentration was 1 g/L. 
PEG-(NH2)2 
Conc. 
g/L 
CBC  
Mean ± SD 
P 
(Mann-
Whitney) 
Test Control  
Erythrocytes (106/µL) 
0.01 4.99± 0.25  4.91 ± 0.26 0.4857 
0.1 5.05 ± 1.76 4.91 ± 0.26 0.2000 
Leukocytes (103/µL) 
0.01 6.44 ± 0.83  6.45 ± 0.70 0.8824 
0.1 6.22 ± 0.56  6.45 ± 0.70 0.1832 
Platelets (103/µL) 
0.01 206.04 ± 33.01  215.00 ± 26.41 0.6857 
0.1 194.15± 24.96 215.00 ± 26.41 0.4857 
Hemoglobin (g/dL) 
0.01 15.81 ± 1.40 15.53± 1.22 0.3094 
0.1 15.98± 1.07 15.53± 1.22 0.4678 
Hematocrit (%) 
0.01 46.66± 3.43 45.75± 3.56 0.4857 
0.1 47.22± 2.71 45.75± 3.56 0.4857 
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Figure 4.22: The effect of DMSA on: (a) Erythrocytes, (b) Leukocytes, (c) Platelets, (d) Haemoglobin 
and (e) Haematocrit. Values represent mean ± SEM (n=4).  
 
4.4.5 Haemolysis studies  
4.4.5.1 Blood treated with P4VP-g-APEG bioferrofluids 
Whole blood treated with P4VP-g-APEG bioferrofluids at concentration 0.07 g/L 
Fe2O3 did not show any haemolytic effect observed with naked eyes. 
Spectrophotometric measurements did not show any peak referred to the free 
haemoglobin at wavelength 580 nm as shown in Fig. 4.24(b), in addition, the curve 
was concave (normal) consistent with its control shown in Fig. 4.24(a). This result is 
confirmed by the results obtained from CBC, where there is no significant decrease in 
erythrocytes, haemoglobin and haematocrit. However, this assay is not suitable for 
haemolysis detection at high concentration (0.7 g/L Fe2O3) of P4VP-g-APEG 
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bioferrofluids, since their high concentration could interfere with the 
spectrophotometric measurements. 
 
Figure 4.23: The effect of PEG-(NH2)2 on: (a) Erythrocytes, (b) Leukocytes, (c) Platelets, (d) 
Haemoglobin and (e) Haematocrit. Values represent mean ± SEM (n=4).  
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Figure 4.24: Haemolysis detection using spectrophotometer (a) control blood, (b) blood treated with 
P4VP-g-APEG bioferrofluids at concentration 0.07 g/L Fe2O3.  
 
4.4.5.2 Blood treated with DMSA bioferrofluids and with DMSA PEG-(NH2)2 
bioferrofluids 
Whole blood was treated with different concentrations (0.05 and 0.1 g/L Fe) of 
DMSA bioferrofluids and DMSA PEG-(NH2)2 bioferrofluids, haemolysis results did 
not show any haemolytic effect observed with naked eyes. Spectrophotometric 
measurements did not show any peak referred to the free haemoglobin at wavelength 
580 nm as shown in Figs. 4.25 and 4.26. These curves were concave, consistent with 
their control ones. This result is confirmed by the results obtained from CBC, where 
there is no significant decrease in erythrocytes, haemoglobin and haematocrit. 
.
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Figure 4.25: Haemolysis detection 
using spectrophotometer (a) blood  
control, (b) blood treated with DMSA 
bioferrofluids at concentration 0.05 
g/L Fe and (c) blood treated with 
DMSA bioferrofluids at 
concentration 0.1 g/L. 
 
 
 
Figure 4.26: Haemolysis detection using spectrophotometer (a) blood  control, (b) blood treated with 
DMSA-PEG-(NH2)2 bioferrofluids at concentration 0.05 g/L Fe and (c) blood treated with DMSA-PEG-
(NH2)2 bioferrofluids at concentration 0.1 g/L Fe. 
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4.5 Discussion and conclusions 
As explained above, the coagulation cascade is consisting of two pathways; the 
extrinsic and the intrinsic ones. The efficiency of these pathways is evaluated by 
measuring PT and aPTT respectively.  
In general, a prolonged aPTT suggests either deficiency of one or more 
coagulation factors or the presence of an anticoagulant in plasma. The usual procedure 
to elucidate which of these two options is true is to mix the abnormal plasma with 
normal plasma to see if it corrects the prolongation of aPTT. If that happens, it 
indicates a deficiency of one or more haemostasis factors (normal plasma corrects the 
factor deficiency). The next step is to measure the activity of individual coagulation 
factors involved in the aPTT test. In the event that the normal plasma does not correct 
the aPTT, the most likely explanation is that an anticoagulant (which inhibits the 
normal factors) is present in the plasma. Then, it is important to find out if it is a 
specific or nonspecific anticoagulant with new tests, including the thrombin time and 
quantifying the activity of factors potentially affected by the anticoagulant at various 
dilutions. 
In this study, it was evident that a prolongation of aPTT was associated with high 
concentration of P4VP-g-APEG bioferrofluids in plasma. To explore this behaviour, a 
mixture test was performed. Results showed no correction for the prolongation in 
aPTT (above 37 s), which indicates the presence of an anticoagulant in the plasma. In 
order to elucidate whether it is specific or nonspecific a thrombin time test was carried 
out. The TT value was normal and the activities of all clotting factors (VIII, IX, XI, 
XII) in the intrinsic pathway were equally decreased, thus indicating that inhibitory 
activity is non-specific. We therefore conclude that the P4VP-g-APEG bioferrofluid 
behaves as a non-specific anticoagulant in vitro. In one way, this behaviour is similar 
to that of heparin from the fact that it lengths the aPTT, although heparin has also a 
specific effect on antithrombin III. In fact, the degrees of aPTT lengthening are 
comparable in both cases and therefore well within the therapeutic range.
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In order to gain insight into the origin of the anticoagulant effect of P4VP-g-
APEG bioferrofluids we have studied the P4VP-g-APEG bioferrofluids components 
separately. The surface of the nanoparticles in the P4VP-g-APEG bioferrofluids is 
formed by 1/10 in weight of APEG long chains (MW=1000) ending on carboxylic 
groups and 9/10 of APEG short chains (MW=200) ending on hydroxyl groups 
(diagram 1). It seems that either component is not likely to be at the origin of aPTT 
lengthening, because a solution of these compounds in the same concentration as in 
the P4VP-g-APEG bioferrofluids does not show any effect on aPTT, as shown in Fig 
4.9. The APEG hydrophilic chains are linked to the P4VP core by pyridine-acrylate 
bonds that generate a positive charge on the N atom of the pyridine, thus the resulting 
P4VP-g-APEG copolymer is polycationic and has a brush-like structure. This 
copolymer alone produced a strong aPTT lengthening (see Table 4.4), larger than the 
whole P4VP-g-APEG bioferrofluids, and must be the responsible for the anticoagulant 
effect. However, the mechanism of action is not clear. In fact, although their effects 
are comparable to those of heparin, the molecular structure is very different because 
heparin action is associated to the large presence of negatively charged groups such as 
sulfate, sulfonamide and carboxylic groups, whereas P4VP-g-APEG copolymer is 
positively charged. Our results are consistent with some studies [18,20]. For instance, 
Fernández-Pacheco et al. showed an anticoagulant effect caused by bioferrofluids 
[18]. The particle structure in this case was very different from ours as they consisted 
of a mixture of iron and iron oxide nanoparticles encapsulated in a carbon matrix. 
Although they share as a common feature the presence of carboxylic groups on the 
surface, this cannot cause of aPTT lengthening as inferred from APEG blank 
experiments. In another study carried out by Chouly et al. using magnetite dextran 
nanoparticles, their bioferrofluids (MD1) were similar to our P4VP-g-APEG 
bioferrofluids in terms of hydrodynamic diameter (75.4 ± 21 nm) and charge (0 mV), 
in addition they used similar concentrations (0.72 and 7.2 mM Fe). Their results show 
that these bioferrofluids did not provoke either haemolysis nor platelets aggregations, 
however, they induce an anticoagulant effect indicated by lengthening of aPTT, while 
TT values were normal. Authors illustrated the anticoagulant effect due to the particles 
affinity for blood phospholipids [20]. 
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CBC studies for blood treated with P4VP-g-APEG bioferrofluids and its 
components (APEG, P4VP-g-APEG) did not show any prejudicial effect on 
erythrocytes, leukocytes, platelets, haemoglobin and haematocrit. No haemolytic 
action was detected upon blood treatment with P4VP-g-APEG bioferrofluids at 
concentration 0.07 g/L Fe2O3. These results are in agreement with other studies 
[20,58]. However, a haemolytic action was detected in some other studies [19]. 
In addition, in this work we explore the haemostatic behaviour of other two 
bioferrofluids; DMSA and DMSA PEG-(NH2)2 ones. These bioferrofluids are 
different than P4VP-g-APEG bioferrofluids, in terms of hydrodynamic size and 
charge, as the hydrodynamic diameters of their particles are smaller (22 and 27 nm, 
respectively, compared to 80 nm of P4VP-g-APEG nanoparticles) and they are 
negatively charged (-35 mV and -15 mV, respectively, compared to 0 mV of P4VP-g-
APEG nanoparticles). The coagulation behaviour of DMSA and DMSA PEG-(NH2) 2 
bioferrofluids was similar to P4VP-g-APEG bioferrofluids, as a prolongation in aPTT 
was observed, as shown in Figs. 4.11 and 4.12. However, the effect was more 
pronounced in DMSA bioferrofluids than in DMSA PEG-(NH2)2 and P4VP-g-APEG 
ones at lower concentrations (see Table 4.7). To explore this behaviour, a mixture test 
was performed. Results showed correction for the prolongation in aPTT in plasma 
treated with DMSA bioferrofluids and DMSA PEG-(NH2)2 bioferrofluids, and in 
addition, the TT values were normal. 
The difference in the anticoagulant behaviour between DMSA bioferrofluids and 
DMSA PEG-(NH2)2 bioferrofluids, motivated us to measure the PT and aPTT in PPP 
treated with DMSA or with PEG-(NH2)2. Results show that both components are not 
the cause of the aPTT lengthening associated with the bioferrofluids, as normal levels 
of PT and aPTT were detected, as shown in Figs. 4.14 and 4.15. Several studies 
showed the effect of coating on the nanomaterial behaviour in blood and it has been 
reported that PEGylated poly(N-isopropylacrylamide) nanoparticles are 
haemocompatible with insignificant toxicity respect to the non-PEGylated ones [7]. 
Similar results have been reported for poly(lactide-co-glycolide) acid [59]. Negatively 
charged surfaces are proposed to be a pro-coagulant. In contrast, in this work, 
negatively charged bioferrofluids have an anticoagulant effect. This could be 
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explained as a result of their small sizes (22 nm and 27 nm) that make them unable to 
act as coagulation activating surfaces, as explained by Cecilia et al. using negatively 
charged polystyrene particles of 24 nm size [60]. We hypothesised that the increase in 
the negative charge is the responsible factor for the decease of the anticoagulant effect 
associated with DMSA PEG-(NH2)2 bioferrofluids in compared with DMSA 
bioferrofluids.  
CBC studies for blood treated with DMSA bioferrofluids and DMSA PEG-(NH2)2 
bioferrofluids and their components (DMSA, PEG-(NH2)2) did not show any effect on 
erythrocytes, leukocytes, platelets, haemoglobin and haematocrit. In addition, no 
haemolytic action was detected upon blood treatment with these both bioferrofluids at 
concentrations 0.05 and 0.1 g/L [Fe]. 
Then, we can conclude that P4VP-g-APEG bioferrofluids, DMSA bioferrofluids 
and DMSA PEG-(NH2)2 bioferrofluids do not cause any pro-coagulant effect that 
would prevent them use in intravenous applications. On the contrary, they show an 
anticoagulant effect that is reflected on a lengthening of the aPTT. The anticoagulant 
effect of P4VP-g-APEG bioferrofluids is non-specific because it does not affect to the 
thrombin time and it reduces equally the activity of clotting factors (VIII, IX, XI, XII) 
in the intrinsic pathway. DMSA bioferrofluids and DMSA PEG-(NH2)2 bioferrofluids 
do not affect the TT and the studies of the coagulation factors is mandatory. Therefore, 
these three bioferrofluids act as circulating anticoagulant agents in vitro. APEG 
component does not seem to have any effect on the coagulation process. The coating 
copolymer P4VP-g-APEG shows strong anticoagulant behaviour indicating that P4VP 
is at the origin of the anticoagulant effect associated with P4VP-g-APEG 
bioferrofluids. DMSA and PEG-(NH2)2 components do not seem to have any effect on 
the coagulation process. Therefore, the difference in the anticoagulant response 
between DMSA bioferrofluids and DMSA PEG-(NH2)2 bioferrofluids seems to be 
related to the surface charge. P4VP-g-APEG bioferrofluids, DMSA bioferrofluids and 
DMSA PEG-(NH2)2 bioferrofluids, and their components (APEG, P4VP-g-APEG, 
DMSA and PEG-(NH2)2) have no effect on the CBC. No haemolytic effect on blood 
treated with these bioferrofluids was detected in vitro. Further experiments using small 
animals in vivo are required to assess the validity of these conclusions.  
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Chapter 5  
Biodistribution studies of polymer coated 
superparamagnetic iron oxide 
nanoparticles  
 
5.1 Introduction  
Biomedical imaging is a non-invasive technique that is used not only for clinical 
purposes (e.g. disease diagnosis) but also for fundamental biological studies (e.g. 
anatomical or physiological studies). This field dates back to November 1895, when 
the first biomedical imaging technique called “X-ray” was discovered by W. C. 
Röntgen. Few months later, X-rays were used for clinical diagnosis [1]. X-ray 
technique was associated with several disadvantages and unwanted side effects, which 
in turn prompted scientists to develop new techniques able to exceed its limitations. 
Over the years, invention of new imaging techniques and development of the existing 
ones came out. Nowadays, many imaging techniques such as X-ray computed 
tomography (CT), ultrasound, magnetic resonance imaging, Single Photon Emission 
Computed Tomography (SPECT), Positron Emission Tomography (PET), and optical 
imaging are commonly used for diagnostic purposes in hospitals [2]. These techniques 
have received enormous attention, as their possibilities are not limited only to provide 
images that help in disease diagnosis, but also extended to visualise the molecular 
abnormalities within cells that are the cause of the disease [3]. As a result, a new 
discipline known as “molecular imaging” has emerged.  
In this chapter we will make use of MRI technique, complemented with 
histological and analytic prospections, to study the biodistribution of the polymer-
coated SPIONs whose toxicity is studied in this thesis.  
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5.1.1 Magnetic resonance imaging   
MRI is considered as one of the most promising non-invasive diagnostic tools in 
medical science, since it provides three-dimensional anatomical images with high 
spatial resolution in the sub-millimeter range and high soft tissue contrast [4]. MRI is 
used widely for brain imaging, the central nervous system imaging, tumours detection 
and the assessment of the cardiovascular system function [5]. 
 MRI technique is based on nuclear magnetic resonance (NMR) together with the 
proton relaxation in a magnetic field. Its efficiency as an imaging tool is based on the 
fact that the human body contains fats and water, these two elements possess a large 
amount of hydrogen atoms that make the human body contains about 63% hydrogen 
nuclei (1H). 
The NMR phenomenon in liquids and in solids was discovered by Edward Purcell 
and Felix Bloch in 1946, for this discovery they were awarded the Nobel Prize in 
physics in 1952. Over two decades (up until 1970s), the NMR technique was used for 
chemical and physical analysis. In 1971, Raymond Damadian used NMR technique in 
biomedical applications, where he observed that both normal and tumour tissues 
possess different relaxation times, this discovery has contributed to motivate the 
scientists to use the magnetic resonance technique as a tool for medical diagnosis. In 
1973, Paul C. Lauterbur and Peter Mansfield described the use of magnetic field 
gradients to localise NMR signals, a technical development that laid the foundation for 
MRI as it is currently performed nowadays. Afterward, MRI has received the FDA 
approval in 1985. In 2003, Paul C. Lauterbur and Peter Mansfield received the Nobel 
Prize in physiology and medicine for their discoveries concerning MRI [6].   
MRI by itself can provide diagnostic images that help in distinguishing between 
normal and diseased tissues. Often these images are not sufficiently accurate due to 
the small difference in the relaxation time between tissues. It is therefore necessary to 
use a supplement material that improves the sensitivity of the technique and provides 
clearer images. This supplement material is known as contrast agent.  
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Before reviewing the subject of contrast agents, a brief introduction to the MRI 
technique will be provided first.  
5.1.1.1 Principles of MRI  
MRI is based on the detection of NMR signals from hydrogen protons in the body 
when it is placed in a magnetic field [7].  
Protons possess a spin and have their own magnetic moment. In the absence of a 
magnetic field protons are randomly oriented. However, when protons are exposed to 
an external magnetic field (B0), their spins align either parallel or anti-parallel to the 
magnetic field, more spins prefer to align in the lower energy state (parallel). 
Therefore, the sum of spins moments per volume unit (net magnetisation) is in the 
direction of the applied magnetic field that we define as the Z axis. Under the effect of 
the magnetic field the protons perform a motion called precession Fig. 5.1, the 
precession frequency depends on the strength of the magnetic field, a relation which is 
described as Larmor equation: 
Ѡ0= ɣB0 
Ѡ0 is the Larmor frequency (MHz), ɣ is gyromagnetic ratio whose value for the 
proton is (ɣp) = 42.577 MHz/T and B0 is the strength of the magnetic field (T). 
 
 
Figure 5.1: Proton precession described by the Larmor equation [8].  
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When a radio-frequency (RF) pulse of the same frequency of the precessing 
protons is introduced, Fig. 5.2(a), it has two effects: (a) it causes a resonance process, 
which transfers energy to protons at the lower energy level (parallel). These protons 
absorb energy and are excited to the anti-parallel state (higher energy level) resulting 
in a decrease of the longitudinal magnetisation (Mz), Fig. 5.2(b). Depending on the 
radio frequency pulse, the longitudinal magnetisation may even totally disappear. At 
the same time, (b) it makes the protons to precess in phase (pointing at the same 
direction, at the same time) Fig. 5.2(c), which leads to increase the magnetisation 
component in the direction transverse to the external magnetic field. This new 
magnetic vector is called the transverse magnetisation (Mxy), Fig. 5.2(c). The 
transversal magnetic vector does not stand still, but it moves around with the 
precessing protons, under the precession frequency. The movement of the transverse 
magnetic vector induces an electric current, which is the MRI signal. 
After the disappearance of the RF pulse, the excited protons relax to their initial 
state, resulting in a decrease of the transverse magnetisation Fig. 5.2(d), which 
originates a loss of the MRI signal, in a process called transverse relaxation, Fig. 
5.3(b). This process is associated with an increase (recovery) of the longitudinal 
magnetisation, Fig. 5.2(d), in a process called longitudinal relaxation, Fig. 5.3(a). 
Figure 5.2: Basic principle of magnetic resonance imaging: protons align parallel to the external 
magnetic field (B0) with a net magnetisation called longitudinal magnetisation (Mz) (a), when RF pulse of 
the same frequency of the precessing protons is introduced, some protons absorb energy and go to the 
anti-parallel state leading to a decrease of the longitudinal magnetisation (b), in addition, RF pulse makes 
protons to precess in phase, which in turn establishes a new magnetic vector in the transverse direction of 
the external magnetic field, this magnetic vector is called transverse magnetisation (Mxy) (c), when the 
RF pulse is switched off, protons possess different precession frequencies and become out of phase, 
which results in a decrease of the transverse magnetisation; in addition, the excited protons relax to its 
original state (parallel) leading to an increase (recovery) of the longitudinal magnetisation to its original 
value (d).
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Figure 5.3: The longitudinal relaxation curve (T1 relaxation curve) (a) and the transverse relaxation curve 
(T2 relaxation curve) [8].  
The longitudinal relaxation is associated with an exchange of thermal energy with 
the surrounding (lattice), to where the excited protons transfer energy during their 
relaxation. Therefore, longitudinal relaxation can also be called spin-lattice relaxation.  
During the longitudinal relaxation process, excited protons take time to relax, 
associated with an increase (recovery) of the longitudinal magnetisation to its original 
value, Fig. 5.3(a). This time is known as longitudinal/spin-lattice relaxation time (T1) 
that can be defined as the time to reduce the difference between the longitudinal 
magnetisation (Mz) and its equilibrium value (M0) by a factor of e.  
Mz=Mo (1-e-t/T1) 
Also, the time constant T1 can be defined as the time when 63% of original 
longitudinal magnetisation is reached.  
T1 depends on the strength of the external magnetic field. The stronger the 
magnetic field the larger T1 value. The value of T1 in biological tissues is between 
300-2000 msec. 
The transverse relaxation occurs due to the loss of phase coherence in the 
precessing spins, which has two origins: (a) inhomogeneity of the external magnetic 
field, which results in difference in the protons precession frequencies (b) 
inhomogeneity of the local magnetic field in the tissue- each spin is influenced by the 
small magnetic field of the neighbour spin (spin-spin interaction)-, which causes 
difference in the protons precession frequencies. Due to spin-spin interaction, the
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transverse relaxation can also be called spin-spin relaxation.  
During the transverse relaxation, protons possess different precession frequencies 
and become out of phase (dephasing), which results in a decrease of the transverse 
magnetisation with time Fig. 5.3(b). The time required to reduce the transverse 
magnetisation is called the transverse/spin-spin relaxation time (T2), which can be 
defined as the time to reduce the transverse magnetisation (Mxy) by a factor of e. 
Mxy=Mxyo  e-t/T2 
Also, the time constant T2 can be defined as the time when the transverse 
magnetisation is decreased to 37% of its original value.  
In comparison with T1, T2 is always shorter, and depends less on the strength of 
the magnetic field. The value of T2 in biological tissues is between 30-150 msec.  
Since the transverse relaxation is affected by the inhomogeneity of the magnetic 
field produced from tissue and external sources, the total T2 relaxation time is known 
as T2* and is described by the following equation:  
1/T2* = 1/T2+ ɣBs 
Where ɣBs represents the relaxation by the field inhomogeneities (1/T2 inhomo) and 
is called susceptibility effect.  
T2* can be defined as the time constant that describes the exponential decay of 
signal, due to spin-spin interactions, magnetic field inhomogeneities and susceptibility 
effects. 
According to the relaxation mechanism, contrast agents (CAs) can be divided into 
two main groups; T1 contrast agents (Paramagnetic contrast agents) and T2 contrast 
agent (superparamagnetic contrast agents). 
5.1.2 Contrast agents  
The word “contrast” indicates the difference in intensities between two adjacent 
regions within an examined object on a gray or colour scale.  According to FDA, a 
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contrast agent is defined as it is a medical imaging agent  that is used to improve the 
visualisation of tissues, organs and physiologic processes by increasing the relative 
difference of imaging signal intensities in adjacent regions of the body [9]. Contrast 
agents are used in many techniques, such as radiography, CT, ultrasonography and 
MRI.  
The MR image contrast is the result of various contributing extrinsic (e.g. strength 
of the magnetic field, etc.) and intrinsic (e.g. T1, T2, T2*, etc.) parameters.  Therefore, 
the image contrast in MRI is classified into 3 categories: (a) proton density-weighted 
image, a sequence that is mainly sensitive to proton density م (b) T1-weighted image, a 
sequence that is mainly sensitive to T1 relaxation time (c) T2-weighted image, a 
sequence that is mainly sensitive to T2 relaxation time [10].  
MRI contrast agents are medical imaging agents that facilitate the performance of 
the imaging tool by improving its sensitivity and detectability, through increasing the 
relaxation rates of water protons in tissues in which the agents accumulate. Usually, 
they are chemical agents, but with the continued rapid development in 
nanotechnology, a new class of contrast agents based on nanoparticles has emerged.  
The mechanism of action of MRI contrast agents is more complicated as 
compared to other techniques, since it depends on the interaction between the MRI 
contrast agent and the neighbouring water protons, which could be affected by many 
intrinsic and extrinsic parameters. however, in X-ray or CT contrast agents the 
mechanism depends on the difference in the electron density [8]. 
The efficiency of MRI contrast agents depends on their longitudinal (r1) and 
transverse (r2) relaxivities (mM-1S-1), which are defined as the increase in the 
relaxation rates (1/T1 and 1/T2 respectively) of protons produced by 1mmol per litre of 
contrast agent.  
1/Ti(post) = 1/Ti(pre) + ri·C 
Where i is 1 or 2, Ti(post) is the relaxation time of the system after CA administration 
(S-1), Ti(pre) is the relaxation time of the system before CA administration (S-1), ri is the 
relaxivity (mM-1S-1), and C is the concentration of the CA (mM).  
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Both r1 and r2 are depending on several factors such as the size of CA (increasing 
the size increases r), chemical structure of the CA molecules, the accessibility of water 
molecules to the magnetic centre, CA concentration, proton density and the chemical 
environment [11].  
For clinical applications, contrast agents should possess several requirements such 
as high relaxivity, specificity, tolerance, safety and low toxicity, stability, optimal 
biodistribution, metabolism and elimination, high contrast enhancement with low dose 
in vivo and minimal cost.  
MRI contrast agents can be classified according their (a) magnetic behaviour into 
soluble paramagnetic metal chelates and superparamagnetic iron oxide particles, (b) 
effect on proton relaxivity into T1 contrast agents and T2 contrast agents, (c) 
biodistribution into blood pool (intravascular), extracellular or organ-specific agents. 
The commercially available MRI contrast agents are summarised in Table 5.1. 
5.1.2.1 Paramagnetic contrast agents 
They are also known as T1 contrast agents, as they increase the longitudinal 
relaxation rate (R1 = 1/T1) of water protons in tissues -where they are accumulated- 
more than the transverse relaxation rate (R2 = 1/T2), thus resulting in an increase in 
signal intensity on T1-weighted images. Therefore, these agents are positive contrast 
agents. At low concentration, these CAs can be used as T1 contrast agent, however at 
high concentration they can be used as T2 contrast agents. 
Paramagnetic species are metal ions with unpaired electrons, including the 
transition metal ions, such as manganese (Mn+2, Mn+3), iron (Fe+2, Fe+3), and 
lanthanide ions, such as gadolinium (Gd+3) and dysprosium (Dy+3). The Gd (III) is the 
preferred paramagnetic metal ion because it has seven unpaired electrons and high 
relaxivity, however, it is toxic in its ionic form. Therefore, these paramagnetic metal 
ions used as CAs are in a complex with a ligand, forming strong chelates, in order to 
limit the high toxicity and the undesirable biodistribution caused by paramagnetic 
metal ions alone [10]. 
These contrast agents can be divided into 3 categories (a) extracellular agents,
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Table 5.1 commercially available MRI contrast agents[12–16].  
Trade name Name of compound   Classification Applications Producer 
Magnevist ® Gd-DTPA  T1- agent Neuro/whole body imaging  Bayer  healthcare pharmaceuticals, Inc  
Omniscan® Gd-DTPA-BMA  T1- agent Neuro/whole body imaging GE healthcare 
Ablavar®  Diphenylcyclohexyl phosphodiester-
Gd-DTPA
 T1- agent Blood pool imaging Lantheus Medical Imaging, Inc 
ProHance ® Gd-HP-DO3A  T1- agent Neuro/whole body imaging Bracco Diagnostic Inc 
Gadovist ® Gd-DO3A- butrol  T1- agent Neuro/whole body imaging Bayer  healthcare pharmaceuticals, Inc 
Dotarem® Gd-DOTA  T1- agent Neuro/whole body imaging Guerbet S.A. 
OptiMARK® Gd-DTPA-BMEA  T1- agent Neuro/whole body imaging Mallinckrodt, Inc 
Multihance ® Gd-BOPTA   T1- agent Centeral nervous system and liver imaging
Bracco Diagnostic Inc 
Eovist® Gd-EOB-DTPA  T1- agent Liver imaging Bayer  healthcare pharmaceuticals, Inc 
Teslascan Mn-DPDP T1- agent Liver imaging GE healthcare 
Lumirem® Ferumoxsil, AMI-121 T2-agent Bowel imaging Guerbet S.A. 
Endorem® * Dextran-coated ferumoxide,  AMI-25 T2-agent Liver imaging Guerbet S.A. 
Resovist® * Ferucarbotran, SHU-555A T2-agent Liver imaging Bayer  healthcare pharmaceuticals, Inc 
Sinerem® * Ferumoxtran-10, AMI-227 T2-agent Blood pool imaging Guerbet S.A. 
Clariscan® * Feruglose T2-agent Blood pool imaging GE healthcare 
Gd-DTPA, a complex of gadolinium with diethylenetriaminepentaacetic acid. Gd-DTPA-BMA, a complex of gadolinium with diethylenetriaminepentaacetic acid-
Bismethylamide. Gd-HP-DO3A, a complex of gadolinium with 10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato. Gd-DOTA, a complex of gadolinium 
with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Gd-DTPA-BMEA, bis(methoxyethylamide) derivative of Gd-DTPA, Gd-BOPTA, a complex of gadolinium 
with the ligand BOPTA, a derivative of DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–CH2C6H5.  Gd-EOB-DTPA, a complex of gadolinium 
with ethoxybenzyl diethylenetriaminepentaacetic acid. MN-DPDP, manganese dipyroxyl diphosphate(*) withdrew from the market. 
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including the ionic Gd-DTPA and Gd-DOTA, and the neutral Gd-DTPA-BMA, Gd-
HP-DO3A, Gd-DO3A-butrol and GD-DTPA-BMEA (b) hepatobiliary (organ specific 
agents), including Gd-BOPTA and Gd-EOB-DTPA (c) blood pool agents, including  
MS-325 (Ablavar® ), see Table 5.1.  
5.1.2.2 Superparamagnetic contrast agents   
Superparamagnetic contrast agents are considered as the first nanoparticle-based 
MRI contrast agents, exploiting the unique physicochemical properties offered by the 
nanoparticles, such as the high surface area and the size-dependent magnetic 
properties. They received a great attention after their development as liver contrast 
agents 20 years ago. This type of CAs has the ability to shorten T2 and T2* relaxation 
times, which is associated with a decrease in the signal intensity, predominant on T2 
and T2*-weighted images. Thus, these agents are generally known as negative contrast 
agents.   
These CAs consist of an iron oxide core (Fe3O4, γFe2O3, or other ferrites) coated 
with macromolecular materials such as dextran, carboxydextran, chitosan, starch, 
heparin, albumin and polystyrene. SPIONs offer several advantages than other CAs 
such as strong magnetic efficacy, biodegradability, low toxicity and ease of 
functionalisation for targeted imaging [17]. The efficiency of CA is based on r2/r1 
ratio, which increases with increasing the particle size. Better T2 CA for MRI is the 
one that increases r2 and decreases r1 [18]. 
According to the overall size of the particles, these CAs can be divided into 3 
classes: (1) ultra-small superparamagnetic iron oxide (USPIO) particles, if they 
possess a hydrodynamic diameter less than 50 nm, (2) superparamagnetic iron oxide 
(SPIO) particles, if they possess a hydrodynamic diameter more than 50 nm, (3) large 
particles, if they possess a hydrodynamic diameter more than 200 nm. In the three 
cases the core diameters are such that the particles are superparamagnetic. Both 
USPIO and SPIO particles are feasible for intravenous administration, however, the 
larger particles with their large diameter that could reaches to several micrometers, 
limits their use only for gastrointestinal tract exploration. 
Iron oxide (IO) particles are considered as reticuloendothelial system agents, 
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therefore, they are used for liver, spleen and lymph node imaging. In addition, they are 
used for gastrointestinal tract (bowel) imaging and MR angiography (see Table 5.1). 
Targeted imaging has been achieved using SPIONs conjugated to several targeting 
moieties, for instance, transferrin conjugated SPIONs for tumour imaging, asialofetuin 
conjugated SPIONS for liver-specific imaging, secretin conjugated SPIONS for 
pancrease-specific imaging [17,19,20]. 
5.1.3 Biodistribution  
Nanomaterial biodistribution studies its accumulation in certain organs, which in 
turn reflects on the toxic behaviour of this nanomaterial. The toxicity of nanomaterials 
depends on their persistence or clearance from their target organs. Accumulation of 
nanomaterials in several organs has been detected, for instance accumulation of starch 
coated SPIONs in lymph nodes [21].  
The biodistibution of nanomaterials in biological system depends on several 
factors:  
1) Mode of administration. The fate of nanomaterials inside the body is 
determined by the way it is administrated [22]. For instance, 
subcutaneous route is generally considered more appropriate for targeting 
the regional lymph nodes [23].  
2) The body anatomy and physiology. Human body possesses several 
biological barriers that hinder the passage of nanomaterials to their target 
tissue, such as: 
  Epithelium: it acts as a general barrier to prevent the entry of any 
material to the body, it can be overcome by parenteral injection [24]. 
 Blood: when nanomaterials undergo intravenous administration, 
several circulating plasma proteins tend to adsorb on their surfaces 
forming “protein corona”. Protein corona confers a new 
physicochemical properties to the nanomaterials, and therefore 
determines the nanomaterial fate in body [25]; for instance, 
adsorption of certain proteins called opsonin (e.g. immunoglobulin 
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and complement proteins) to the surface of the nanomaterials leads to 
clearance of the nanomaterials from the circulation by RES (e.g. 
macrophages, neutrophils, etc.), through a process called 
opsonisation. Opsonisation process depends on the size and surface 
characteristics of the nanomaterial. The majority of opsonised 
nanomaterials are cleared from circulation to liver and spleen in less 
than 5 minutes [24]. Opsonisation can be overcome by coating the 
nanomaterial hydrophobic surface with suitable hydrophilic polymers 
such as PEG. This reduces the non-specific binding of proteins, 
leading to prolonged blood circulation time [26]. In addition, 
formation of protein corona could lead to specific targeting of the 
nanomaterial to particular organs; for instance, adsorption of 
apolipoprotein E (apoE) to the surface of several nanomaterials leads 
to their delivery to brain tissue [27–29].   
 Vascular endothelium: is a continuous and tight junction layer of 
endothelial cells that lines the inner surface of the blood vessels. 
Nanomaterials can leave the circulation by breaching the endothelium 
either by paracellular or transcellular routes. The tight junction makes 
the gap distance between neighbour cells of less than 2 nm, which in 
turns prevents the nanomaterials to slip between the cells 
(Paracellular route). However, in some organs such as liver and 
spleen, the endothelium is fenestrated, allowing the passage of 
nanomaterials. In addition, the leaky endothelium is observed in some 
diseases conditions such as inflammation and tumours, allowing 
accumulation of nanomaterial in tumours through EPR mechanism 
[30]. The transcellular route occurs through endocytosis mechanism 
and requires surface modifications of the nanomaterials [31].   
 Plasma membrane and uptake by cells: the internalisation of 
nanomaterials into the cells is governed by endocytosis mechanism, 
which defines the fate of the nanomaterials inside the cells whether in 
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the cytoplasm or in degradative organelles such as lysosomes. This 
section is explained in detail in chapter 3 (section 3.1.1.3.1).  
3) Nanomaterial physicochemical properties. Nanomaterial composition 
[32], size [33], shape [34], surface charge [35] and surface modification 
(e.g. coating [31], targeting [36]) have shown to have influence on the 
nanomaterial biodistribution. For instance, the accepted size for in vivo 
application is ranging between 10-100 nm [37], larger sizes increase the 
chance of rapid clearance by opsonisation, while sizes smaller than 5.5 
nm are rapidly cleared by glomerular filtration in the kidneys [38]. 
5.2 Objectives  
The aim of this chapter is to study the in vitro relaxation, in vivo biodistribution -
using MRI, histological and analytical studies- and the in vivo toxicity for two 
polymer coated SPIONs; P4VP-g-APEG coated SPIONs (our bioferrofluids) and 
dextran coated SPIONs (Endorem®). 
5.3 Materials and methods 
5.3.1 Bioferrofluids preparation and characterisation 
Bioferrofluids preparation and characterisation methods are the same as described 
in Annex I. The preparation conditions of the maghemite polymer nanocomposites 
used in this chapter is the same as described in the corresponding section of chapter 3 
(see section 3.3.1).  
5.3.2 In vitro relaxation measurement  
In vitro MR imaging was performed with a Biospec Tomograph system (Bruker 
Medical systems, Karlsruhe, Germany) operating at 200 MHz (4.7 T) and equipped 
with a 33 cm bore magnet (Oxford Ltd., UK). The system was operating using 
Paravision 5.1 software (Bruker, Germany). Samples were prepared in physiological 
saline solutions at different concentrations of bioferrofluids and Endorem® (in mM 
iron), then inserted in a 7.2 cm internal diameter (i.d) birdcage coil. The transverse 
relaxation times (T2) were measured using a standard spin echo multi echo sequence 
with the following parameters: Repetition time (TR)/echo times (TE) = 2000/5.9 ms, 
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field of view (FOV) = 8x4cm2, matrix size (MTX) = 128x128, slice thickness of 2 
mm, number of echoes = 16. For the measurement of the longitudinal relaxation time, 
a fast T1 mapping technique based on a IR-SNAPSHOT sequence was used [39]. The 
acquisition parameters were FOV = 8x8cm2, MTX = 128x128, slice thickness of 2 
mm, TR/TE = 10/3.7 ms, excitation pulse angle = 5º, and a 5ms Sech-shaped inversion 
pulse.  
Longitudinal and transversal relaxation rates (1/T1 and 1/T2) were plotted as a 
function of iron concentration and r1 and r2 relaxivities were obtained by the slope of 
the fitting straight line.  
5.3.3 In vivo MR imaging   
To obtain MR images, 6-7 weeks old BALB/c mice weighting 19-22 grams were 
anesthetised by inhalation in an induction box with O2 containing 1:1.5% isofluorane. 
An animal bed and a magnetic field compatible small animal physiological monitor 
(SA instrument, Inc, USA) were used to fix the animal and monitor the respiration 
rate. Mice were fixed to the animal bed in the supine position and a receiver surface 
coil was placed over their head. The mice were inserted in a 7.2 cm i.d transmitter coil 
and then into the magnet 4.7T Fig. 5.4. A Standard tube containing 1mM gadolinium-
DTPA was inserted in the FOV to standardise images. Aqueous suspensions of either 
bioferrofluid or Endorem® were intravenously injected via the tail vein at a dose of 
23.5 mg Fe/Kg body weight.  
In order to evaluate the performance of the bioferrofluid as a contrast agent 
compared to Endorem®, mapping of the cerebral blood flow (CBF) and cerebral blood 
volume (CBV) was carried out through bolus tracking method (first passage) [40]. 
Regional CBV (rCBV) can be also measured using blood pool contrast agents at the 
steady-state concentration of contrast agent in blood, by acquiring T2* images before 
and after contrast agent injection and using the relationship [41]: 
ݎܥܤܸ ൌ ܭ ൈ ln ܵܫ	ሺ݌ݎ݁ሻܵܫ	ሺ݌݋ݏݐሻ 
Where K is a constant depending on instrumental parameters, SI pre and SI post are 
brain signal intensity values before and after contrast agent injection respectively. 
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First-passage images were acquired using an EPI sequence with the following 
parameters: MTX = 128x128, FOV = 2.5x2.5cm2, slice thickness = 2mm, 4 EPI shots, 
TR/TE = 25/6.6ms, number of excitation (NEX) = 2 (time resolution of 5 images/s). 
Images were continuously recorded for 60 s.   
Steady-state images were acquired before and during 2 h after injection of the 
contrast agent using a gradient echo sequence with the following parameters: TR/TE = 
186.4/ 12 ms, flip angle = 30º, MTX = 256x256, FOV = 2.5x2.5 cm2, slice thickness = 
1 mm, NEX = 4. Since the drop of signal in brain is purely due to the contrast agent 
present in the blood, the time dependence of SI in the brain will provide an insight in 
the time of permanence of contrast agents in the blood.  
Figure 5.4: Procedure illustration of MRI experiments in vivo. Mouse was anesthetised by inhalation 
inside an induction box with O2 containing 1:1.5% isofluorane (A, B). To fix the animal and monitor its 
respiration rate, an animal bed and a magnetic field compatible sensor for respiration were used, a 
standard tube containing 1mM gadolinium-DTPA is also used to standardise images (C). For brain 
imaging, mouse was fixed to the animal bed in the supine position and a receiver surface coil was placed 
over his head. (D). For whole body MR imaging, mouse was fixed to the animal bed in the supine 
position with the help of adhesive, then inserted into transmitter/receiver coil (3.5 cm i.d birdcage coil) 
(E, F). Mouse was inserted into 4.7T Biospec Tomograph system (G). MR imaging was operating using 
Paravision 5.1 software (H) and the animal respiration rate was monitored during the whole experiment 
time (I).  
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5.3.3.1 Imaging analysis  
In the first passage images, signal enhancement was calculated according to the 
following equation: 
ܧ݄݊ܽ݊ܿ݁݉݁݊ݐ	ሺ%ሻ ൌ ܵܫ	ሺݐሻ െ ܵܫ	ሺ0ሻܵܫ	ሺ0ሻ ൈ 100 
Where SI(t) is the signal intensity at time t, SI(0) is the signal intensity before 
injection.  
Steady state images were acquired using T2*-weighted sequence. Signal Intensity 
ratio values were obtained by defining the regions-of-interest (ROIs) in the brain. 
These values were normalised to the standard, divided by the pre-contrast value and 
plotted as a function of time. 
 Regional CBV maps were calculated according to the following equation: 
ݎܥܤܸ ൌ ܭ ൈ ln ܵܫ	ሺ݌ݎ݁ሻܵܫ	ሺ݌݋ݏݐሻ 
Where K is a constant depending on instrumental parameters, SI pre and SI post are 
brain signal intensity values before and after contrast agent injection respectively.  
5.3.4 Biodistribution studies using MRI  
A total number of 16, 8 for each contrast agent, 6-7 weeks old BALB/c mice 
weighting 19-22 grams were used. MR imaging studies were performed with 4.7T 
Biospec Tomograph system using a transmitter/receiver coil (3.5 cm i.d birdcage coil). 
Mouse was anesthetised and fixed in the supine position to an animal bed. A magnetic 
field compatible sensor for respiration was placed under the mouse abdomen and 
connected to a small animal physiological monitor to record the respiration rate. A 
Standard tube containing 1mM gadolinium-DTPA was inserted in the FOV to 
standardise images. Aqueous suspensions of either bioferrofluids or Endorem® were 
intravenous injected via the tail vein at the clinical dose (20µmole Fe/kg body weight). 
Images for the whole body were taken before injection (Pre) and at different time 
points after injection (5 min-2 h, 24 h, 7 days, 15 days, 30 days and 60 days). 
Quantitative T2 maps were acquired using a spin echo multi-echo sequence with the 
following parameters: TR/TE = 2000/5.9 ms, FOV = 3x6cm2, MTX = 128x128, slice 
 
 
 
 
5.3. Materials and methods 189 
 
thickness of 2 mm, number of echoes = 16. T2*-weighted images were acquired using 
gradient echo sequence with the following parameters: TR/TE = 1000/4.4 ms, FOV = 
3x6 cm2, MTX = 256x128, slice thickness of 2 mm, flip angle (FA) = 10º.  All animal 
studies were approved by the Institutional Animal care and Use Committee. 
5.3.4.1 Imaging analysis  
For the quantitative analysis of obtained images, regions-of-interest were defined 
in the identical site of liver and kidney. The T2 values in these ROIs were obtained by 
using the image sequence analysis (ISA) tool of Paravision 5.1 software, which 
performs a best fitting of the equation: 
 
where, SI(TE) is the signal intensity at certain echo time, SI(0) is the signal intensity at 
zero time, TE is the echo time, T2 is the transverse relaxation time, C is a constant, to 
the experimental data, thus providing T2 value in each selected ROI.  
T2*-weighted images were analysed by calculating the ratio between signal 
intensity after contrast agent injection (SI(post)) and signal intensity before (SI(pre)) 
at each time point for each organ: 
ܴ ൌ ܵܫ	ሺ݌݋ݏݐሻ ܵܫ	ሺܲݎ݁ሻ⁄  
Within a given image, signal intensity values were normalised to the signal 
intensity of brain instead of the standard due to its absence in some images. This 
normalisation is needed to account for possible instrumental drifts during the 
acquisition times. Preliminary experiments showed that the signal intensity of brain is 
not affected by the used contrast agent dosages.  
5.3.5 Statistical analysis  
Not all the 16 mice were used for the statistical analysis. This is because some 
animals were excluded from the experiment due to image artifacts arising from animal 
respiration movement, also at each time point one animal was sacrificed. Obtained 
data were presented in the curves as (mean ± SEM), the number of readingsat each 
time point is indicated by symbol (n), data were analysed using Mann-Whitney test.  
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5.3.6 In vivo toxicity studies  
At each time point (2 h, 24 h, 7 days, 15 days, 30 days and 60 days), animals were 
sacrificed, dissected tissues (liver, spleen, kidney, lungs and heart) were fixed in 10% 
neutral buffered formalin for 4h followed by a dehydration in ascending grades of 
ethanol (70%, 80%, 90% and 100%), emersion in xylol, and then inclusion within 
paraffin wax. Coronal sections (4-6 µm thick) were cut using microtome (Leitz 
Wetzlar, Germany). Slides mounted sections were deparaffinised, rehydrated, and 
stained with using hematoxylin and eosin (H&E) according to standard clinical 
pathology protocols. Slides were dehydrated and then mounted. Prepared slides were 
visualised under Olympus BX51 microscope equipped with a digital camera. A 
pathologist was consulted to evaluate any signs of toxicity present.  
5.3.7 Qualitative iron detection using Prussian blue assay 
The principle of this assay is that ferric ion in the presence of ferrocyanide ion 
forms ferrous ferrocyanide salt (white color), oxidation of this salt using hydrochloric 
acid produces ferric ferrocyanide (Prussian blue), which is highly coloured and highly 
water-insoluble complex.  
The slides mounted liver and kidney sections were deparaffinised, rehydrated and 
processed for iron detection using Prussian blue assay. Samples were incubated with a 
mixture of 5% potassium hexacyanoferrate II [K4[Fe(CN)6].3H2O] and 5% HCL for 
45 mins. Stained sections were washed and counter-stained with nuclear fast red for 1 
min to provide histological cellular distributions. The slides were dehydrated and then 
mounted. Prepared slides were observed under Olympus BX51 microscope equipped 
with a digital camera.  
5.3.8 Quantitative iron detection by atomic absorption  
6-7 weeks old BALB/c mice weighting 19-22 grams were used. Aqueous 
suspensions of either bioferrofluids or Endorem® were intravenous injected via the 
tail vein at the dose of 23.5 mgFe/kg body weight. Mice were sacrificed 2 h and 24 h 
after injection. Dissected tissues (liver and kidney) were processed for quantitative 
iron detection, tissue samples were placed in a Teflon tubes and left for 24 h at 80°C 
to dryness. 2 mL of highly purified HNO3 (>69.0%) was added, and then the samples 
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digested using a microwave digestor (MVS-2 Berghof). Samples were cooled and then 
diluted to 5 mL with Milli-Q water. Iron content was determined by Inductively 
Coupled Plasma Optical Emission Spectrometry (ICP-OES) Perkin–Elmer plasma 40.  
5.4 Results  
5.4.1 Bioferrofluids characterisation 
The bioferrofluids used in this chapter is (R8`), the same bioferrofluids that has 
used in chapter 3 (see section 3.4.1). Briefly, the bioferrofluids concentration is 8.1 
g/L Fe2O3. The core diameter is 13.08 ± 2.33 nm and the hydrodynamic diameter is 
163 nm.  
A well-known commercialised MRI contrast agent, Endorem®, (Guerbet, 
France), was used in this work. Endorem® is composed of magnetite core with a size 
range between 6-9 nm, which is coated with a polymeric coating of dextran. The 
hydrodynamic diameter of Endorem® is ranging between 80-150 nm.  Measurement 
of the hydrodynamic diameter in our laboratory yields an average of hydrodynamic 
diameter of 110 nm. The Endorem® concentration is 11.2 g/L Fe.   
5.4.2 In vitro relaxation measurement 
Transverse (T2) and longitudinal relaxation times (T1) were measured for both, 
Endorem® and bioferrofluids, prepared in physiological saline solutions at different 
iron concentrations (in mM). It was evident that these bioferrofluids exhibit the typical 
property of superparamagnetic iron oxide nanoparticles of shortening T2 relaxation 
time, as increasing the nanoparticles concentration is associated with a decrease in the 
signal intensity Fig. 5.5. Obtained values of transverse and longitudinal relaxation 
rates (1/T2, s-1 and 1/T1, s-1, respectively) of bioferrofluids and Endorem® were plotted 
versus the iron concentration in mM Fig. 5.6. Both 1/T2 and 1/T1 relaxation rates are 
linearly proportional to the iron concentration, see Figs. 5.6(a) and 5.6(b). The 
relaxivity coefficient values (r2 and r1) were obtained by the slope of the fitting 
straight lines. r2 values are  113.99 ± 11.08 (r ± C.I) and 82.8 ± 8.28 mM-1s-1, while r1 
values are 2.11 ± 0.21and 0.45 ± 0.05 mM-1s-1 for Endorem® and bioferrofluids 
respectively. These results indicate that these bioferrofluids have a lower r2 and r1 
compared to commercial Endorem®. The efficiency of a T2 contrast agent depends on 
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its r1, r2, and r2/r1 ratio. A better efficiency is associated with higher r2/r1 ratio [42]. 
The r2/r1 ratio values were 54.02 and 184 for Endorem® and bioferrofluids 
respectively, these results indicate that these bioferrofluids are useful as T2 contrast 
agent. 
Figure 5.5: T2-weighted MR imaging of bioferrofluids and Endorem® in physiological saline at different 
iron concentrations (in mM).  
Figure 5.6:  Comparative analysis of the transverse relaxation rates (1/T2, s-1) (a) and longitudinal 
relaxation rates (1/T1, s-1) (b) of bioferrofluids and Endorem® as a function of iron concentration (mM). 
Relaxation coefficients (r2, r1) were calculated from the slopes of each plot.  
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5.4.3. In vivo MR imaging  
First passage experiments were performed in order to assess the usefulness of 
investigated contrast agent in cerebral perfusion experiments. A dynamic first-passage 
bolus tracking method was used. Mice were injected with Endorem® and 
bioferrofluids at a dose of 23.5 mg Fe/Kg body weight, and images were acquired 
during 60s following the injection. The obtained signal intensity values were 
normalised according to the following equation:   
ܧ݄݊ܽ݊ܿ݁݉݁݊ݐ	ሺ%ሻ ൌ ܵܫ	ሺݐሻ െ ܵܫ	ሺ0ሻܵܫ	ሺ0ሻ ൈ 100 
Where SI(t) is the signal intensity at time t, SI(0) is the signal intensity before 
injection.  
A first-passage contrast agent curve plotting the enhancement (%) versus the 
acquisition times is shown in Fig. 5.7. These results clarify the effect of both 
Endorem® and bioferrofluids on the signal intensity in vivo. Both cause a decrease in 
the signal intensity values with a different extent. The signal intensity decreases more 
with Endorem® than with the bioferrofluids. These results are in agreement with the 
in vitro studies. 
Figure 5.7: A dynamic first-passage bolus tracking curve for both Endorem® and bioferrofluids during 
an acquisition time of 60s. 
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To evaluate the performance of the bioferrofluid as a contrast agent compared to 
Endorem® in steady-state condition, T2*-weighted images in brain were acquired 
before (pre) and during 2 h after (post) injection of Endorem® and bioferrofluids at a 
dose of 23.5 mg Fe/Kg body weight. Before injection, the brain appeared clear Figs. 
5.8(a) and 5.8(e). Few minutes after injection of Endorem® and bioferrofluids, a 
decrease in the signal intensity was observed for both contrast agents Figs. 5.8(b) and 
5.8(f), which is indicated by darkening in the brain vasculature (hypointense) that 
emphasises the existence of the contrast agents in the circulation. Two hours after 
injection, a hypointense brain was observed for the mouse injected with Endorem® 
Fig. 5.8(c), however, a cleared brain was observed for the mouse injected with 
bioferrofluids that emphasises the clearance of bioferrofluids from the circulation Fig. 
5.8(g).  Figs. 5.8(d) and 5.8(h) show rCBV maps calculated according to the 
previously mentioned equation (section 5.3.3.1) for Endorem® and bioferrofluid 
respectively. 
Figure 5.8: T2*-weighted images for a mouse brain before (a, e), 5 min (b, f), and 2 h (c, g) after injection 
of Endorem® (upper panel) and bioferrofluids (lower panel). rCBV maps for Endorem® and 
bioferrofluids are shown in (d) and (h) respectively. 
For a quantitative data analysis, signal intensity values in T2*-weighted images 
were obtained by identifying the ROIs in the brain. These values were normalised to 
the signal intensity of the standard, and then the signal intensity ratio was calculated 
according to the following equation: 
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ܴ ൌ ܵܫ	ሺ݌݋ݏݐሻ ܵܫ	ሺܲݎ݁ሻ⁄  
Where, SI(post) is the signal intensity after injection, SI(pre) is the signal intensity 
before injection. 
These data were plotted in a curve as a function of the acquisition time Fig. 5.9. It 
was evident that both contrast agents attenuate the signal intensity inside the brain in 
few minutes after injection, since signal intensity ratio values were 0.51± 0.11 and 
0.67 ± 0.16 (mean ± SD) for Endorem® and bioferrofluids respectively. With time 
increasing, a very little increase in the signal intensity ratio was observed for 
Endorem®, however, a dramatic increase in the signal intensity ratio was observed for 
bioferrofluids, which is after 2 h returns to the pre-injection value Fig. 5.9, indicating a 
complete clearance from the circulation. From Fig. 5.9 curve, it is apparently clear that 
bioferrofluids have a half life time in blood shorter than Endorem®. Statistical 
significant difference between Endorem® and bioferrofluids in signal intensity ratio 
results was detected using Mann-Whitney test. Data are summarised in Table 5.2. 
Figure 5.9: Signal intensity ratio values of bioferrofluids and Endorem® in brain during 2 h after 
injection. Data are presented as (mean ± SEM). (*) marks significant differences between Endorem ® and 
bioferrofluids, according to Mann-Whitney test (P = 0.0079), (n = 5).  
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Table 5.2: Signal intensity ratio (R) values of bioferrofluids and Endorem® in brain 
during 2 h after contrast agent injection, n = 5. 
Time 
(min.) 
R 
( mean ± SD) 
P 
(Mann -Whitney) 
Bioferrofluids Endorem® 
0 1.00 ± 0.18 1.00 ± 0.14 1.0000 
4 0.67 ± 0.16 0.51 ± 0.11 0.2222 
7 0.75 ± 0.17 0.53 ± 0.10 0.0556 
12 0.79 ± 0.18 0.57 ± 0.11 0.0749 
17 0.83 ± 0.18 0.59 ± 0.10 0.0556 
22 0.86 ± 0.19 0.59 ± 0.10 0.0079 
27 0.87 ± 0.18 0.59 ± 0.10 0.0079 
32 0.90 ± 0.19 0.59 ± 0.11 0.0079 
37 0.90 ± 0.19 0.59 ± 0.10 0.0079 
42 0.92 ± 0.19 0.58 ± 0.11 0.0079 
47 0.93 ± 0.19 0.59 ± 0.11 0.0079 
52 0.94 ± 0.19 0.58 ± 0.11 0.0079 
57 0.94 ± 0.19 0.59 ± 0.11 0.0079 
62 0.94 ± 0.19 0.61 ± 0.11 0.0079 
67 0.93 ± 0.19 0.61 ± 0.11 0.0079 
72 0.94 ± 0.19 0.62 ± 0.11 0.0079 
77 0.94 ± 0.18 0.62 ± 0.11 0.0079 
82 0.95 ± 0.19 0.62 ± 0.10 0.0079 
87 0.97 ± 0.19 0.63 ± 0.10 0.0079 
92 0.97 ± 0.19 0.64 ± 0.10 0.0079 
97 0.98 ± 0.19 0.63 ± 0.10 0.0079 
102 0.99 ± 0.19 0.63 ± 0.10 0.0079 
107 1.01 ± 0.19 0.64 ± 0.10 0.0079 
112 1.02 ± 0.19 0.64 ± 0.10 0.0079 
117 1.01 ± 0.19 0.64 ± 0.10 0.0079 
122 1.03 ± 0.19 0.64 ± 0.10 0.0079 
 
5.4.4 Biodistribution studies  
Superparamagnetic iron oxide nanoparticles are known for their ability to shorten 
the transverse relaxation times (T2 and T2*). Therefore, accumulation of SPIONs in 
any organ will produce a decrease in MR signal intensity. In other words, the organs 
will appear darker (hypointense).   
To evaluate the biodistribution of bioferrofluids and Endorem® in mouse body, T2 
and T2*-weighted images were performed. Mice were injected with bioferrofluids and 
Endorem® at the clinical dose (20 µmole Fe/Kg), T2 and T2*-weighted images were 
acquired before (pre), 5 min-2 h, 24 h, 7 days, 15 days, 30 days and 60 days after 
(Post) injection.  
Signal intensity values in T2*-weighted images, as well as quantitative T2 values 
were obtained by identifying ROIs in liver and kidney. T2 values were obtained by
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using the ISA tool of Paravision 5.1 software, according to the following equation: 
SI(TE) is the signal intensity at certain echo time, SI(0) is the signal at zero time, TE is 
the echo time, T2 is the transverse relaxation time, C is a constant.  
 
Signal intensity values in T2*-weighted images were normalised to the signal 
intensity of brain, and then the signal intensity ratio was calculated according to the 
following equation:  
ܴ ൌ ܵܫ	ሺ݌݋ݏݐሻ ܵܫ	ሺܲݎ݁ሻ⁄  
Where, SI(post) is the signal intensity after injection, SI(pre) is the signal intensity 
before injection. 
Before injection, T2 values in the liver were 39.27 ± 2.98 (mean ± SD) and 40.30 
± 1.46 ms in the bioferrofluid and Endorem® groups, respectively. Few minutes after 
contrast agent injection, a decrease in T2 values was detected; 33.11 ± 2.93 and 29.11 
± 1.47 ms for bioferrofluids and Endorem® injected mice groups respectively Fig. 
5.10(a). These results are compatible with signal intensity ratio results Fig. 5.10(b), as 
a decrease in the signal intensity ratio values was also observed. Statistical significant 
difference was detected using Mann-Whitney test between Endorem® and 
bioferrofluids in T2 and signal intensity ratio results. Data are summarised in Tables 
5.3 and 5.4. The darkening in the liver tissue due to contrast agent accumulation after 
2 h of injection is shown in Fig. 5.11. 
Estimation for the iron concentration in liver could be obtained from the 
following equation:  
 
Where, 1/T2(t) (in s-1) is the transverse relaxation rate of a system after contrast agent 
administration, 1/T2(0) (in s-1) is the transverse relaxation rate of a system before 
 
 
 
 
198   Chapter 5  Biodistribution studies 
 
contrast agent administration, r2 (in s-1mM-1) is the relaxivity of the contrast agent in 
the desired system, C is the concentration (in mM).   
By using the experimentally determined T2 values for the liver in both 
bioferrofluids and Endorem® after 2 h of injection and the r2 relaxivity (measured in 
physiological saline) we could estimate an iron concentration of about of 0.05 µM in 
both cases. This concentration confirms the similarity between the bioferrofluids and 
Endorem® in decreasing the T2 and T2*. 
Figure 5.10: Transverse relaxation time values (a) and signal intensity ratio values (b) of bioferrofluids 
and Endorem® in liver during 2 h after contrast agent injection. Data are presented as (mean ± SEM), (*) 
marks significant differences between Endorem ® and bioferrofluids, according to Mann-Whitney test, n 
= 10 
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Table 5.3: Transverse relaxation time values of bioferrofluids and Endorem® in 
liver during 2 h after contrast agent injection, n = 10.  
Time 
(min.) 
T2 (ms) 
( mean ± SD) 
P 
(Mann -Whitney) 
Bioferrofluids Endorem® 
0 39.27 ± 2.98 40.30 ± 1.46 0.7169 
2 33.11 ± 2.93 29.11 ± 1.47 0.0014 
11 33.03 ± 3.48 30.07 ± 3.61 0.0602 
22 32.54 ± 1.70 31.83 ± 3.05 0.6209 
34 32.34 ± 3.61 30.87 ± 2.93 0.3734 
45 31.83 ± 2.18 30.67 ± 3.01 0.3734 
56 32.23 ± 3.45 31.81 ± 2.77 0.5752 
68 33.01 ± 2.36 31.50 ± 2.49 0.1563 
79 33.31 ± 2.63 31.71 ± 1.65 0.0927 
90 33.44 ± 2.93 32.46 ± 1.71 0.4887 
101 33.61 ± 3.24 32.77 ± 2.28 0.5310 
113 33.71 ± 2.78 32.80 ± 2.10 0.4483 
Table 5.4: Signal intensity ratio values of bioferrofluids and Endorem® in liver 
during 2 h after contrast agent injection, n = 10. 
Time 
(min.) 
R 
( mean ± SD) 
P 
(Mann -Whitney) 
Bioferrofluids Endorem® 
0 1.00 ± 0.04 1.00 ± 0.09 1.0000 
6 0.57 ± 0.15 0.68 ± 0.19 0.1655 
18 0.57 ± 0.07 0.54 ± 0.09 0.2263 
29 0.55 ± 0.11 0.45 ± 0.07 0.0342 
40 0.58 ± 0.07 0.42 ± 0.10 0.0022 
52 0.60 ± 0.10 0.44 ± 0.09 0.0015 
63 0.47 ± 0.08 0.40 ± 0.11 0.0961 
74 0.51 ± 0.10 0.41 ± 0.10 0.0115 
85 0.52 ± 0.13 0.41 ± 0.17 0.1655 
97 0.52 ± 0.18 0.41 ± 0.10 0.1617 
108 0.56 ± 0.18 0.42 ± 0.08 0.0058 
120 0.52 ± 0.16 0.44 ± 0.12 0.3527 
 
T2 and signal intensity ratio values were also calculated for the Kidney. T2 values 
before injection were 85.76 ± 11.85 and 94.94 ± 22.63 ms (mean ± SD), while few 
minutes after injection T2 values became 83.66 ± 8.51 and 79.49 ± 15.16 ms for 
bioferrofluids and Endorem® respectively Fig. 5.12(a), results of signal intensity ratio 
are shown in Fig. 5.12(b). Statistical significant difference was detected using Mann-
Whitney test between Endorem® and bioferrofluids in T2 and signal intensity ratio 
results. Data are summarised in Tables 5.5 and 5.6. 
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Figure 5.11: Coronal sections of T2- weighted images of mice bodies before (pre) and 2 h after (post) 
injections of bioferrofluids and Endorem® at a dose of 20 µmole Fe/Kg body weight. (a) is before 
injection of bioferrofluids, (b) is 2 h after bioferrofluids injection, (c) is before injection of Endorem®, (d) 
is 2 h after Endorem® injection.  
Figure 5.12: Transverse relaxation time values (a) and signal intensity ratio values (b) of bioferrofluids 
and Endorem® in kidney during 2 h after contrast agent injection. Data are presented as (mean ± SEM), 
(*) marks significant differences between Endorem ® and bioferrofluids, according to Mann-Whitney 
test, n = 10. 
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Table 5.5: Transverse relaxation time values of bioferrofluids and Endorem® in 
kidney during 2 h after contrast agent injection n = 10.  
Time 
(min.) 
T2 (ms) 
( mean ± SD) 
P 
(Mann -Whitney) 
Bioferrofluids Endorem® 
0 85.76 ± 11.85 94.94 ± 22.63 0.6936 
2 83.66 ± 8.51 79.49 ± 15.16 0.7427 
11 92.85 ± 7.71 86.65 ± 9.88 0.1310 
22 88.48 ± 8.06 87.25 ± 9.19 0.5994 
34 85.49 ± 7.88 89.64 ± 9.91 0.4307 
45 85.08 ± 5.27 88.55 ± 9.91 0.3933 
56 84.66 ± 3.52 88.32 ± 8.28 0.1679 
68 82.50 ± 5.17 87.36 ± 7.22 0.0569 
79 81.15 ± 6.24 88.64 ± 7.38 0.0256 
90 79.72± 6.71 87.52 ± 8.87 0.0256 
101 80.47 ± 6.41 86.74 ± 9.71 0.1007 
113 79.02 ± 5.05 84.37 ± 8.25 0.0878 
 
Table 5.6: Signal intensity ratio values of bioferrofluids and Endorem® in kidney 
during 2 h after contrast agent injection n = 10. 
Time 
(min.) 
R 
( mean ± SD) 
P 
(Mann -Whitney) 
Bioferrofluids Endorem® 
0 1.00 ± 0.04 1.00 ± 0.11 1.0000 
6 0.98± 0.06 1.03 ± 0.10 0.3405 
18 0.99 ± 0.06 0.99 ± 0.11 0.8325 
29 0.98 ± 0.13 0.99 ± 0.10 0.8053 
40 0.97 ± 0.06 1.02 ± 0.11 0.5034 
52 0.94 ± 0.07 0.96 ± 0.14 0.9719 
63 0.97 ± 0.06 0.95 ± 0.12 0.5726 
74 0.98 ± 0.05 1.01 ± 0.14 0.9718 
85 0.96 ± 0.08 1.01 ± 0.14 0.3786 
97 0.95 ± 0.08 0.99 ± 0.11 0.5973 
108 0.96 ± 0.06 0.93 ± 0.16 1.0000 
120 0.95 ± 0.07 0.98 ± 0.15 0.8326 
 
T2 and T2*-weighted images were also acquired at several time points after 
injection (24 h, 7 days, 15 days, 30 days and 60 days) for liver and kidney. As it can 
be noticed, by increasing the time a decrease in darkness of the liver was observed for 
both contrast agents Fig. 5.13. T2 and signal intensity ratio values in liver and kidney 
were calculated and plotted as a function of the acquisition time Figs. 5.14 and 5.15. 
Statistical significant difference was detected using Mann-Whitney test between 
Endorem® and bioferrofluids, control (pre) and bioferrofluids and control (pre) and 
Endorem® in T2 and signal intensity ratio results. Data are summarised in Tables 5.7 -
5.10.
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Figure 5.13: Coronal sections of T2- weighted images of mice bodies before (pre) (a, g), 24 h (b, h), 7 
days (c, i), 15days (d, j), 30 days (e, k) and 60 days (f, l) after (post) injections with bioferrofluids (upper 
panel) and Endorem® (lower panel), at a dose of 20 µmole Fe/Kg body weight. 
Fig. 5.14 shows the time dependence in liver T2 (Fig. 5.14(a)) and signal intensity 
ratio (Fig. 5.14(b)). After the sharp decrease in both T2 and signal intensity ratio 
values observed at 2 h after injection, increasing time was associated with an increase 
in T2 and R values as expected as contrast agent clearance from liver. In T2 results, 
statistical significance difference between bioferrofluids and Endorem® was observed 
at 7, 15 and 30 days after injection Fig. 5.14(a), which is not observed in signal 
intensity ratio results that showed no significance difference between both contrast 
agents Fig. 5.14(b). 
Comparing the pre-contrast values to post-contrast values in both contrast agents, 
showed a significance difference in T2 values between bioferrofluids and control (pre) 
till 30 days after injection Table 5.7, while in signal intensity ratio showed 
significance difference till 15 days after injection Table 5.8. However, in the case of 
Endorem®, both T2 and signal intensity ratio values showed statistical significance 
difference to the control (pre) till 15 days after injection Table 5.7 and 5.8.  
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Table 5.7: Transverse relaxation time values of bioferrofluids and Endorem® in 
liver during 60 days after contrast agent injection, (till 15 days n = 10, at 30 days n = 
8 and at 60 days n = 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Transverse relaxation time values (a) and signal intensity ratio values (b) of bioferrofluids 
and Endorem® in liver during 60 days after contrast agent injection. Data are presented as (mean ± 
SEM), (*) marks significant differences between Endorem ® and bioferrofluids, according to Mann-
Whitney test, (till 15 days n = 10, at 30 days n = 8 and at 60 days n = 4). 
Time 
(days) 
T2 (ms) 
( mean ± SD) 
P 
(Mann -
Whitney) 
Bioferrofluids 
vs. Endorem 
P 
(Mann -
Whitney) 
Bioferrofluids 
vs. control 
P 
(Mann -
Whitney) 
Endorem 
vs. control 
Bioferrofluids Endorem® 
0 39.27 ± 2.98 40.30 ± 1.46 0.7169 - - 
0.083 33.71 ± 2.78 32.80 ± 2.10 0.4483 0.0005 < 0.0001 
1 32.08 ± 2.83 32.81 ± 1.88 0.4483 0.0001 < 0.0001 
7 29.60 ± 2.88 34.26 ± 1.44 0.0003 < 0.0001 < 0.0001 
15 31.32 ± 2.93 35.36 ± 2.44 0.0051 0.0001 0.0002 
30 35.41 ± 1.56 38.38 ± 3.46 0.0155 0.0062 0.3599 
60 36.47 ± 0.89 37.67 ± 2.11 0.7302 0.1264 0.0759 
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Table 5.8: Signal intensity ratio values of bioferrofluids and Endorem® in liver 
during 60 days after contrast agent injection, (till 15 days n = 10, at 30 days n = 8 and 
at 60 days n = 4).  
 
 
 
 
 
In Fig. 5.15, both T2 and signal intensity ratio values of the kidney are reported. 
No significance difference was observed between bioferrofluids and Endorem® in T2 
results during 60 days after contrast agent injection Fig. 5.15(a). However, a 
significance difference between bioferrofluids and Endorem® in signal intensity ratio 
was detected at 15 days after contrast agent injection Fig. 5.15(b).In case of 
Endorem® injection, T2 values were decreased until 15 days and then increased from 
30 days and above after injection Fig. 5.15(a). However, T2 values of the kidney in 
case of bioferrofluids injection decreased monotonically with time until 60 days after 
injection Fig. 5.15(a). Statistical significance difference between pre-contrast and after 
Endorem® injection in T2 values was observed at 15 days after injection, while in case 
of bioferrofluids, statistical significance was observed at 2 h, 15 and 60 days after 
injection Table 5.9. 
Table 5.9: Transverse relaxation time values of bioferrofluids and Endorem® in 
kidney during 60 days after contrast agent injection, (till 15 days n = 10, at 30 days n 
= 8 and at 60 days n = 4).  
Time 
(days) 
T2 (ms) 
( mean ± SD) 
P 
(Mann -
Whitney) 
Bioferroflu
ids vs. 
Endorem 
P 
(Mann -
Whitney) 
Bioferrofluids 
vs. control 
P 
(Mann -
Whitney) 
Endorem 
vs. 
control 
Bioferrofluids Endorem® 
0 85.76 ± 11.85 94.94 ± 22.63 0.6936 - - 
0.083 79.02 ± 5.05 84.37 ± 8.25 0.0878 0.0356 0.2372 
1 86.36 ± 8.54 85.16 ± 12.65 0.6936 0.7427 0.3579 
7 81.64 ± 12.45 87.71 ± 13.82 0.3579 0.3246 0.5545 
15 77.19 ± 8.43 61.05 ± 22.01 0.0726 0.0256 0.0054 
30 77.45 ± 7.38 72.47 ± 22.32 0.6070 0.0806 0.0630 
60 64.65 ± 5.59 72.53 ± 15.64 0.7302 0.0127 0.1027 
Time 
(days) 
R 
( mean ± SD) 
P 
(Mann -
Whitney) 
Bioferrofluids 
vs. Endorem 
P 
(Mann -
Whitney) 
Bioferrofluids 
vs. control 
P 
(Mann -
Whitney) 
Endorem 
vs. control 
Bioferrofluids Endorem® 
0 1.00 ± 0.04 1.00 ± 0.09 1.0000 - - 
0.083 0.52 ± 0.16 0.44 ± 0.12 0.3527 0.0002 < 0.0001 
1 0.53 ± 0.06 0.42 ± 0.12 0.0630 0.0002 < 0.0001 
7 0.59 ± 0.14 0.61 ± 0.17 0.7925 0.0002 0.0002 
15 0.75 ± 0.10 0.75 ± 0.11 0.8939 0.0002 < 0.0001 
30 0.89 ± 0.31 0.92 ± 0.17 0.4772 0.083 0.2198 
60 1.00 ± 0.16 1.16 ± 0.14 0.2454 1.000 0.0475 
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Signal intensity ratio values of Kidney after Endorem® Injection was concurrent 
with T2 values, as R values decreased until 15 days and then increased from 30 days 
and above after injection Fig. 5.15(b), a statistical significance between “pre” and 
“post” contrast values was detected at 1 and 15 days after injection Table 5.10.  In 
case of Bioferrofluids, the R values decreased until 7 days then increased at 15 days 
and decreased again at 60 days Fig. 5.15(b), a statistical significance between “pre” 
and “post” contrast values was detected at 1 and 60 days after injection Table 5.10. 
Difference between T2 and R values in Kidney in case of bioferrofluids is due to the 
experimental error; however, after 60 days of injection both R and T2 values were 
lower than the pre-contrast values.  
Figure 5.15: Transverse relaxation time values (a) and signal intensity ratio values (b) of bioferrofluids 
and Endorem® in kidney during 60 days after contrast agent injection. Data are presented as (mean ± 
SEM), (*) marks significant differences between Endorem ® and bioferrofluids, according to Mann-
Whitney test, (till 15 days n = 10, at 30 days n = 8 and at 60 days n = 4). 
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Table 5.10: Signal intensity ratio values of bioferrofluids and Endorem® in kidney 
during 60 days after contrast agent injection, (till 15 days n = 10, at 30 days n = 8 and 
at 60 days n = 4).  
Time 
(days) 
R 
( mean ± SD) 
P 
(Mann -
Whitney) 
Bioferrofluids 
vs. Endorem 
P 
(Mann -
Whitney) 
Bioferrofluids 
vs. control 
P 
(Mann -
Whitney) 
Endorem 
vs. 
control 
Bioferrofluids Endorem® 
0 1.00 ± 0.04 1.00 ± 0.11 1.0000 - - 
0.083 0.95± 0.07 0.98 ± 0.15 0.8326 0.1138 0.7333 
1 0.94 ± 0.15 0.85 ± 0.11 0.3150 0.0375 0.0091 
7 0.90 ± 0.19 0.87 ± 0.18 1.0000 0.0837 0.1748 
15 1.03 ± 0.18 0.73 ± 0.18 0.0067 0.8600 0.0039 
30 1.01 ± 0.15 1.00 ± 0.19 0.4381 0.2898 0.5049 
60 0.78 ± 0.08 1.02 ± 0.14 0.0571 0.0048 0.8318 
 
5.4.5 Qualitative iron detection using Prussian blue assay 
In order to confirm that the shortening in the transverse relaxation times and 
signal intensity ratio results from contrast agent accumulation in organs, Prussian blue 
assays were carried out to detect free ferric ions in liver and Kidney. Results showed 
that there is an accumulation of both bioferrofluids and Endorem® in liver after 2 h of 
injection, which is indicated by presence of blue dots Fig. 5.16. 
Figure 5.16: Prussian blue assay in liver of non-injected mouse (a) and 2 h after bioferrofluids (b) and 
Endorem®(c) injection. Ferric ion existence is indicated as blue coloured dots.  Upper panel images are at 
low magnifications, while lower panel (a`, b`, c`) is the same images but at high magnification.  
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Ferric ion detection was also evaluated in liver of mice after 1, 7, 15, 30 and 60 
days of contrast agent injection Fig. 5.17. In case of Endorem®, high amount of iron 
was detected till 7 days after injection Figs. 5.17(a) and 5.17(c), and then the amount 
decreased at 15 days Fig. 5.17(e). Endorem® was not detected from 30 days and 
above Figs. 5.17(g) and 5.17(i). While, in the case of bioferrofluids, however the 
amount of iron seems to be less to that of Endorem® but iron exists for longer period, 
iron was detected till 30 days after bioferrofluids injection Figs. 5.17(b), 5.17(d), 
5.17(f), 5.17(h). Bioferrofluids were not detected at 60 days after injection Fig. 
5.17(j). Table 5.11 shows results regarding ferric ion concentration in liver tissue after 
contrast agent injection. Prussian blue results confirmed the obtained results by MRI. 
Table 5.11: a perspective idea about ferric ion concentration in liver of mice after 
contrast agent injection using Prussian blue assay 
 
 
 
 
In the case of kidney, after 2 h of injection of both Endorem® and bioferrofluids, 
only a very few separated dots were detected Fig. 5.18. Ferric ion detection was also 
evaluated in kidney of mice after 1, 7, 15, 30 and 60 days of contrast agent injection 
Fig. 5.19. Accumulation of ferric ions was just detected in the period between 7-15 
days after Endorem® injection Fig. 5.19(c), 5.19(e). However, in case of 
bioferrofluids, ferric ions accumulate until 60 days after injection Figs. 5.19(b), 
5.19(d), 5.19(f), 5.19(h) and 5.19(j). These results are in agreement with obtained 
results by MRI. 
 
 
 
Time Endorem® Bioferrofluids 
0 - - 
2 h +++ + 
1 day +++ ++ 
7 days +++ + 
15 days + + 
30 days - + 
60 days - - 
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Figure 5.17: Prussian blue assay in mouse liver after 1 day (a, b), 7 days (c, d), 15 days (e, f), 30 days (g, 
h) and 60 days (i, j) of Endorem® (left panel) and bioferrofluids (right panel) injection. Black arrows are 
pointing ferric ions which appear as blue coloured dots  
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Figure 5.18: Prussian blue assay in Kidney of non-injected mouse (a) and 2 h after bioferrofluids (b) and 
Endorem® (c) injection, black arrows are pointing ferric ion, which is visualised in a blue colour.  
 
5.4.6 Quantitative iron detection using atomic absorption 
The amount of iron was detected in mouse liver and kidney before, 2 h and 24 h 
after bioferrofluids and Endorem® injection at a dose of 23.5 mg Fe/Kg body weight.  
Fig. 5.20 and Fig. 5.21 show the accumulation of iron in mouse liver and kidney, 
respectively.  It is evident the accumulation of iron in mice liver after bioferrofluids 
and Endorem® injection, after 2 h of CAs injection, the amount of iron in case of  
bioferrofluids injection is higher than Endorem® Fig. 5.20(a), while after 24 h of 
injection, similar iron concentration was detected for both CAs. Fig. 5.20(b). In case 
of kidney, no accumulation of iron was detected after 2 h Fig. 5.21(a) and 24 h 
Fig.5.21(b) of CAs injection. 
5.4.7 In vivo toxicity studies  
To study the toxicity of bioferrofluids and Endorem® on mice organs, tissues 
were collected at different time points (0, 2 h, 1 day, 7 days, 15 days, 30 days and 60 
days) after contrast agent injection at a dose of 20 µmole Fe/Kg body weight. Results 
showed that both Endorem® and bioferrofluids did not generate any notable 
histological lesions in organs (liver, kidney, spleen, lungs and heart) after the indicated 
periods of times. Fig. 5.22 shows the histopathological studies in mouse liver after 
contrast injection.   
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Figure 5.19: Prussian blue assay in mouse kidney after 1 day (a, b), 7 days (c, d), 15 days (e, f), 30 days 
(g, h) and 60 days (i, j) of Endorem® (left panel) and bioferrofluids (right panel) injection. Black arrows 
are pointing ferric ions which appear as blue coloured dots. 
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 Figure 5.20: Iron detection by atomic absorption in mouse liver before, 2 h (a) and 24 h (b) after 
bioferrofluids and Endorem® injection at a dose 23.5 mg Fe/kg body weight.  
Figure 5.21: Iron detection by atomic adsorption in mouse kideny before, 2 h (a) and 24 h (b) after 
bioferrofluids and Endorem® injection at a dose 23.5 mg Fe/kg body weight.  
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Figure 5.22: Hematoxin and Eosin stain in liver of non-injected mouse (a) and after 2 h (b, c), 1 days (d, 
e), 7 days (f, g) of Endorem® (left panel) and bioferrofluids (right panel) injection.  
5.5  Discussion and conclusions  
Two polymer coated SPIONS, P4VP-g-APEG coated SPIONs (bioferrofluids) 
and dextran coated SPIONs (Endorem®) were subjected to the in vitro relaxation 
measurements. Obtained results showed that both bioferrofluids and commercial 
Endorem® exhibit similar behaviour in shortening T2 relaxation time, as increasing in 
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the nanoparticles concentration is associated with a decrease in the signal intensity, as 
shown in Fig 5.5. The efficiency of T2 contrast agents is depending on the transverse 
relaxivity (r2) more than the longitudinal relaxivity (r1). A better T2 CA is considered 
to be the one that increases r2 and decreases r1 (higher r2/r1 ratio) [18,42]. Longitudinal 
and transverse relaxivities (r1 and r2 respectively) are depending on the nanoparticle 
size in a direct proportion relationship. Therefore, it was expected that r1 and r2 values 
for bioferrofluids (Dp = 13 nm) are larger than for Endorem® (Dp = 6-9 nm). But, that 
has not been the case, as bioferrofluids showed lower values of r2 and r1 compared to 
Endorem®. In a study carried out by Amiri et al., they measured the relaxivities (r1 
and r2) of these bioferrofluids and Endorem®, exploring the effect of nanoparticle size 
[43]. Results showed that bioferrofluids of Dp = 15 nm has a higher r2 value as 
compared to commercial Endorem®. Differences between Amiri’s and our study stay 
in the operating frequencies. Our experiment was carried out at a frequency of 200 
MHz (corresponding to 4.7T clinical imager), however, Amiri et al. study was carried 
out at lower frequencies (8.5, 21 and 63 MHz corresponding to about 0.2, 0.5, and 1.5 
T clinical imagers, respectively). In their study, it is evident that r1 is size-dependent at 
low frequencies (0.01-0.1 MHz); larger nanoparticle sizes have higher r1 values. At 
higher frequencies (1-100 MHz), a decrease in r1 values was detected for all samples, 
however, Endorem® showed higher r1 in compared to other. This may explain the 
lower value of r1 obtained by our bioferrofluids in compared to Endorem® at high 
frequency (200 MHz). Similar behaviour could be the reason for the lower values of r2 
obtained by our bioferrofluids compared to Endorem® at high frequency (200 MHz), 
although this hypothesis needs further verification. Calculating the r2/r1 ratio for both 
bioferrofluids and Endorem®, showed that our bioferrofluids have a higher r2/r1 ratio 
than Endorem®. These results indicate that these bioferrofluids are useful as T2 
contrast agent and more efficient than commercial Endorem®. 
In order to assess the usefulness of bioferrofluids and Endorem® in cerebral 
perfusion experiments, first passage experiment were performed, as shown in Fig. 5.7. 
Results showed that both bioferrofluids and Endorem® decrease the signal intensity 
values, however, Endorem® decreases the SI values more than the bioferrofluids. 
These results are in agreement with the in vitro results, as the contrast enhancement 
effects is directly related to the relaxivity value of the nanoparticle.  
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To evaluate the efficiency of the bioferrofluid and of Endorem® as a contrast 
MRI agent in steady-state condition, T2*-weighted images in brain were acquired as 
pre-contrast and during 2 h post-contrast injection. Results showed a decrease in the SI 
ratio in few minutes after CAs injection Fig. 5.9. Therefore, the brain vasculatures 
appear darker, emphasising the existence of the CAs in the circulation Figs. 5.8(b), 
5.8(f). Two hours after injection, in the case of Endorem®, the SI ratio was still low 
Fig.5.9 (indicated as hypointense brain Fig.5.8(c)), however, an increase in the SI ratio 
was detected for bioferrofluids, which returns to the pre-injection value, indicating a 
complete clearance from the circulation, as shown in Fig 5.9 (clear brain Fig. 5.8(g)). 
It is clear that bioferrofluids have a half-life time in blood shorter than Endorem®. 
The clearance of the nanoparticles from the circulation could be by RES 
“opsonisation”, but in any case such clearance affects the half life time of the CA in 
blood. Opsonisation is depending on several factors such as nanoparticle size, charge, 
surface coating and dose. The opsonisation effect can be reduced by coating the 
nanoparticles with a hydrophilic polymer that reduces the non-specific binding of 
opsonin proteins. Therefore, Endorem® is composed of magnetite core coated with 
dextran, and our bioferrofluids are composed of maghemite cores coated with P4VP-
g-APEG. Several studies show that the long blood circulation time is achieved by 
increasing the chain length of PEG [44]. The surface of the nanoparticles in the P4VP-
g-APEG bioferrofluids is formed by 1/10 in weight of APEG long chains (MW=1000) 
and 9/10 of APEG short chains (MW=200). Therefore, these short chains of PEG 
might not protect the nanoparticles from the non-specific protein adsorption and 
subsequent the opsonisation, leading to short blood circulation time. A study to 
identify protein corona formation is recommended. In addition to the surface coating, 
the nanoparticle size plays a crucial role in nanoparticle opsonisation; larger size 
nanoparticles are cleared faster than smaller size ones. The hydrodynamic diameter of 
bioferrofluids is 163 nm, while for Endorem® is 110 nm. Therefore, the large size of 
bioferrofluids increases their chance for opsonisation and clearance from the 
circulation.  
Regional cerebral blood volume maps for Endorem® and bioferrofluids at the 
steady-state were calculated as described in section 5.3.3.1. rCBV map after 
Endorem® injection depicted very well the space arrangement of cerebral blood 
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vessels, as shown in Fig.5.8(d). In the case of bioferrofluids, however, lower effect 
was observed, as shown in Fig 5.8(h). 
T2 CAs are negative contrast agents, therefore, they appear dark in tissues where 
they are accumulated. Biodistribution studies showed the accumulation of both 
bioferrofluids and Endorem® in liver, indicated as darkening in the liver tissue Fig. 
5.11 after 2 h of CAs injection at the clinical dose (20 µmole Fe/Kg body weight). 
Both T2 and SI ratio values decreased few minutes post-contrast injection as shown in 
Figs. 5.10(a) and 5.10(b). After 2 h, T2 values and SI ratio values showed no 
significant difference between bioferrofluids and Endorem®. T2 values were 33.71 ± 
2.78 and 32.80 ± 2.10 ms and SI ratio values were 0.52 ± 0.16 and 0.44 ± 0.12 for 
bioferrofluids and Endorem®, respectively. Estimation for the iron concentration in 
liver yields a similar concentration of 0.05 µM for both CAs. The similarity between 
both CAs in the accumulated iron concentration in liver tissues confirms their 
similarity in decreasing the T2 and T2* values after 2 h of CAs injection. Qualitative 
detection of iron using Prussian blue assay showed more amount of iron in the liver of 
mice injected with Endorem® than with bioferrofluids, as shown in Fig.5.16. 
However, T2 and SI ratio results and estimated iron concentration showed that both 
contrast agents have similar effect. This may be due to the presence of Endorem® in 
Kupffer cells as agglomerates. However, our bioferrofluids are distributed in Kuppfer 
cells and hepatocytes.  This hypothesis is confirmed by the quantitative determination 
of iron using atomic absorption, as higher amount of bioferrofluids than Endorem® 
was detected in mice liver after 2 h of injection Fig. 5.20.  
CAs biodistribution was evaluated at several time points till 60 days post 
injection, it was clear that by increasing the time a decrease in darkness of the liver 
was observed Fig. 5.13, which indicates CAs degradation and clearance from liver 
tissue. Both T2 and SI ratio values showed time dependence. T2 values between 
bioferrofluids and control (pre) showed a significant difference till 30 days after 
injection, while, SI ratio values showed significance difference till 15 days after 
injection. In the case of Endorem®, both T2 and signal intensity ratio values showed 
statistical significance difference to the control (pre) till 15 days after injection. These 
results were confirmed by Prussian blue assay. Bioferrofluids were observed as blue 
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coloured dots till 30 days post injection (Fig.5.17(h)) and disappeared at 60 days after 
injection (Fig.5.17(j)), while Endorem® was observed till 15 days after injection 
(Fig.5.17(e)) and absent at 30 and 60 days after injection (Figs.5.17(g) and 
5.17(i)).These results indicate that our bioferrofluids persist for longer time in liver 
with no toxic effect as compared to Endorem®. 
Measurements of T2 and T2* values in kidney after CAs injection showed a 
decrease in the T2 values, few minutes after CAs injection, as shown in Fig.5.12(a), 
while the SI ratio values showed almost similar values to pre-contrast, as summarised 
in Table 5.6. Two hours after injection, the decrease in T2 values was observed for 
bioferrofluids and Endorem®, as summarised in Table 5.5, while the SI ratio results 
were almost similar to pre-contrast. Prussian blue assay showed only few blue 
coloured dots in kidney of mice injected with Endorem® and bioferrofluids, as shown 
in Fig.5.18., confirming the T2 values results. However, a quantitative measurement of 
iron did not indicate iron accumulation in kidney, as shown in Fig. 5.21. 
T2 and T2* were also evaluated in kidney untill 60 days post CAs injection. Both 
T2 and SI ratio values decreased untill 15 days and then increased from 30 days and 
above after Endorem® injection. A significant difference between pre- and post-
contrast was observed at 15 days for T2 values and at 1 and 15 days for SI ratio values. 
These results were confirmed by Prussian blue assays for iron detection, as the iron 
was detected in the period between 7-15 days after Endorem® injection, see Figs. 
5.19(c) and 5.19(e). While, in the case of the bioferrofluids, T2 values decreased 
monotonically untill 60 days after injection. However, SI ratio values showed a 
fluctuation, as they decreased untill 7 days then increased at 15 days and decreased 
again at 60 days. This effect maybe due to animal respiration. Prussian blue assay 
confirmed the obtained results by T2 measurements as iron was detected as blue 
coloured dots untill 60 days after injection, as shown in Fig. 5.19(j). Differences 
between T2 and SI ratio values in kidney in case of bioferrofluids are due to the 
experimental error. However, after 60 days of injection both SI ratio and T2 values 
were lower than the pre-contrast values. A significant difference between pre- and 
post-contrast was observed at 2 h, 15 days and 60 days for T2 values and at 1 and 60 
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days for SI ratio values. Results obtained for kidney needed further confirmation, as 
some contradict results are obtained. 
In vivo toxicity studies showed that both Endorem® and bioferrofluids did not 
generate any toxic effect in mice organs (liver, kidney, spleen, lungs and heart) Fig. 
5.22.  
Then, we can conclude that our bioferrofluid is a good T2 contrast agent with a 
higher r2/r1 ratio than commercial Endorem®. It has short blood circulation time 
compared to Endorem®, and they are efficient RES agents as they are accumulated in 
liver. Our bioferrofluid persists in liver for longer period of time (up to 30 days post-
injection) than Endorem® with no toxic effect observed in liver tissue or other body 
tissues. Accumulation of CAs in kidney was not clear and requires further studies to 
be confirmed. Studies pertaining to protein adsorption on the nanoparticle surface 
“protein corona” are recommended.  
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Annex I  
Bioferrofluids preparation and 
characterisation 
 
This annex describes the general preparation and characterisation of bioferrofluids 
used in this thesis.  
1. Preparations  
1.1 Preparation of bioferrofluids  
The bioferrofluids used in this Thesis were prepared by Angel Millán, Rafael 
Piñol and Lierni Gabilondo, from the Instituto de Ciencias de Materiales de Aragón 
(ICMA), CSIC – Universidad de Zaragoza, and Department of Física de la Materia 
Condensada.  
The synthesis of bioferrofluids was performed in two steps following described 
methods in ref [1]: i) synthesis of maghemite (ɣ-Fe2O3) nanoparticles in a poly(4-
vinylpyridine) (P4VP) matrix, and ii) coating with polyethylene glycol (PEG) 
hydrophilic polymer and suspension in a phosphate buffered saline (PBS) solution.  
Maghemite nanoparticles with a controlled size were prepared by in situ 
precipitation in a P4VP solid matrix, following the procedure described in ref [2]. 
Briefly, a solution of FeBr2, FeBr3 and 60 kD P4VP (all three from Sigma-Aldrich, St. 
Louis, MO, USA), was evaporated in a Petri dish to obtain a film of iron-polymer 
precursor. The film was immersed in a 1M NaOH solution for 1 hour, washed with 
water, and dried in open air to obtain a polymer composite containing maghemite 
nanoparticles uniformly distributed. The maghemite nanoparticles size in the samples 
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was varied under control by using different Fe(II)/Fe(III) and Fe/P4VP ratios (see ref 
[2]).The preparation ratios are given in each corresponding chapter when required.  
Commercially available poly(ethylene glycol) monoacrylates (from 
Monomer&Polymer, Trevose PA, USA) APEG(200) and APEG(1000), where 200 
and 1000 are the average molecular weight (Da) of the pendant poly(ethylene glycol) 
chain, were purified before use by improving an extraction/fractionation method 
previously described in ref. [3] and [4]. Carboxyl end-capped polyethylene glycol 
monoacrylate (APEG(1000)COOH) was prepared by reacting succinic anhydride with 
the hydroxyl end group of polyethylene glycol monoacrylate (APEG(1000)) following 
the procedure described elsewhere [5,6]. APEG(1000) (10 mmol), succinic anhydride 
(15 mmol), and 4-dimethylaminopyridine (0.5 mmol) were dissolved in 50 mL of dry 
CH2Cl2 under argon atmosphere. The reaction was carried out at room temperature for 
48 hours. The reaction mixture was filtered and concentrated under vacuum. Product 
was precipitated three times in cold diethyl ether from tetrahydrofuran and then dried 
in vacuum. The molecular structure and purity of all the polyethylene glycol 
derivatives used in this work was confirmed by proton NMR spectroscopy (1H-NMR) 
using CDCl3 as solvent in a BRUKER AV-400 spectrometer (400 MHz) and by mass 
spectroscopy (MALDI TOF-MS) using dithranol (DTH) as matrix and sodium 
trifluoroacetate (NaTFA) as cationization agent in a BrukerMicroFlex spectrometer. 
In a second step, the dispersions of maghemite-P4VP nanocomposites in PBS, 
hereon referred to as bioferrofluids, were prepared as described elsewhere [6,7]. In 
short, maghemite-P4VP nanocomposites were first dispersed in water at pH=3. Then, 
amounts of APEG(200) and APEG(1000)COOH were added under stirring. The 
dispersion was then heated to 70 ºC for 24 hours and, after cooling, amounts of 
Na2HPO4, NaOH, NaCl and KCl were added to achieve 0.01M phosphate 
concentration, pH 7.40 and ionic strength (I) 0.15. Finally, the dispersion was filter-
sterilized using a 0.22 µm nitrocellulose filter to obtain the bioferrofluid. 
1.2 Preparation of the fluorescent nanoparticles  
Fluorescent nanoparticles were prepared as described above with substituting a 
1/10 molar ratio of APEG(200) by methyl fluorescein poly(ethylene glycol) acrylate 
(APEG(200)MeFlu), which is described below.  
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1.2.1 Synthesis of Fluorescein methyl ester (MeFluOH) 
Fluorescein methyl ester (MeFluOH) was prepared by the method described in 
ref.[8]. 18.8 mL of concentrated sulfuric acid was carefully added to a suspension of 
25 g of fluorescein in 75 mL methanol kept cooled in a water-ice bath. The solution 
with dark-red color was heated to reflux (100oC) during 15 hours. The suspension was 
cooled down to room temperature and 25 mL very cold water was added in a 500 mL 
beaker. 75 g sodium bicarbonate was added carefully and with strong agitation to the 
previous mixture. The mixture was filtered through a porous plate and the obtained 
solid was washed with 150 mL distilled water. The solid was re-suspended in 600 mL 
of an aqueous solution of sodium bicarbonate (2 weight %); after stirring for 15 
minutes, it was filtered through a porous plate and washed with 150 mL distilled 
water. The process of washing with bicarbonate/water was repeated for a second time 
using the same volumes. Finally, the solid is re-suspended in 300 mL of an aqueous 
solution of acetic acid (1%); after stirring for 15 minutes, it was recovered by filtration 
through a porous plate and the obtained solid washed with 150 mL water. The 
obtained reddish solid was dried in the oven for 2 hours at 125oC. After drying, 14.87 
g of solid with orange colour (42.9 mmol) were obtained. 
1.2.2 Synthesis of methyl fluorescein poly(ethylene glycol) acrylate 
(APEG(200)MeFlu). 
To a suspension of 3.46 g of MeFluOH (10 mmol) in 50 mL anhydrous 
tetrahydrofuran, (THF), a 2.89 g of triphenylphosphine (TPP) (11 mmol) and 2.75 g of 
APEG(200)  (11 mmol) ,  were added under argon atmosphere. The reaction was 
cooled in an ice-water bath and then 2.3 mL of diisopropyl-azodicarboxylate (11 
mmol) were added dropwise under argon atmosphere. Once the addition finished and 
after stirring at 0oC for 15-20 minutes, the water-ice bath was removed and the 
mixture was stirred at room temperature for three days. Then 0.25 mL of distilled 
water were added to quench the reaction, and the mixture stirred for 25 minutes. 
Afterwards, the mixture was filtered  and the solvent was evaporated under vacuum. 
The crude residue was dissolved in 50 mL dichloromethane. The organic phase was 
washed successively with three fractions of 25 mL of potassium carbonate 1M, 25 mL 
of a saturated solution of sodium chloride, dried over anhydrous magnesium sulfate 
and concentrated under vacuum. The product was purified twice by precipitation in 
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excess of cold diethyl ether from a THF solution. Finally, the pure compound was 
obtained by flash column chromatography on silica gel increasing the solvent polarity 
from ethyl acetate to ethyl acetate/methanol (9.5:0.5). Yield 45%. 
1.3 Preparation of polymer blank solutions  
To obtain 100 mL of P4VP-grafted to poly (ethylene glycol) acrylate (P4VP-g-
APEG) solution, 1.336 g of P4VP, 1.203 mL of APEG(200) and 0.133 g of 
APEG(1000)COOH were dissolved in water at pH=3 and heated to 70oC during 21 
hours. Then, Na2HPO4 was added to the solution for a 0.01 M final concentration. The 
pH was adjusted to 7.40 by addition of a 0.2 M NaOH solution and the ionic strength 
was adjusted to 0.15 by addition of NaCl and KCl. Finally, the volume adjusted to 100 
mL and then filtered through a sterile 0.22 µm nitrocellulose filter. To obtain 100 mL 
of APEG solution, the same procedure was followed in the absence of P4VP.  In this 
way, the concentration of P4VP in the P4VP-g-APEG blank solution and the total 
concentrations of APEG (APEG(200)+APEG(1000)COOH) in the P4VP-g-APEG and 
APEG blank solutions were 13.36 g/L, the same as in the bioferrofluid sample. 
 2. Characterisation  
2.1 Atomic absorption spectroscopy 
The experiments were performed at the Laboratorio Central de Análisis of the 
Universidad de Zaragoza in order to determine the total iron content in the samples.  
The iron content in samples was determined by atomic absorption spectroscopy. 
With this purpose, the samples were placed in a Teflon tubes and left for 24 hours at 
80°C to dryness. 3 mL of highly purified HNO3 were added and then the samples 
digested using a microwave digestor (MVS-2 Berghof). Samples were cooled and then 
diluted to 15 mL with Milli-Q water. The total iron content in the samples was 
determined by atomic absorption in a plasma 40 ICP Perkin–Elmer spectrometer.  
2.2 Transmission electron microscopy (TEM) 
The experiments to determine the size of the iron oxide nanoparticles were 
performed in a Transmission Electron Microscopy (TEM) (Jeol 2000-FXII at the 
Servicio Microscopía Electrónica of the Universidad de Zaragoza.  
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Samples were prepared by grinding the nanocomposites in acetone and 
evaporating drops of the resulting suspension on carbon coated copper grids. Samples 
for cryo-TEM experiments were prepared by plunge-freezing of a grid previously 
immersed in the bioferrofluid and partially dried in a liquid ethane bath. Cryo-TEM 
observations were performed in a FEI Tecnai F30 microscope. 
2.3 Dynamic light scattering (DLS) 
 The experiments to determine the hydrodynamic size of the nanoparticles 
dispersed in PBS (bioferrofluids) were performed at the laboratory facilities of the 
Instituto de Ciencias de Materiales de Aragón (ICMA), CSIC – Universidad de 
Zaragoza.  
The bioferrofluids were characterized by Dynamic Light Scattering (DLS). With 
this purpose, samples were placed in a plastic cell and measured in a Zetasizer Nano 
ZS ZEN3600 from Malvern Instruments. Several sample dilutions were used in order 
to avoid any influence of the concentration in the results. 
3. References   
[1] H. Amiri, R. Bustamante, A. Millán, N. J. O. Silva, R. Piñol, L. Gabilondo, F. Palacio, 
P. Arosio, M. Corti, and A. Lascialfari, “Magnetic and relaxation properties of 
multifunctional polymer-based nanostructured bioferrofluids as MRI contrast agents.,” 
Magn Reson Med. , vol. 66, no. 6, pp. 1715–21, 2011. 
[2] A. Millan, F. Palacio, A. Falqui, E. Snoeck, V. Serin, A. Bhattacharjee, V. 
Ksenofontov, P. Gütlich, and I. Gilbert, “Maghemite polymer nanocomposites with 
modulated magnetic properties,” Acta Mater., vol. 55, no. 6, pp. 2201–2209, 2007. 
[3] J. Klier, A. B. Scranton, and N. A. Peppas, “Self-associating networks of 
poly(methacrylic acid-g-ethylene glycol),” Macromolecules, vol. 23, no. 23, pp. 4944–
4949, 1990. 
[4] M. M. Ali and H. D. H. Stöver, “Well-Defined Amphiphilic Thermosensitive 
Copolymers Based on Poly(ethylene glycol monomethacrylate) and Methyl 
Methacrylate Prepared by Atom Transfer Radical Polymerization,” Macromolecules, 
vol. 37, no. 14, pp. 5219–5227, 2004. 
[5] Z. Yang, W. Zhang, J. Zou, and W. Shi, “Synthesis and thermally responsive 
characteristics of dendritic poly(ether-amide) grafting with PNIPAAm and PEG,” 
Polymer (Guildf)., vol. 48, no. 4, pp. 931–938, 2007. 
 
 
 
 
226   Annex I 
 
[6] A. Millán, F. Palacio, G. Ibarz, and E. Natividad, Systems containing magnetic 
nanoparticles and polymers, like nanocomposites and ferrofluids, and their 
applications, Patent No. ES2308901B1, Spain (2007).  
[7] L. M. A. Ali, M. Gutiérrez, R. Cornudella, J. A. Moreno, R. Piñol, L. Gabilondo, A. 
Millán, and F. Palacio, “Hemostasis disorders caused by polymer coated iron oxide 
nanoparticles.,” J. Biomed. Nanotechnol., vol. 9, no. 7, pp. 1272–85, 2013. 
[8] M. Adamczyk, J. Grote, and J. A. Moore, “Chemoenzymatic synthesis of 3’-O-
(carboxyalkyl)fluorescein labels.,” Bioconjug. Chem., vol. 10, no. 3, pp. 544–7.  
 
 
 
 
 
 
Annex II 
List of acronyms 
 
ADP, Adenosine diphosphate  
AFM, Atomic force microscopy 
AM,  Alveolar macrophages 
AMF, Alternating magnetic field 
AO, Acridine orange 
AO/EB, Acridine orange plus Ethidium bromide 
AP-1, Activated protein 1 
APC, Activated protein C  
APEG, Polyethylene glycol monoacrylate (generic) 
APEG(200), Polyethylene glycol monoacrylate of MW= 200 Da  
APEG(1000), Polyethylene glycol monoacrylate of MW= 1000 Da  
APEG(1000)-COO- Carboxyl end-capped polyethylene glycol monoacrylate 
APEG(200)MeFlu  methyl fluorescein poly(ethylene glycol) acrylate 
aPTT, Activated partial thromboplastin time  
apoE, Apolipoprotein E 
AT, Antithrombin  
ATF, Amino-terminal fragment  
B0, External magnetic field  
BBB, Blood brain barrier 
BMA, Bismethylamide 
bp, Base pair  
CA, Contrast agent 
CAs,  Contrast agents  
CBC, Complete blood count  
CBF, Cerebral blood flow  
CBV, Cerebral blood volume  
C.I, Confidence interval  
CME, Clathrin-mediated endocytosis  
CPPs, Cell penetrating peptides  
CT, X-ray computed tomography  
Da, Dalton  
DAPI, 4’,6-diamidino-2-phenylindole 
DEVD, Aspartic (ASP)-Glutamic (Glu) –Valine (Val)-Aspartic (Asp)  
DH, Hydrodynamic size 
DIH, Direct injection hyperthermia 
DLS, Dynamic Light Scattering   
DMEM/F12, Dulbecco’s Modified Eagle’s Medium  
DMSA, Meso-2,3-dimercaptosuccinic acid  
 
 
 
 
228   Annex II 
 
DMSA-bioferrofluids, Magnetite nanoparticles coated with DMSA and 
dispersed in water  
DMSA-PEG-(NH2)2-bioferrofluids, Magnetite nanoparticles coated with 
DMSA and short chain diamine PEG and dispersed in water  
DNA, Deoxyribonucleic acid 
DNase I, Deoxyribonuclease I 
DNP, 2, 4-dinitrophenyl 
DNP-hydrazone, 2,4- dinitrophenylhydrazone  
DNPH, 2,4dinitrophenylhydrazine  
DO3A, 1,4,7,10-tetraazacyclododecane-1,4,7-triacetato 
DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
Doxil, Liposomes-encapsulated doxorubicin 
Dp, Maghemite nanoparticle diameter or core diameter 
DTH, Dithranol  
DTPA, Diethylenetriaminepentaacetic acid 
dUTP, 2´-Deoxyuridine, 5´-Triphosphate 
EAA1, Early endosome antigen 1  
EB, Ethidium Bromide 
ED, Electron diffraction 
EDC, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide  
EDTA, Ethylenediaminetetraacetic acid 
ELISA, Enzyme-linked immunosorbent assay  
EPR, Enhanced permeability and retention  
ESF, The European Science Foundation´s 
FCS, Fetal calf serum  
FDA, Food and Drug Administration  
FOV, Field of view  
FR8, Fluorescein-labelled R8 nanoparticles  
FRET, Fluorescence resonance energy transfer  
Gd-BOPTA, a complex of gadolinium with the ligand BOPTA, a derivative of 
DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–
CH2C6H5 
Gd-DTPA, a complex of gadolinium with diethylenetriaminepentaacetic acid 
Gd-DTPA-BMA, a complex of gadolinium with diethylenetriaminepentaacetic 
acid-Bismethylamide 
Gd-DTPA-BMEA, Bis(methoxyethylamide) derivative of Gd-DTPA 
Gd-HP-DO3A, a complex of gadolinium with 10-(2-Hydroxypropyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triacetato 
Gd-DOTA, a complex of gadolinium with 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid 
Gd-EOB-DTPA, a complex of gadolinium with ethoxybenzyl 
diethylenetriaminepentaacetic acid. 
 GI, Gastrointestinal  
GP, Glycoprotein  
GRAS, Generally recognized as safe 
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GSH, Glutathione in its reduced form 
GTPase, Guanosine triphosphate hydrolase 
HIV, Human immunodeficiency virus 
HK, High molecular weight kininogen  
1H-NMR, Proton NMR spectroscopy 
HRP, Horseradish peroxidase  
I, Ionic strength  
i.d, Internal diameter  
IFP, Interstitial fluid pressure  
IL-1, Interleukin-1 
IL-6, Interleukin-6 
IL-8, Interleukin-8 
IL-18, Interleukin-18 
IL-1β, Interleukin-1β 
IO, Iron oxide  
IONPs , Iron oxide nanoparticles  
ISA, Image sequence analysis  
IV, Intravenous injection 
kDa, Kilo dalton 
LC50, Mean lethal concentration  
LDH, Lactate dehydrogenase 
LDL , Low-density lipoprotein  
LFA, Lateral-flow immune assay  
MACS , Magnetic-activated cell sorting technique 
Maghemite–P4VP, Nanocomposites formed by maghemite and P4VP  
MALDI TOF-MS, Matrix-assisted laser desorption/ionization time-of-flight 
mass spectroscopy 
mβCD, Methyl-β-cyclodextrin  
MDR, Multidrug resistance   
MeFluOH, Fluorescein methyl ester  
MEM, Minimal Eagle’s Medium  
MNPs, Magnetic nanoparticles 
MNP, Magnetic nanoparticle 
MR, Magnetic resonance 
MRI, Magnetic resonance imaging  
mRNA , Messenger ribonucleic acid 
MSC, Mesenchymal stem cells  
MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide 
MTX, Matrix size  
Mxy, Transverse magnetisation  
Mz, Longitudinal magnetisation  
NaTFA , Sodium trifluoroacetate  
nm, Nanometer 
NMR, Nuclear magnetic resonance  
NPs, Nanoparticles 
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NP, Nanoparticle 
NLS, Nuclear localising signal 
N/L, Number of composite beads per litre of suspension 
NF-KB, Nuclear factor kappa B  
NAD+, Nicotinamide adenine dinucleotide 
NADH, Reduced form of NAD+ 
NADP+, Nicotinamide adenine dinucleotide phosphate  
NADPH, NADPH is the reduced form of NADP+  
OK, Opossum Kidney  
PBS, Phosphate buffered saline 
PDI, Polydispersity index 
PEG, Polyethylene glycol  
PEG-(NH2)2, Short-chain diamine PEG  
PET, Positron Emission Tomography  
PK, Prekallikrein  
PM, Particulate matter  
PM0.1, Particulate matter with a diameter less than 0.1 µm 
PPP, Platelets-poor plasma 
PRINT , Particle replication in non-wetting template  
PSMA, Prostate-specific membrane antigen  
PT, Prothrombin time  
PVA, Polyvinyl alcohol  
PVP,Polyvinylpyrrolidone  
PVP-IONPs, Polyvinylpyrrolidone-coated iron oxide nanoparticles 
P4VP, Poly(4-vinylpyridine)   
P4VP-g-APEG, P4VP-grafted to APEG  
P4VP-g-APEG, Bioferrofluids maghemite coated with P4VP-grafted to APEG 
and dispersed in PBS 
QDs, Quantum dots 
HER 2  
r1, Longitudinal relaxivity  
R1, Longitudinal relaxation rate (= 1/T1) 
r2, Transverse relaxivity  
R2, Transverse relaxation rate (= 1/T2) 
rCBV, Regional cerebral blood volume  
RES, Reticuloendothelial system  
RF, Radio frequency  
RID, Radial immunodiffusion  
RM, Regenerative medicine  
RNA, Ribonucleic acid 
ROIs, Regions-of-interest  
ROS, Reactive oxygen species 
RT, Reptilase time 
SAR, Specific absorption rate  
SD, Standard deviation  
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SEM, Standard error of mean  
SEM, Scanning electron microscope  
SI, Signal intensity  
siRNA, Small interfering RNA 
SPECT, Single Photon Emission Computed Tomography  
SPIO, Superparamagnetic iron oxide  
SPIONs, Superparamagnetic iron oxide nanoparticles  
SPION, Superparamagnetic iron oxide nanoparticle 
SV40, Simian virus 40  
T1, Longitudinal relaxation time or spin-lattice relaxation time  
T2, Transversal relaxation time or spin-spin relaxation time 
T2*, Total T2 relaxation time 
TB, Blocking temperature 
TAFI, Thrombin activatable fibrinolysis inhibitor  
TdT, Terminal deoxynucleotidyl transferase  
TE, Tissue engineering  
TE, Echo times  
TEM, Transmission Electron Microscopy 
TF, Tissue factor  
Tfn, Iron-laden transferrin  
TFPI, Tissue factor pathway inhibitor  
TGFβ, Transforming growth factor beta  
THF, Anhydrous tetrahydrofuran 
TMB, 3,3’,5,5’-Tetramethylbenzidine  
TNFα, Tumour necrosis factor alfa  
tPA, Tissue-type plasminogen activator  
TPP, Triphenylphosphine  
TR, Repetition time  
TT, Thrombin time  
TUNEL, Deoxynucleotidyl transferase- dUTP nick end labeling  
UFPs, Ultrafine particles  
UK,  United Kingdom  
uPAR,  Urokinase plasminogen activator receptor  
US, United States 
USA, United States of America 
USPIO, Ultra-small superparamagnetic iron oxide  
USPION, Ultrasmall superparamagnetic iron oxide nanoparticle  
UV, Ultraviolet 
UV-Vis, Ultraviolet-visible 
VSGF, Vascular endothelial growth factor 
VSMC , Vascular smooth muscle cells  
vWF, Von Willebrand factor  
 
